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The Eph receptor tyrosine kinases mediate juxtacrine signals by interacting “in trans” 
with ligands anchored to the surface of neighboring cells via a GPI-anchor (ephrin-As) or 
a transmembrane segment (ephrin-Bs), which leads to receptor clustering and increased 
kinase activity. Additionally, soluble forms of the ephrin-A ligands released from the cell 
surface by matrix metalloproteases can also activate EphA receptor signaling. Besides 
these trans interactions, recent studies have revealed that Eph receptors and ephrins 
coexpressed in neurons can also engage in lateral “cis” associations that attenuate 
receptor activation by ephrins in trans with critical functional consequences. Despite the 
importance of the Eph/ephrin system in tumorigenesis, Eph receptor-ephrin cis 
interactions have not been previously investigated in cancer cells. Here we show that in 
cancer cells, coexpressed ephrin-A3 can inhibit the ability of EphA2 and EphA3 to bind 
ephrins in trans and become activated, while ephrin-B2 can inhibit not only EphB4 but 
also EphA3. The cis-inhibition of EphA3 by ephrin-B2 implies that in some cases ephrins 
that cannot activate a particular Eph receptor in trans can nevertheless inhibit its signaling 
ability through cis association. We also found that an EphA3 mutation identified in lung 
cancer enhances cis interaction with ephrin-A3. These results suggest a novel mechanism 
that may contribute to cancer pathogenesis by attenuating the tumor suppressing effects 







1- RECEPTOR TYROSINE KINASES 
 
Receptor tyrosine kinases are part of the larger family of protein tyrosine kinases. Protein 
tyrosine kinases encompass the receptor tyrosine kinase, which are a single pass 
transmembrane proteins, and the non-receptor tyrosine kinases, which do not possess a 
transmembrane domain (Robinson et al. 2000). 
A search of the human genome identified ninety tyrosine kinase genes containing 
a highly conserved catalytic domain, of these fifty-eight encode receptor tyrosine kinases. 
Nineteen of the twenty-four human chromosomes contain tyrosine kinases genes, which 
through a phylogenetic analysis of the amino acid sequence of the kinase domain can be 
grouped into twenty receptor and ten non-receptor classes. The twenty receptor tyrosine 
kinase classes include: RTK class I (EGF receptor family) (ErbB family), RTK class II 
(Insulin receptor family), RTK class III (PDGF receptor family), RTK class IV (FGF 
receptor family), RTK class V (VEGF receptors family), RTK class VI (HGF receptor 
family), RTK class VII (Trk receptor family), RTK class VIII (Eph receptor family), 
RTK class IX (AXL receptor family), RTK class X (LTK receptor family), RTK class XI 
(TIE receptor family), RTK class XII (ROR receptor family), RTK class XIII (DDR 
receptor family), RTK class XIV (RET receptor family), RTK class XV (KLG receptor 
family), RTK class XVI (RYK receptor family), and RTK class XVII (MuSK receptor 
family) (Robinson et al. 2000). 
The non-receptor tyrosine kinases are critical components of the signaling 
pathways triggered by the receptor tyrosine kinases and other cell surface receptors. This 
group of proteins includes Src, Abl and Janus (Jaks) kinases and many others (Hubbard 
and Till 2000). 
Receptor tyrosine kinases possess intrinsic cytoplasmic enzymatic activity, with 
which they promote the transfer of the ATP γ-phosphate to tyrosine residues of protein 
substrates. They function as receptors for cytokines, growth factors, hormones and other 
signaling molecules and they play critical roles in a variety of cellular processes 
including growth, differentiation, angiogenesis and metabolism as well as in the 
development and progression of many types of cancer. In fact, mutations that impair 
receptor functions result in developmental defects, emphasizing how important the 
regulated activity of these proteins is (Lemmon and Schlessinger 2010). 
 
 
1.1- DOMAIN ORGANIZATION OF RECEPTOR TYROSINE 
KINASES 
 
Generally the receptor tyrosine kinases consist of several domains: the extracellular 
domain, which is important for the binding of the ligand or external signal, a 
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transmembrane helix, which connects the extracellular domain to the intracellular 
domain, a small juxtamembrane region followed by the tyrosine kinase domain, which 
retains catalytic activity. The tyrosine kinase domain is highly conserved in the receptor 
tyrosine kinase family and is generally followed by a C-terminal region. The cytoplasmic 
domain contains multiple binding sites for adaptor proteins. Most of the receptor tyrosine 
kinases are monomeric in the absence of ligand and consist of a single polypeptide chain. 
The exceptions are the insulin-like growth factor 1 (IGF1) receptor, which is formed by 
two disulfide-linked dimers, and the Met HGF receptor, which contains a short α-chain 
disulfide-linked to a transmembrane β-chain (Hubbard and Till 2000). The global 
structure of the tyrosine kinase domain is comparable to that of serine/threonine kinases 
and is formed by an amino-terminal lobe comprising an α-helix and a five-stranded β 
sheets followed by a bigger carboxy-terminal lobe composed of several α-helices. Some 
receptor tyrosine kinases contain a kinase insert domain, which together with the C-
terminal region and the juxtamembrane domain contains tyrosine residues that are 
autophosphorylated upon ligand binding to the receptor (Cadena et al. 1994; Hubbard 
1999). In contrast, the extracellular portion of the receptor is structurally more complex 
and accommodates different globular domains, such as Immunoglobulin Ig-like domains, 
fibronectin type III-like domains, cysteine rich-domains and EGF-like domains (Fig. 1) 




Figure 1: Domain organization of several receptor tyrosine kinases. Legend on the right side. 
The horizontal double line represents the plasma membrane, which divides the extracellular 






1.2- RECEPTOR TYROSINE KINASE SIGNALING 
 
 
High affinity ligand binding is the first step in the activation of the receptor. Most 
receptor tyrosine kinase ligands are soluble polypeptides, except for the ligands of the 
Eph receptors, which are membrane-bound proteins. The ligand in its monomeric or 
dimeric form binds the extracellular domain of the cognate tyrosine kinase receptor and 
induces conformational changes that result in receptor dimerization and oligomerization. 
The activation of the receptor requires the binding of the ligand to stabilize the active 
conformation of the receptor and to destabilize cis-autoinhibitory interactions, whether 
the initial inactive state of the receptor is monomeric or dimeric. Receptor dimerization 
promotes activation of the tyrosine kinase catalytic domain, which autophosphorylates on 
specific tyrosine residues localized in the activation loop of the kinase domain. In 
addition, this process promotes the phosphorylation of tyrosine residues in the C-terminal 
and juxtamembrane domains, disrupting autoinhibitory interactions with the kinase 
domain and creating binding sites for adaptor proteins containing phosphotyrosine 
recognition domains of 50-100 amino acids, such as Src homology 2 (SH2) domains and 
phosphotyrosine-binding (PTB) domains. The adaptor proteins are recruited directly by 
the activated receptor or indirectly by binding to docking proteins that are associated with 
the phosphorylated receptor, such as FRS2, IRS1 (insulin receptor substrate-1) and Gab1 
(the Grb2-associated binder) (Pawson 1995; Lemmon and Schlessinger 2010). Once the 
adaptor proteins are recruited by the receptor at the cell membrane, the activated receptor 
catalyzes the transfer of the adenosine triphosphate γ-phosphate (ATP) to the hydroxyl 
group of side-chain tyrosine residues in the protein substrates. Some of these proteins are 
the GTPase activating protein (GAP), the phospholipase C-γ (PLC-γ) and the 
phosphatidylinositol 3-kinase (PI 3-kinase). Finally, the activated adaptor proteins can 







Figure 2: Schematic representation of receptor tyrosine kinase activation and signal 
transduction. 1- ligand binding to the receptor extracellular domain, 2- receptor dimerization, 3- 
receptor autophosphorylation and fully activation, 4- binding of adaptor proteins containing 
phosphotyrosine-recognition domains to the activated receptor and activation of downstream 
signal pathways (bio1151.nicerweb.com). 
 
An example of a signaling pathway activated by the binding of growth factors to a 
tyrosine kinase receptor is the Ras-dependent Erk1/2 mitogen-activated (MAP) kinase 
pathway. This signaling pathway is one of the most studied and most frequently 
deregulated in human cancer. In this signaling pathway the binding of the growth factor 
to the receptor tyrosine kinase induces receptor dimerization and autophophorylation of 
tyrosine residues in the C-terminal region. This creates binding sites for the adaptor 
proteins such as Grb2, which subsequently recruits the guanine nucleotide exchange 
factor Sos. By catalyzing the substitution of GDP with GTP, Sos activates the membrane-
bound Ras, which, in turn, phosphorylates and activates the Raf kinase (MAPKKK). Raf 
catalyzes the activation of MEK1 and MEK2 (MAPKKs), which subsequently activate 
the MAP kinases, Erk1 and Erk2. Once activated, Erk1/2 translocates in the nucleus 
where it regulates several cellular responses, such as cell proliferation, growth and 
survival (Fig. 3). CI-1040 was the first MEK1/2 inhibitor to enter clinical trials, however 
the insufficient antitumoral activity and poor solubility of this compound precluded 
further clinical development. PD0325901 and AZD6244 are second-generation inhibitors 
of MEK1/2 with better potency and solubility than CI-1040. AZD6244 is currently 
undergoing further clinical trials, while the clinical development of PD0325901 has been 
stopped due to its ocular toxicity in cancer patients (Fig. 3) (Fremin and Meloche 2010). 
Other promising MEK inhibitors are in development, such as BAY867966 and 




      
 
Figure 3: Rapresentation of the Ras-dependent Erk1/2 mitogen-activated (MAP) kinase 
pathway (Fremin and Meloche 2010).  
 
Termination of receptor tyrosine kinases signaling occurs via distinctive 
processes: dephosphorylation by protein tyrosine phosphatases (PTPs), protein 
degradation following ubiquitination and receptor endocytosis (Hubbard and Till 2000). 
Upon ligand binding and receptor clustering, the occupied receptor can be internalized 
through clathrin-mediated endocytosis. In the endosomal lumen the ligand dissociates 
from the receptor, which becomes dephosphorylated and ubiquitylated. At this point the 
receptor may be degraded or recycled to the plasma membrane, which affects receptor 
number and signaling (Lemmon and Schlessinger 2010). 
 
 
1.3- RECEPTOR TYROSINE KINASES AND CANCER 
 
Receptor tyrosine kinases not only are key regulators of normal cellular processes but 
also have a critical role in the development and progression of many types of cancer. 
Deregulation of receptor tyrosine kinases has been found in a variety of human diseases. 
Abnormal receptor tyrosine kinases activation in human tumors may be caused by 
receptor overexpression, gain-of-function mutations, chromosomal translocation and 
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autocrine activation. Recent sequencing studies in a wide array of human cancers have 
identified mutations in numerous receptor tyrosine kinases (Lemmon and Schlessinger 
2010). 
Activating mutations in the KIT and PDGFR families of receptors have been 
identified in several human tumors, such as melanoma and gastrointestinal tumors. The 
gain-of-function-mutations of KIT are usually clustered in exons 8, 9, 11 and 17 of the 
KIT gene and cause constitutive receptor dimerization by removing the normal receptor 
cis-autoinhibition (Yuzawa et al. 2007). 
Deregulation of EGFR family receptors also has a strong impact in human cancer. 
Different mechanisms of constitutive activation of EGFR in tumors have been identified 
(Gschwind et al. 2004). Amplifications of the EGFR gene and activating mutations have 
been found in ~35% of glioblastoma cases (Lemmon and Schlessinger 2010). Impaired 
receptor downregulation is another mechanism of EGFR deregulation (Peschard and Park 
2003). In addition, ErbB2 protein overexpression is frequent in breast cancer patients and 
is associated with poor prognosis (Lemmon and Schlessinger 2010). 
Furthermore, receptors of the FGFR family are mutated in several human cancers. 
In lymphoblastic lymphoma, multiple myeloma and myelogenous leukemia the FGFR 
receptor undergoes chromosomal translocation, which results in the formation of a 
constitutively active heterodimer containing FGFR1 and FGFR3 (Eswarakumar et al. 
2005). 
Small molecule inhibitors targeting the ATP-binding site, which is located in the 
receptor kinase domain, and monoclonal antibodies that block receptor activation or 
target the cell expressing the receptor tyrosine kinase for destruction by the immune 
system have been developed and approved by the US Food and Drug Administration 
(FDA). An example is the HER2-specific monoclonal antibody (mAb) Trastuzumab 
(Herceptin, Genentech, Inc) used to treat metastatic breast cancer. This antibody binds 
HER2 on the surface of tumor cells and induces receptor internalization, inhibition of 
cell-cycle progression and recruitment of immune cells (Gschwind et al. 2004). Although 
several treatments have been successfully used to fight different cancers, unfortunately 
the gain of drug resistance and the side effects that arise from lack of selectivity of the 
small molecule inhibitors towards an individual target are still a big limitation of these 
anticancer therapies. New strategies to solve the problem of drug resistance in the clinical 
therapies are focused on using simultaneously multiple receptor tyrosine kinase inhibitors 
that target different receptors and on developing inhibitors that target key processes 




2- EPH RECEPTOR SIGNALING AND EPHRINS 
 
The Eph receptors are the largest of the RTK families. Like other RTKs, they transduce 
signals from the cell exterior to the interior through ligand-induced activation of their 
kinase domain. However, the Eph receptors also have distinctive features. Instead of 
binding soluble ligands, they generally mediate contact-dependent cell-cell 
communication by interacting with surface-associated ligands – the ephrins – on 
neighboring cells. Eph receptor-ephrin complexes emanate bidirectional signals that 
affect both receptor- and ephrin-expressing cells. Intriguingly, ephrins can also attenuate 
signaling by Eph receptors co-expressed in the same cell. Additionally, Eph receptors can 
modulate cell behavior independently of ephrin binding and kinase activity. The 
Eph/ephrin system regulates many developmental processes and adult tissue homeostasis. 
Its abnormal function has been implicated in various diseases, including cancer. Thus, 
Eph receptors represent promising therapeutic targets. However, more research is needed 
to better understand the many aspects of their complex biology that remain mysterious 
(Lisabeth et al. 2013b).  
 
 




The Eph receptors have the prototypical RTK topology, with a multidomain extracellular 
region that includes the ephrin ligand-binding domain, a single transmembrane segment, 
and a cytoplasmic region that contains the kinase domain (Fig. 4). There are nine EphA 
receptors in the human genome, which promiscuously bind five ephrin-A ligands, and 
five EphB receptors, which promiscuously bind three ephrin-B ligands (Pasquale 2004; 
Pasquale 2005). Additionally, EphA4 and EphB2 can also bind ephrins of a different 
class. Two members of the family, EphA10 and EphB6, have modifications in conserved 
regions of their kinase domains that prevent kinase activity. Furthermore, a variety of 
alternatively spliced forms identified for many Eph receptors differ from the prototypical 
structure and have distinctive functions (Zisch and Pasquale 1997; Pasquale 2010).  
Both ephrin classes include a conserved Eph receptor-binding domain, which is 
connected to the plasma membrane by a linker segment whose length can be affected by 
alternative splicing (Fig. 4). The ephrin-As are attached to the cell surface by a 
glycosylphosphatidylinositol (GPI) anchor, although they can also be released to activate 
EphA receptors at a distance (Bartley et al. 1994; Wykosky et al. 2008), whereas the 
ephrin-Bs contain a transmembrane segment and a short cytoplasmic region. Ephrin-A3 
and ephrin-B3 also bind heparan sulfate proteoglycans through an interaction that 
involves their extracellular linker region and that, at least in the case of ephrin-A3, 




Figure 4: Domain structure of Eph receptors and ephrins (Lisabeth et al. 2013b). 
 
 
The Eph receptor family has greatly expanded during evolution, and includes 
almost a fourth of the 58 human RTKs (Schlessinger and Lemmon, this issue). A large 
number of Eph receptors and ephrins may be required to achieve and maintain the 
sophisticated tissue organization of higher organisms. Indeed, many are highly expressed 
in the most complex organ, the brain, particularly during the establishment of its complex 
architecture and intricate wiring of neuronal connections (Yamaguchi and Pasquale 
2004). Besides the brain, Eph receptors and ephrins are also present in most – if not all – 
other tissues, often in a combinatorial manner and with dynamically changing expression 
patterns (Pasquale 2005). In some regions Eph receptors and ephrins are both co-
expressed in the same cells, in others they have mutually exclusive expression patterns, 
or they can be expressed in complementary gradients. These situations likely reflect 
different signaling modalities with different biological outcomes.  
Eph receptors and ephrins engage in a multitude of activities. They typically 
mediate contact-dependent communication between cells of the same or different types to 
control cell morphology, adhesion, movement, proliferation, survival and differentiation 
(Pasquale 2005). Through these activities, during development the Eph/ephrin system 
plays a role in the spatial organization of different cell populations, axon guidance, 
formation of synaptic connections between neurons, and blood vessel remodeling. In the 
adult, the Eph/ephrin system regulates remodeling of synapses, epithelial differentiation 
and integrity, bone remodeling, immune function, insulin secretion, and stem cell self-
renewal (Pasquale 2008; Genander and Frisen 2010). In addition, Eph receptors and 
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ephrins are often upregulated in injured tissues, where they inhibit some regenerative 
processes but promote angiogenesis, as well as in cancer cells, where they seem to be 
able to both promote and suppress tumorigenicity (Du et al. 2007; Pasquale 2008; 
Pasquale 2010).  
Here we provide an overview of Eph receptor and ephrin signaling mechanisms 
and biological effects, with emphasis on recent findings. More detailed information on 
specific aspects of Eph receptor/ephrin biology and downstream signaling networks can 
be found in other recent reviews (Pasquale 2005; Arvanitis and Davy 2008; Lackmann 
and Boyd 2008; Pasquale 2008; Klein 2009; Genander and Frisen 2010; Pasquale 2010).  
 
 
2.2- EPH RECEPTOR FORWARD SIGNALING 
 
“Forward” signaling corresponds to the prototypical RTK mode of signaling, which is 
triggered by ligand binding and involves activation of the kinase domain. However, the 
activation mechanisms of Eph receptors have unique features as compared to other RTK 
families (Nikolov, this issue). Binding between Eph receptors and ephrins on juxtaposed 
cell surfaces leads to oligomerization through not only Eph receptor-ephrin interfaces but 
also receptor-receptor cis interfaces located in multiple domains (Himanen et al. 2010; 
Seiradake et al. 2010) (Fig. 5). In fact, Eph receptor clusters induced by ephrin binding 
can enlarge to incorporate Eph receptors that are not bound to ephrins (Wimmer-
Kleikamp et al. 2004). The cellular context can also affect Eph receptor clustering ability, 
which depends on association with the actin cytoskeleton (Salaita and Groves 2010). 
Given the promiscuity of Eph receptor-ephrin interactions, and also receptor-receptor cis 
interactions, the clusters can include Eph receptors of both A and B classes (Janes et al. 
2011).  
The proximity of clustered Eph receptor molecules leads to trans-phosphorylation. 
Phosphorylation of two conserved tyrosines in the juxtamembrane domain relieves 
inhibitory intramolecular interactions with the kinase domain, enabling efficient kinase 
activity (Binns et al. 2000; Zisch et al. 2000; Wybenga-Groot et al. 2001). 
Phosphorylation of the conserved tyrosine in the activation loop appears to be less critical 
for Eph receptor activation than it is for many other RTKs, although it may be important 
for maximal activity (Binns et al. 2000; Singla et al. 2011). There are also differences in 
the kinase domains within the Eph receptor family. For example, the “gatekeeper” 
residue in the hinge region between the kinase domain lobes, which controls access to a 
hydrophobic pocket adjacent to the ATP binding site, is a threonine in most Eph 
receptors but a valine in EphA6 and an isoleucine in EphA7. Hence, EphA6 and EphA7 
likely differ from the other Eph receptors in their sensitivity to kinase inhibitors and 
possibly substrate specificity (Skaggs et al. 2006; Zhang et al. 2009a).  
The Eph receptors modulate many of the same networks of adaptor and effector 
proteins that also function downstream of other RTK families (Pawson, this issue). 
Various tyrosine autophosphorylation sites in activated Eph receptors – including the two 
regulatory juxtamembrane sites – enable recruitment of downstream signaling proteins 
that contain SH2 domains, including non-receptor tyrosine kinases of the Src and Abl 
families and adaptors such as Nck and Crk, which are crucial for signal transduction 
(Jorgensen et al. 2009; Pasquale 2010) (Fig. 5). Binding of PDZ domain-containing 
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proteins to the carboxy-terminal tails of Eph receptors also contributes to signaling. 
Particularly important effectors are Rho and Ras family GTPases and Akt/mTORC1. 
Interestingly, while most other RTK families use these central regulators of cellular 
physiology to stimulate cell proliferation, survival and forward movement, the Eph 
receptors can use them to inhibit cell growth and achieve cell repulsion. In cancer cells, 
this can result in tumor suppression. 	  	  	  	  	  	  
	  	  	   	  	  
Figure 5: Eph receptor clustering and bidirectional signaling. SH2 and PDZ indicate proteins 
containing these domains. All types of signaling proteins shown can associate with both EphA 
and EphB receptors. Asterisks indicate receptor-receptor interactions favoring clustering; yellow 
circles indicate tyrosine phosphorylation and the orange circle indicates serine phosphorylation. 
 
Signaling by the Eph receptors, however, is not always consistent and can lead to 
divergent outcomes. The kinase inactive Eph receptors and alternatively spliced forms 
lacking the kinase domain can modulate signaling outcome by reducing signal strength in 
the clusters as well as by contributing distinctive signals. For example, the kinase inactive 
EphB6 can be phosphorylated by other Eph receptors and subvert the effects of EphB4 in 
breast cancer cells (Truitt and Freywald 2011). Moreover, a truncated membrane-
anchored form of the EphA7 extracellular domain can convert repulsion to cell-cell 
adhesion in the developing neural tube by decreasing signaling by full-length EphA7 
(Holmberg et al. 2000) and a secreted truncated form of EphA7 acts as a tumor 
suppressor in follicular lymphoma by binding EphA2 and blocking its oncogenic signals 
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(Oricchio et al. 2011). There is also evidence that small and large Eph receptor clusters 
differ in their ability to recruit certain signaling molecules (Salaita and Groves 2010). 
Other aspects of the cellular context, and implementation of positive and negative 
feedback loops, further contribute to the diversity of Eph receptor activities.  
 
 
2.2.1- Rho Family GTPases 
 
The Eph receptors are well known for their effects on the actin cytoskeleton, which 
impact cell shape, adhesion and movement through regulation of the Rho GTPase family, 
including RhoA, Rac1 and Cdc42 (Pasquale 2008; Pasquale 2010). GTPases cycle 
between a GDP bound (inactive) state and a GTP bound (active) state that binds 
dowstream effectors. The Eph receptors can influence these conversions by regulating 
both guanine nucleotide exchange factors (GEFs, which facilitate GDP to GTP exchange) 
and GTPase-activating proteins (GAPs, which promote GTP hydrolysis to GDP). 
Regulation of GEFs and GAPs by Eph receptors can involve constitutive or ephrin-
induced association, tyrosine phosphorylation, or even ubiquitination and degradation.  
RhoA is mostly involved in the formation of stress fibers and focal adhesions as 
well as contraction of the actomyosin cytoskeleton, whereas Rac1 and Cdc42 drive the 
formation of protrusive structures such as lamellipodia and filopodia, respectively 
(Heasman and Ridley 2008). An increased balance of RhoA versus Rac1/Cdc42 activities 
has been implicated in the characteristic repulsive effects of Eph receptor forward 
signaling, including process retraction and inhibition of cell migration/invasiveness (Fig. 
6A-C). The collapse or local retraction of neuronal growth cones and dendritic spines (the 
small protrusions on dendrites bearing excitatory synapses) are well-known repulsive 
effects of EphA receptors that depend on Rho family GTPases (Wahl et al. 2000; Murai 
et al. 2003; Fu et al. 2007) (Fig. 6B,C). Growth cone collapse involves RhoA activation, 
for example by the GEF Ephexin1 (Shamah et al. 2001; Sahin et al. 2005), and Rac1 
inactivation, for example by the GAP α2-Chimaerin (Beg et al. 2007; Iwasato et al. 2007; 
Shi et al. 2007; Wegmeyer et al. 2007). However Rac1 activation, which can occur 
downstream of Vav family GEFs, is also required for growth cone collapse and process 
retraction by enabling endocytic removal of adhesive Eph receptor-ephrin complexes 
from sites of cell-cell contact (Cowan et al. 2005; Yoo et al. 2011). Activation and 
inactivation of Rho family GTPases may occur with different spatial and/or temporal 
resolution to achieve growth cone collapse and regulate dendritic spines. In other cell 
types, Eph repulsive signaling involving Rho family GTPases can lead to mesodermal-
ectodermal tissue separation during gastrulation (Park et al. 2011; Rohani et al. 2011), 
Schwann cell-astrocyte segregation in the injured nervous system (Afshari et al. 2010), 
and contact inhibition of locomotion (Astin et al. 2010). 
Regulation of Rho family GTPases by Eph receptors can also control cellular 
processes beyond repulsion. For example, the maturation of neuronal filopodial 
protrusions into dendritic spines (Fig. 6D) entails ephrin-B/EphB-dependent activation of 
the Rac-GEFs Kalirin and Tiam1 and the Cdc42-GEF Intersectin to promote the 
formation of branched actin filaments that enlarge the distal portion of the filopodial 
protrusions (Irie and Yamaguchi 2002; Penzes et al. 2003; Tolias et al. 2007) while RhoA 
activation through focal adhesion kinase and a RhoGEF shortens the protrusions (Moeller 
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et al. 2006). Interestingly, EphB receptor forward signaling can also promote synapse 
formation through ubiquitination and degradation of the Rho-GEF Ephexin5, which 
decreases RhoA activity without obvious effects on spine morphology (Margolis et al. 
2010). Furthermore, EphA2 forward signaling can promote endothelial angiogenic 
responses by activating Rac1 through Vav family GEFs (Hunter et al. 2006) and enhance 
epithelial characteristics by inhibiting RhoA through p190RhoGAP (Wakayama et al. 
2011). In addition, EphB receptor activation by ephrin-B-expressing stromal cells 
promotes HGF-dependent invasiveness of metastatic PC3 prostate cancer cells through 




Figure 6: Eph receptor-ephrin repulsive effects and dendritic spine maturation. (A) An 
EphB-expressing cell encounters an ephrin-B-expressing cell and retracts after the internalization 
of EphB-ephrin-B complexes enables cell separation. (B) An EphA-expressing growth cone at the 
leading edge of an axon encounters an ephrin-A-expressing cell, collapses and begins to retract 
after the cleavage of ephrin-A molecules enables cell separation. (C) An EphA-expressing spine 
on a dendrite (bearing an excitatory post-synaptic terminal represented as a darker oval) comes in 
contact with an ephrin-A-expressing glial process and retracts becoming shorter. (D) An EphB-
expressing filopodial protrusion on a dendrite acquires an enlarged “head” and shortens following 




Further work is needed to understand in detail the mechanisms leading to 
activation versus inhibition of Rho GTPases by Eph receptors and examine the role of the 




2.2.2- Ras Family GTPases 
 
Perhaps the most prototypical RTK signaling pathway involves activation of the H-Ras 
GTPase by the GEF Sos, which is recruited by the adaptors Shc and/or Grb2 bound to 
activated RTKs (McKay and Morrison 2007). H-Ras-GTP triggers a phosphorylation 
cascade that culminates in activation of the Erk1 and Erk2 serine/threonine kinases. 
Through phosphorylation of cytoplasmic effectors and nuclear transcription factors, the 
Ras-Erk pathway regulates many physiological processes – including cell proliferation, 
survival, differentiation, adhesion and migration – and its deregulation can cause cancer 
and other diseases.  
 Remarkably, Eph receptor forward signaling frequently inhibits the Ras-Erk 
pathway  and can override its activation by other RTKs (Pasquale 2008; Pasquale 2010). 
For example, polarized Eph receptor activation in progenitor cells of the ascidian embryo 
attenuates Erk activation by the FGF RTK, leading to asymmetric division and fate 
specification (Picco et al. 2007; Shi and Levine 2008). Furthermore, ephrin-A/EphA 
signaling induced by contact between myoblasts suppresses Erk activation by the IGF-1 
RTK, facilitating myogenic differentiation (Minami et al. 2011). In neurons, EphA-
dependent Erk inhibition suppresses the effects of the TrkB RTK on growth cone motility 
and gene expression (Meier et al. 2011) and promotes growth cone collapse (Nie et al. 
2010). In cancer cells, ephrin-A/EphA signals that suppress Erk activation by RTKs can 
inhibit tumorigenicity (Miao et al. 2001; Macrae et al. 2005). 
A common mechanism of Eph receptor-dependent Erk inhibition is through 
p120RasGAP, which inactivates H-Ras (Elowe et al. 2001; Minami et al. 2011). Through 
p120RasGAP, the Eph receptors can also inhibit another Ras family GTPase, R-Ras, 
causing the reduced integrin activity that is important for retraction of cell processes and 
decreased malignancy (Dail et al. 2006). Eph receptors can also negatively regulate Rap1, 
another member of the Ras family involved in integrin activation, by inhibiting the GEF 
C3G or activating the GAP SPAR (Riedl et al. 2005; Richter et al. 2007; Huang et al. 
2008; Pasquale 2008). 
In some cases, however, Eph receptors behave similarly to other RTKs and 
activate the Ras-Erk pathway. For example, in cultured mouse mesenchymal cells, 
ephrin-B1/EphB signaling activates Erk to promote proliferation and regulate immediate 
early gene transcription (Bush and Soriano 2010). In P19 embryonal carcinoma cells and 
microvascular endothelial cells, ephrin-stimulated EphB1 recruits the adaptors Shc and 
Grb2 to activate H-Ras and increase cell migration (Vindis et al. 2003). Interestingly, the 
activation of EphB4 by ephrin-B2 in MCF7 breast cancer cells promotes Erk1/2 
activation through an unusual pathway that seems to require the PP2A serine/threonine 
phosphatase (Xiao et al. 2012). In stably transfected HEK293 cells, EphB2 forward 
signaling activates Erk to promote cell repulsion (Poliakov et al. 2008). The interplay 
between Eph receptors and Ras GTPases also involves feedback loops where Ras-Erk 
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signaling reciprocally influences Eph receptors, for example by reinforcing ephrin-
B1/EphB2 signaling or upregulating EphA2 gene transcription (Menges and McCance 





Akt is a serine/threonine kinase that regulates cell size, proliferation and survival through 
various downstream effectors such as mTOR complex 1 (mTORC1). RTKs typically 
activate Akt through PI3 kinase, a lipid kinase that initiates a pathway leading to Akt 
activation through phosphorylation on T308 and S473 (Manning and Cantley 2007). In 
contrast, Eph receptor forward signaling can suppress Akt activation. For instance, in a 
variety of cancer cells ephrin-dependent EphA2 activation leads to rapid 
dephosphorylation of Akt T308 and S473, which likely depends on regulation of a 
phosphatase, leading to mTORC1 inactivation and decreased cell growth and migration 
(Menges and McCance 2008; Miao et al. 2009; Yang et al. 2011). Remarkably, this can 
occur even in cancer cells where the PI3 kinase-Akt pathway is activated by oncogenic 
mutations. EphB3 kinase activation can also inhibit Akt, which leads to suppression of 
non-small-cell lung cancer migration and metastasis, by promoting the assembly of a 
complex involving the EphB3 binding partner RACK1 (receptor for activated C-kinase 
1), the serine/threonine phosphatase PP2A and Akt itself (Li et al. 2012). However, Eph 
receptors can also activate Akt, for example in pancreatic cancer cells stimuated with 
ephrin-A1 (Chang et al. 2008) or in malignant T lymphocytes where ephrin-B treatment 
suppresses apoptosis (Maddigan et al. 2011). 
Akt signaling can reciprocally influence Eph receptors through feedback loops. 
For example, phospho-RTK arrays suggest an upregulation of several tyrosine 
phosphorylated Eph receptors in cancer cells treated with Akt inhibitors (Chandarlapaty 
et al. 2011). Furthermore, Akt can phosphorylate EphA2 on S897 drastically altering 
receptor function (see below), while ephrin-A1 stimulation causes loss of S897 
phosphorylation (Miao et al. 2009). 
 
 
2.3- EPHRIN REVERSE SIGNALING 
 
Besides forward signaling, the Eph receptors can also stimulate “reverse” signaling in the 
ephrin-expressing cells (Pasquale 2005; Pasquale 2010) (Fig. 5). A central feature 
enabling signaling by the ephrins, which lack an enzymatic domain, is the activation of 
Src family kinases. Eph receptor binding causes ephrin-B phosphorylation by Src 
kinases, creating binding sites for the SH2 domains of signaling proteins such as the 
adaptor Grb4 (Cowan and Henkemeyer 2001; Palmer et al. 2002). Ephrin-B signaling 
through Grb4 controls axon pruning, synapse formation and dendritic spine 
morphogenesis in the developing mouse hippocampus (Segura et al. 2007; Xu and 
Henkemeyer 2009). Phosphorylation of a serine near the ephrin-B carboxy terminus, 
which is also induced by EphB receptor binding, leads to stabilization of AMPA 
neurotransmitter receptors at synapses (Essmann et al. 2008). This might regulate 




Recruitment of signaling proteins containing PDZ domains to the ephrin-B 
carboxy terminus is also crucial for reverse signaling. For example, the adaptor PDZ-
RGS3 connects ephrin-B to G-protein coupled receptors that control neuronal cell 
migration and neural progenitor self-renewal (Lu et al. 2001; Qiu et al. 2010). Ephrin-B 
interaction with PDZ domain proteins also promotes angiogenesis and lymphangiogensis 
by enabling VEGF receptor endocytosis, and can regulate axon guidance and synaptic 
plasticity (Makinen et al. 2005; Bouzioukh et al. 2007; Bush and Soriano 2009; 
Sawamiphak et al. 2010; Wang et al. 2010). Furthermore, ephrin-B signaling controls 
neuronal migration in the developing mouse brain through crosstalk with the secreted 
glycoprotein Reelin (Senturk et al. 2011), modulates epithelial cell-cell junctions through 
the Par polarity complex (Lee et al. 2008), disrupts gap junctional communication 
(Mellitzer et al. 1999; Davy et al. 2006), and enhances glioma cell invasiveness by 
activating Rac1 (Nakada et al. 2006).  
The ephrin-As lack a cytoplasmic domain and it is not well understood how they 
activate intracellular signaling. Studies in neurons have implicated the p75 neurotrophin 
receptor and the TrkB and Ret RTKs as transmembrane binding partners that enable 
ephrin-A-dependent reverse signals involved in axon guidance and branching (Lim et al. 
2008; Marler et al. 2008; Marler et al. 2010; Bonanomi et al. 2012) (Fig. 5). Through 
these and likely other binding partners, the ephrin-As have diverse signaling activities. 
Ephrin-A2 reverse signaling can inhibit neural progenitor cell proliferation, perhaps 
opposing the positive effects of ephrin-B1 (Holmberg et al. 2005). In the adult 
hippocampus, glial ephrin-A3 functions together with neuronal EphA4 to modulate 
uptake of the neurotransmitter glutamate by glial cells and, thus, synaptic plasticity 
(Carmona et al. 2009; Filosa et al. 2009). Ephrin-A4 can inhibit apoptotic cell death in 
Jurkat immune cells by activating Src family kinases and Akt (Holen et al. 2008). Ephrin-
A5 reverse signaling in pancreatic β cells can stimulate Rac1 activity, which is necessary 
for insulin secretion after glucose stimulation (Konstantinova et al. 2007). Ephrin-A5 can 
also increase cell-substrate adhesion in fibroblasts and astrocytes by activating the Src 
family kinase Fyn and integrins, and seems able to also promote invasiveness (Davy et al. 
1999; Davy et al. 2000; Campbell et al. 2006). Furthermore, this ephrin promotes Fyn 
activation in glioma and HEK293 cells, leading to Cbl-dependent EGF RTK 
ubiquitination and degradation (Li et al. 2009). Interestingly, Fyn can in turn function in a 
negative feedback loop to downregulate cell surface ephrin-A levels by modulating the 
metabolism of sphingomyelin (Baba et al. 2009).  
 
 
2.4- BEYOND BIDIRECTIONAL SIGNALING 
 
2.4.1- Internalization and Proteolytic Cleavage 
 
Following ligand-dependent activation, RTKs are typically internalized by endocytosis 
and can continue to signal from intracellular compartments until they are inactivated by 
dephosphorylation and degradation or traffic back to the cell surface (Sorkin, this issue). 
For the Eph receptors, this process has unique features due to the plasma membrane 
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association of the ephrins (Marston et al. 2003; Zimmer et al. 2003; Pitulescu and Adams 
2010). Eph receptor-ephrin complexes can be internalized into either the Eph receptor- or 
the ephrin-expressing cells through the formation of vesicles containing plasma 
membrane fragments derived from both cells (Fig. 6A). This Rac1-dependent process, 
which has been defined “transendocytosis”, is critical for removal of adhesive complexes 
from cell-cell contact sites to allow cell separation and repulsive effects. Another protein 
that contributes to Eph receptor internalization and degradation is the ubiquitin ligase 
Cbl, which can interact with several Eph receptors promoting their ubiquitination 
(Walker-Daniels et al. 2002; Fasen et al. 2008). 
Besides transendocytosis, Eph receptor-ephrin complexes can convert adhesive 
interactions into cell repulsion by activating metalloproteases, such as ADAM family 
members. For example, the transmembrane ADAM10 protease can associate with ephrin-
A2 on the same cell surface and cleave it following EphA receptor binding in trans to 
enable repulsive axon guidance (Hattori et al. 2000). ADAM10 can also associate with 
EphA3, whose active conformation promotes protease activity towards the ephrin in trans 
(Janes et al. 2005; Janes et al. 2009) (Fig. 7A). EphB receptors also interact with 
ADAM10, as well as the cell adhesion molecule E-cadherin, and their binding to ephrin-
Bs in trans provokes shedding of E-cadherin by ADAM10 preferentially in the ephrin-B 
expressing cells (Solanas et al. 2011) (Fig. 7A). Cleavage by metalloproteases also plays 
a role in other Eph receptor/ephrin activities. For example, ephrin-B cleavage by 
ADAM13 can terminate EphB/ephrin-B signals that inhibit canonical Wnt signaling in 
the Xenopus embryo, thus enabling cranial neural crest induction (Wei et al. 2010). 
Furthermore, ADAM19 functions independently of its protease activity to stabilize 
developing neuromuscular junctions by preventing internalization of the complexes 
between ephrin-A5 on the muscle and EphA4 on the innervating motor neuron (Yumoto 
et al. 2008). 
Ephrin binding and other stimuli can also induce cleavage of the Eph receptor 
extracellular domain, followed by further intramembrane proteolytic processing via γ-
secretase to generate cytoplasmic fragments capable of signaling (Litterst et al. 2007; 
Inoue et al. 2009; Xu et al. 2009). For example, calcium influx can induce combined 
metalloprotease/γ-secretase processing of both EphA4 and EphB2 (Litterst et al. 2007; 
Inoue et al. 2009). The released EphA4 cytoplasmic fragment increases dendritic spine 
numbers through kinase-independent Rac1 activation (Inoue et al. 2009). Instead, the 
EphB2 cytoplasmic fragment can phosphorylate NMDA neurotransmitter receptors, 
which promotes their cell surface localization and may lead to a positive feedback loop 
by increasing NMDA receptor-mediated calcium currents (Litterst et al. 2007; Xu et al. 
2009). Interestingly, stress in mice can also cause cleavage of EphB2 by the extracellular 
serine protease neuropsin in the amygdala (Attwood et al. 2011). This cleavage results in 
EphB2 dissociation from the NMDA receptor as well as enhances NMDA receptor ion 
currents and the behavioral signatures of anxiety. Whether this may also be a 
consequence of NMDA receptor phosphorylation by a proteolytically released EphB2 
cytoplasmic fragment remains to be determined. 
Ephrin-B ligands can also undergo metalloprotease/γ-secretase processing 
following binding to EphB receptors. The released ephrin-B2 cytoplasmic fragment can 
promote Src activation and Src-dependent phosphorylation of uncleaved ephrin-B2, 
which is important for reverse signaling (Georgakopoulos et al. 2006). This involves 
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regulating the interplay between Src and the Csk-binding protein Cbp/PAG, an adaptor 
that controls Src activity (Georgakopoulos et al. 2011). Moreover, ephrin-B1 cytoplasmic 
fragments present in the developing mouse brain can associate with the ZHX2 
transcriptional repressor and enhance its activity in the nucleus to prevent neural 
progenitor differentiation (Wu et al. 2009).  
 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	    
 
Figure 7: (A) Roles of the ADAM10 metalloprotease in Eph receptor/ephrin signaling. (B) 
Inhibition of Eph receptor forward signaling by cis interaction with ephrins. (C) Ephrin-
independent Eph receptor signaling. 
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2.4.2- Ephrin-Mediated Cis Attenuation of Eph Receptor Forward 
Signaling 
 
Eph receptors and ephrins can be co-expressed in normal and cancer cells (Carvalho et al. 
2006; Pasquale 2010; Kao and Kania 2011). In contrast to the autocrine signaling 
occurring when other RTKs and their soluble ligands are co-expressed (Zwick et al. 
2002), a lateral cis interaction between Eph receptors and ephrins on the same cell 
surface can attenuate forward signaling (Bohme et al. 1996; Yin et al. 2004) (Fig. 7B). 
For example, EphA cis attenuation plays a role in topographic mapping of retinal axons 
(Hornberger et al. 1999; Carvalho et al. 2006) and ephrin-B3 inhibits signaling by EphB2 
co-expressed in hippocampal synapses, decreasing tyrosine phosphorylation of NMDA 
neurotransmitter receptors (Antion et al. 2010). Ephrins also cause cis attenuation of 
EphA and EphB signaling in spinal cord motor neuron populations where they are highly 
expressed, which is important for proper axon guidance in the limb (Kao and Kania 
2011). In contrast, in motor neuron populations where they are present at lower levels, 
ephrin-As segregate in different membrane microdomains than the co-expressed EphA 
receptors (Marquardt et al. 2005; Kao and Kania 2011). This segregation allows parallel 
activation of forward and reverse signaling in the same neurons. Biochemical and 
structural studies have implicated the second Eph receptor fibronectin type III domain in 
the cis interaction (Carvalho et al. 2006; Seiradake et al. 2010) (Fig. 7B). Consistent with 
this, an ephrin-A5 mutant that cannot engage the EphA ephrin-binding pocket was shown 
to still induce cis attenuation (Bohme et al. 1996; Carvalho et al. 2006; Kao and Kania 
2011). However, how cis binding inhibits forward signaling remains unclear. While a 
mechanism involving decreased Eph receptor cell surface localization seems unlikely 
(Yin et al. 2004; Carvalho et al. 2006), the association with co-expressed ephrins might 
induce Eph receptor translocation to an environment rich in phosphotyrosine 
phosphatases or sterically inhibit Eph receptor clustering, which is necessary for 
activation. Through cis attenuation of Eph receptor forward signaling, co-expressed 
ephrins can fine-tune the responsiveness of cells to ephrins in trans beyond what is 
achieved by mere regulation of Eph receptor levels.  
 
 
2.4.3- Ephrin-independent activities of Eph receptors 
 
In addition to their ephrin-dependent activities, the Eph receptors can signal 
independently of ephrin ligands, for example through crosstalk with other receptor 
systems and cytoplasmic signaling molecules. Ephrin-independent signaling can have 
opposite effects compared to ephrin-dependent signaling, as exemplified by EphA2. This 
receptor is widely upregulated in many cancers, which often correlates with low ephrin-A 
expression or failure of co-expressed ephrin-As to activate forward signaling (Zelinski et 
al. 2001; Macrae et al. 2005; Wykosky et al. 2005; Pasquale 2010; Tandon et al. 2011). 
This is consistent with the ability of EphA2 forward signaling to inhibit the Ras-Erk, Akt-
mTORC1 and other oncogenic pathways. However, EphA2 overexpression can induce 
oncogenic transformation, suggesting that this receptor also has tumor-promoting 
activities that may not depend on ephrin binding (Zelinski et al. 2001; Tandon et al. 2011; 
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Udayakumar et al. 2011). Recent studies have begun to unravel the mechanism of tumor 
promotion by EphA2. In cancer cells where Akt is highly activated by oncogenic 
mutations or growth factor stimulation, EphA2 is phosphorylated at S897 by Akt, which 
leads to an increase in cell migration/invasion that is independent of both ephrin binding 
and EphA2 kinase activity (Miao et al. 2009) (Fig. 7C). Other stimuli increasing Akt 
activation also cause S897 phosphorylation. For example, binding of extracellular Hsp90 
to the LRP1 receptor induces Akt-dependent EphA2 S897 phosphorylation and 
association of EphA2 with LRP1, leading to glioblastoma cell invasiveness (Gopal et al. 
2011). Moreover, ephrin-B3 expression in lung cancer cells can enhance the levels of 
EphA2 in its S897 phosphorylated form, concomitant with increasing resistance to γ-
radiation (Stahl et al. 2011). Since ephrin-B3 has poor affinity for the ephrin-binding 
pocket of EphA2 (Gale et al. 1996), it will be interesting to investigate the connection 
between ephrin-B3 and EphA2 phosphorylation.  
Remarkably, EphA2 seems to be at least in part responsible for the proliferative, 
migratory and tumorigenic activities of the EGF RTK family, as shown in several 
cultured cancer cell lines and in a mouse ErbB2 mammary tumor model (Larsen et al. 
2007; Brantley-Sieders et al. 2008; Hiramoto-Yamaki et al. 2010; Argenzio et al. 2011). 
EGF stimulation can promote the association of EphA2 with the Rho-GEF Ephexin4, and 
it will be interesting to investigate the involvement of S897 phosphorylation in this 
ephrin-independent association (Hiramoto-Yamaki et al. 2010). The EphA2-Ephexin4 
interaction promotes RhoG activation and recruitment of the RhoG-GTP-binding protein 
ELMO2 and the Rac-GEF DOCK4 to EphA2, leading to Rac1 activation and cancer cell 
invasiveness (Fig. 7C). The EphA2-Ephexin4-RhoG pathway also suppresses cell death 
due to detachment from the extracellular matrix (anoikis) in epithelial and cancer cells 
(Harada et al. 2011). This involves activation of PI3 kinase and Akt, which might also 
create a positive feedback loop further enhancing EphA2 S897 phosphorylation. 
Overexpression of EphB3 was also recently shown to promote lung cancer cell 
tumorigenicity through a kinase independent mechanism (Ji et al. 2011). It will be 
important to investigate the full extent of ephrin- and kinase-independent activities of 





Phosphotyrosine phosphatases can modulate the Eph receptor/ephrin system by 
terminating forward signaling and favoring tyrosine phosphorylation-independent 
activities. For	  instance,	  the	  cytoplasmic	  phosphatase	  LMW-­‐PTP	  can	  dephosphorylate	  EphA2,	   thus	   counteracting	   the	   tumor	   suppressive	   effects	   of	   EphA2	   forward	  signaling	   and	   promoting	   cell	   transformation	   (Kikawa	   et	   al.	   2002;	   Chiarugi	   et	   al.	  2004;	   Parri	   et	   al.	   2005).	   Similarly,	   the	   cytoplasmic	   phosphotyrosine	   phosphatase	  PTP1B	   can	   attenuate	   ephrin-­‐induced	   EphA3	   phosphorylation,	   endocytosis	   and	  repulsive	   effects	   (Nievergall	   et	   al.	   2010),	  while	   elevated	   endogenous	   phosphatase	  activity	  in	  pre-­‐B	  leukemia	  cells	  can	  switch	  the	  EphA3-­‐mediated	  response	  to	  ephrins	  from	   repulsion	   to	   adhesion	   (Wimmer-­‐Kleikamp	   et	   al.	   2008).	   In	   addition,	   PTP1B	  anchored	   to	   the	   endoplasmic	   reticulum	   has	   been	   reported	   to	   dephosphorylate	  EphA2	  at	  sites	  of	  cell-­‐cell	  contact	  where	  the	  endoplasmic	  reticulum	  comes	  in	  close	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proximity	  to	  the	  plasma	  membrane	  (Haj	  et	  al.	  2012).	  Phosphatase	  activity	  induced	  by	   glucose	   in	   pancreatic	   β-­‐cells	   attenuates	   EphA	   phosphorylation	   and	   forward	  signaling,	  which	  are	  inhibitory	  for	  insulin	  secretion	  (Konstantinova	  et	  al.	  2007).	  The	  protein	  tyrosine	  phosphatase	  receptor	  type	  O	  can	  dephosphorylate	  both	  EphA	  and	  EphB	   receptors,	   and	   it	   targets	   in	   particular	   the	   second	   of	   the	   two	   conserved	  phosphotyrosine	  residues	  in	  the	  juxtamembrane	  domain,	  which	  is	  the	  most	  critical	  for	   activation	   (Shintani	   et	   al.	   2006).	   The	  LAR protein tyrosine phosphatase receptor 
can dephosphorylate EphB2, and LAR downregulation by the FGF RTK results in 
increased ephrin-independent EphB2 tyrosine phosphorylation (Poliakov et al. 2008). LMW-­‐PTP	   is	   also	   involved	   in	   EphB	   receptor	   signaling,	   being	   recruited	   to	   EphB	  clusters	   to	   promote	   cell	   attachment	   (Stein	   et	   al.	   1998).	   However,	   it	   is	   not	   known	  whether	   this	   involves	   EphB	   receptor	   dephosphorylation	   by	   the	   phosphatase. Furthermore,	  the	  lipid	  phosphatase	  Ship2	  can	  interact	  with	  EphA2	  and	  decrease	  its	  ephrin-­‐dependent	   tyrosine	   phosphorylation,	   internalization	   and	   degradation	  through	   a	   mechanism	   likely	   not	   involving	   direct	   receptor	   dephosphorylation	  (Zhuang	  et	  al.	  2007;	  Lee	  et	  al.	  2012).	  Other phosphotyrosine phosphatases, such as the 
PDZ domain-containing PTP-BL, dephosphorylate ephrin-Bs to terminate reverse 
signaling (Palmer et al. 2002). Future studies will likely implicate additional 
phosphatases, including serine/threonine phosphatases (Yang et al. 2011), in the 
regulation of Eph receptor/ephrin signaling. 
 
 
2.5- GENE MUTATIONS 
 
Given the importance of the Eph receptor/ephrin system in developmental processes and 
adult tissue homeostasis, it is not surprising that its aberrant functioning has been 
implicated in a variety of diseases (Pasquale 2008; Pasquale 2010). In particular, somatic 
and germline mutations in Eph receptors and ephrin genes are beginning to be linked to 
cancer and other pathologies. Large scale sequencing of tumor specimens identified 
somatic mutations in all the Eph receptors, with frequencies of up to 2-6% for some Eph 
receptors in lung cancer and melanoma (Ding et al. 2008; Prickett et al. 2009; Peifer et al. 
2012) (http://www.sanger.ac.uk/genetics/CGP/cosmic/). The mutations are scattered 
throughout the Eph receptor domains (Fig. 8), and their functional consequences are 
mostly unknown. However, many of the nearly 40 missense mutations identified in 
EphA3, the receptor found to be most highly mutated in cancer, have been recently 
shown to cause various degrees of loss-of-function through multiple mechanisms 
(Lisabeth et al. 2012; Zhuang et al. 2012). Most mutations in the ephrin-binding domain 
and the neighboring sushi domain impair ephrin binding either by directly affecting the 
high affinity ephrin-binding pocket or by causing overall conformational alterations. 
Mutations in the EphA3 kinase domain inhibit receptor tyrosine phosphorylation and 
kinase activity. A further consequence of many EphA3 mutations is a reduction in cell 
surface localization, which suggests that the mutations cause misfolding and/or alter 
receptor trafficking.  
These findings suggest that the mutations disrupt a tumor suppressive function of 
EphA3 that depends on ephrin binding and kinase activity and, thus, forward signaling. 
The EphA3 cancer mutations indeed have different characteristics compared to mutations 
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in other RTK families, which are typically clustered in “hot spots” and promote 
constitutive activation and tumorigenesis (Lee et al. 2006; Sharma et al. 2007; Greulich 
and Pollock 2011). Furthermore, wild-type EphA3, but not several mutants identified in 
tumor specimens, can suppress lung cancer cell growth in a mouse xenograft models of 
lung cancer (Zhuang et al. 2012). Two mutations in EphA6 and EphA7 correspond to 
inactivating mutations in EphA3, suggesting that these Eph receptors may also suppress 
tumorigenesis (Lisabeth et al. 2012). EphB2 inactivating mutations identified in prostate 
cancer also suggested a tumor suppressor role for this receptor, consistent with the 
growth inhibition induced by EphB2 overexpressed in DU145 prostate cancer cells 
(Huusko et al. 2004). However, other Eph receptors like EphA2 or EphA4 do not seem to 
be frequently mutated in cancer, perhaps suggesting differences in the oncogenic 
activities of these receptors. A mutation in the first FNIII domain of EphA2 identified in 
lung cancer has indeed been proposed to promote invasiveness and survival (Faoro et al. 
2010). 
                       
 
Figure 8: EphA3 receptor somatic mutations in cancer. 
 
Although classical tumor suppressors are typically inactivated by homozygous 
mutations, most of the EphA3 inactivating mutations are heterozygous (Lisabeth et al. 
2012). Hence, the EphA3 mutants may act as dominant negatives, disrupting the function 
of the wild-type receptor (Zhuang et al. 2012) and possibly other Eph receptors that may 
be part of the same signaling clusters. Furthermore, concurrent mutations in multiple Eph 
receptors have been found in a relatively high proportion of tumor samples, suggesting 
that they may be advantageous for tumor cells by more severely disrupting signaling in 
Eph receptor clusters than a single mutation (Lisabeth et al. 2012).  
Germline mutations in Eph receptors and ephrins also play a role in human 
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disease. For instance, EphA2 mutations enhancing basal receptor activation or possibly 
increasing EphA2 association with the LMW-PTP phosphatase have been associated with 
cataract development (Shiels et al. 2008; Jun et al. 2009; Zhang et al. 2009b). Inactivating 
mutations in the X-linked ephrin-B1 gene cause craniofrontonasal syndrome due to 
inhibition of gap junctional communication and improper tissue boundary formation in 
the developing skull (Bush and Soriano 2010; Makarov et al. 2010; Zafeiriou et al. 2011). 
On the other hand, loss of function EphA4 mutations in amyotrophic lateral sclerosis 
patients are associated with long survival (Van Hoecke et al. 2012) and single nucleotide 
polymorphisms in various Eph receptors and ephrins have been implicated as modifiers 
in the pathogenesis of amyotrophic lateral sclerosis as well as Parkinsons’s disease 
(Lesnick et al. 2008). Furthermore, a common EphA1 polymorphism was recently 
associated with late-onset Alzheimer’s disease (Naj et al. 2011) and an EphA6 
polymorphism with responsiveness to an anti-schizophrenic drug (Ikeda et al. 2010). 
Studies on the functional effects of Eph receptor and ephrin mutations and 
polymorphisms will undoubtedly provide a wealth of new information on the 
physiological and pathological roles of this intriguingly complex signaling system.  
 
 
2.6- CONCLUDING REMARKS 
 
Understanding signaling by the Eph RTK family has been challenging due to the many 
idiosyncrasies that distinguish it from the other RTK families. The peculiar 
characteristics of the Eph RTKs include the membrane-bound nature of the ephrins, the 
bidirectional mode of Eph receptor-ephrin signaling, the ability of the ephrins to 
stimulate but also attenuate Eph receptor signaling, and the ability of the Eph receptors to 
signal without ephrin involvement and even independently of kinase activity. Given the 
emerging view that different co-expressed Eph receptors signal cooperatively (Janes et al. 
2011), to correctly interpret the results of signaling studies it will be important to profile 
the entire repertoire of Eph receptors present in a biological system (Noberini et al. 
2012b) as well as survey their post-translational modifications, including tyrosine and 
serine/threonine phosphorylation and ubiquitination. Systems biology approaches are also 
essential for a comprehensive understanding of the complexities of Eph receptor 
signaling networks and feedback loops, and the ability of these receptors to produce 
widely different biological outcomes (Jorgensen et al. 2009; Bush and Soriano 2012). In 
vivo analysis of Eph receptor/ephrin signaling as well as perturbations by designed or 
naturally occurring mutations and gene deletions will be critical to elucidate Eph 
receptor/ephrin physiological functions in the complex in vivo environment. Many 
fascinating activities of the Eph/ephrin system are only beginning to be appreciated, 
including key roles in stem cell biology (Genander and Frisen 2010) and in diseases such 
as Alzheimer’s (Cisse et al. 2011; Hollingworth et al. 2011), or their emerging ability to 
regulate microRNAs (Arvanitis et al. 2010; Bhushan and Kandpal 2011; Khodayari et al. 
2011) and gene transcription (Lai et al. 2004; Bong et al. 2007; Bush and Soriano 2010; 
Parrinello et al. 2010; Bush and Soriano 2012). Resolution of the paradoxes that plague 
our understanding of Eph receptor/ephrin function will enable effective exploitation of 
the many therapeutic opportunities that the Eph/ephrin system offers (Pasquale 2010; 
Noberini et al. 2012a).   
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3- RECEPTOR-LIGAND CIS-INTERACTIONS IN 
THE NERVOUS SYSTEM  
 
 
Several juxtacrine signaling systems in addition to the Eph-ephrin system exhibit 
inhibitory cis-interactions between receptor and ligand co-expressed in the same cell. 
These interactions have been observed mainly in the nervous system and in the immune 
system and they result in the attenuation of receptor activation by the ligand in trans 
(Nitschke 2009; Ware and Sedy 2011; Yaron and Sprinzak 2012). The receptor-ligand 
cis-inhibition mechanism has been identified in three different families of proteins that 
play an important role in the development of the nervous system: Notch-
Delta/Serrate/DSL, Eph-ephrin and plexin-semaphorins. 
 
 
3.1- CIS-INHIBITION IN THE NOTCH SIGNALING 
PATHWAY 
 
The Notch signaling pathway is important for the regulation of neuronal differentiation 
during neurogenesis and neuronal plasticity in the adult nervous system. It is involved in 
the neurogenesis process in both central and peripheral nervous system (Gaiano and 
Fishell 2002; Kageyama et al. 2008; Alberi et al. 2011; Kuzina et al. 2011; Lieber et al. 
2011). 
The Notch receptor family comprises four members, Notch1, Notch2, Notch3 and 
Notch4, which are conserved type I transmembrane proteins that recognize three different 
transmembrane ligands, Delta, Serrate and LAG-2 (DSL). Following the interaction in 
trans with the ligand, the Notch receptor is cleaved at two different sites near the cell 
membrane and the intracellular portion of the receptor translocates to the nucleus where it 
serves as a co-transcription factor to activate downstream genes target (Fig. 9a). Instead, 
the coexpression of the ligand and the Notch receptor in the same cell causes cis-
inhibition of the receptor and consequently blocks Notch signaling (Fig. 9b) (Bray 2006; 
Artavanis-Tsakonas and Muskavitch 2010; Yaron and Sprinzak 2012).  
Evidence of Notch pathway inhibition by different expression levels of ligand was 
initially reported in Drosophila. It was observed that during wing development, the Notch 
ligand Serrate has a dominant negative effect on the activity of Notch that depends on its 
level of expression. Excess of Serrate can attenuate Notch activation and this effect can 
be suppressed by Notch overexpression. Therefore, during wing development the control 
of Serrate expression is important for the regulation of Notch activation that leads to a 




           
 
Figure 9: Notch signaling. a: Notch receptor activation by interaction in trans with the ligand. b: 
Notch receptor silencing by interaction in cis with the ligand co-expressed in the same cell 
(Becam et al. 2010; Yaron and Sprinzak 2012). 
 
A recent study has shown that the Notch receptor cis-inhibition by Delta ligand 
coexpression in the same cell regulates cellular differentiation in the Drosophila 
ommatidia, guiding photoreceptor precursor cells through their distinctive final fate 
(Miller et al. 2009). During development the neuronal photoreceptor precursors (R) are 
organized in a group of equivalent cells. All the cells express the Notch receptor but 
different levels of Delta ligand. In the precursor cells with higher Delta levels the Notch 
receptor is silenced, and consequently the cells adopt the R1 or R6 fate. In the precursor 
cells with lower Delta level, the Notch receptor is activated by Delta ligand in trans and 
the cells adopt the R7 fate (Fig. 10). In a mutant precursor cell lacking Delta (R1 Dl-/-), 
the Notch receptor cannot be silenced by Delta and the cell adopts an erroneous fate 
instead of the R1 fate. Thus, the cis-inhibition of Notch is important for regulation of 
Delta-mediated unidirectional signaling (Fig. 10) (Miller et al. 2009; Yaron and Sprinzak 
2012).  
Sprinzak et al. developed a mathematical model using a quantitative cell culture 
assay in which Notch signaling response to both cis and trans Delta was mapped in order 
to explain the formation of the wing veins in Drosophila (Sprinzak et al. 2011). 
According to this model, the cells can be either sender or receiver depending on the 
relative level of receptor and ligand expression on their surface. A cell with high ligand 
expression is a sender cell, which can send signals but cannot receive them. A cell with 
high receptor expression is a receiver cell, which can receive signals but cannot send 
them. The two states are mutually exclusive and when ligand and receptor are expressed 
at the same level there is no signaling in the cell. When the receptor is uniformly 
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expressed across a tissue and the ligand is expressed in a gradient, the cells in the tissue 
divide in two distinct regions with a sharp boundary defined by the transition between 
sender and receiver cells. This model explains how Notch cis-silencing by Delta ligand 
co-expression regulates the formation of the Drosophila wing veins. Therefore, receptor-
ligand cis-inhibition generates an additional fine level of receptor modulation, which is 
important during cell differentiation (Klein et al. 1997; Klein and Arias 1998; Sprinzak et 
al. 2010; Yaron and Sprinzak 2012). 
 
 
Figure 10: Cis-inhibition model in the Drosophila ommatidia. During the differentiation of 
Drosophila ommatidia, Notch signaling in the R1 and R6 cells (pink) is inhibited by endogenous 
Delta co-expression. The Delta mutant precursor cell R1 Dl -/- lacks Notch cis-inhibition by the 
ligand and therefore adopts the R7 fate (blue) (Yaron and Sprinzak 2012). 
 
 
3.2- CIS-INHIBITION IN THE SEMAPHORIN SIGNALING 
PATHWAY 
 
Receptor-ligand cis-inhibition is also involved in the regulation of the axonal guidance 
process. During neuronal development, two signaling systems that are responsible for 
directing the growing axons towards specific guidance cues are the Eph-ephrin system 
and the semaphorins-plexin system (Yaron and Sprinzak 2012).  
The semaphorins are a large family of secreted and membrane-bound axon 
guidance molecules containing more than twenty genes in vertebrates, which are divided 
into five classes according to structural homology (Fig. 11). They are involved in diverse 
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developmental and biological events: repulsive axon guidance, neuronal migration, 
dendritic guidance, modulation of the immune system, tumor progression and 
angiogenesis.  
The semaphorins bind to two different families of receptors: the neuropilins and 
the plexins. The neuropilin family consists of two genes and neuropilins were the first to 
be identified as semaphorins receptors. They have a short intracellular domain, which 
makes them dependent on additional co-receptors for intracellular signaling. The plexins 
are a large family of transmembrane proteins, which are divided into four classes 
according to sequence similarity (A-D for vertebrate plexins). They are direct signal-
transducing elements for the semaphorins and co-receptors of the neuropilins (Fig. 11) 
(Trusolino and Comoglio 2002; Haklai-Topper et al. 2010; Yaron and Sprinzak 2012).  
 
 
Figure 11: Semaphorins and plexins. a: Schematic domain representation of the five classes of 
vertebrate semaphorins. b: Schematic domain representation of the four classes of vertebrate 
plexins (Trusolino and Comoglio 2002). 
 
It has been observed that sympathetic neurons, which express Plexin-A4, retract in the 
presence of the ligand samaphorin6A (Sema6A) (Haklai-Topper et al. 2010). In contrast, 
the dorsal root ganglion neurons (DRG, sensory neurons), which express not only Plexin-
A4 but also Sema6A, are not responsive to Sema6A. A recent study has shown that DRG 
explants from cells expressing wild type Sema6A were able to grow on a layer of COS7 
cells transfected with Sema6A or control plasmid. In contrast, elimination of Sema6A 
(Sema6A -/-) sensitized DRG neurons to respond to Sema6A and retract in a Plexin-A4 
dependent manner (Fig. 12). Thus, cis-inhibition of the Plexin-A4 receptor by the co-
expressed transmembrane ligand semaphorin attenuates the axonal response towards 





Figure 12: Plexin-A4 cis-inhibition by 
Sema6A coexpression in sensory neurons. 
Sensory neurons are not responsive to Sema6A 
in trans. In contrast, Sema6A-/- sensory neurons 
retract in response to Sema6A in trans (Yaron 













Sema6A and Plexin-A4 form a stable complex when co-expressed in the same cell. The 
cis-interaction between Sema6A and Plexin-A4 depends on the Sema domain of the 
Plexin-A4 receptor.  Coexpression of the ligand Sema6A and the receptor Plexin-A4 
inhibits the binding in trans of exogenous Sema6A ligands to Plexin-A4 through a 
mechanism that does not involve competition with the ligand in trans. Instead, it is 
possible that the cis-interaction may lock the receptor in a non-funtional conformation. 
Further studies need to be done in order to explain the biological function of semaphorin 




3.3- COMMON FEATURES OF THE CIS-INHIBITION 
MECHANISM 
 
The three distinct neuronal signaling systems, Notch-Delta, Eph-ephrin and plexin-
semaphorin present common features in the receptor-ligand cis-inhibition process. In 
vivo and in vitro studies demonstrated that coexpression of the ligands Delta, ephrin or 
Sema6A together with their respective receptor on the cell membrane precludes the 
binding of the ligand to the receptor in trans (Sakamoto et al. 2002; Carvalho et al. 2006; 
Haklai-Topper et al. 2010). 
The receptor later inhibition is a process occurring on the cell surface. Co-
immunoprecipitation and pull down experiments showed that the cis-interaction between 
ligand and receptor involves the extracellular domain of the receptor, but not necessarily 
the ligand-binding domain. Furthermore, biochemical studies demonstrated that co-
expression of the ligand does not decrease the level of receptor expression on the cell 
surface and cleavage of the ligand from the cell surface is able to restore the ability of the 
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receptor to be activated in trans (Hornberger et al. 1999; Sakamoto et al. 2002; Carvalho 
et al. 2006; Haklai-Topper et al. 2010).   
Although cis-inhibition between ligand and receptor has been observed in several 
signaling systems, the underlying mechanism is still not clear. It is possible that co-
expression of ligand and receptor on the same cell surface blocks the receptor clustering 
that is important for its activation or changes the conformation of the receptor 
extracellular domain disabling binding of the ligand in trans. Further experiments are 








In addition to the nervous system, receptor-ligand cis-interactions have been reported in 
the immune system. The herpes virus entry receptor protein HVEM can engage in either 
cis or trans interactions with its ligands, which lead to opposite signaling outputs. HVEM 
is a cell surface receptor of the TNF receptor superfamily and it was discovered as first 
entry route for the herpes simplex virus HSV. HVEM recognizes two different families of 
ligands, the TNF-related cytokines LIGHT (TNFSF14) and lymphotoxin-α (LTα) and 
the Ig superfamily members BTLA (B and T lymphocyte attenuator) and CD160. In 
addition, the herpes simplex virus HSV uses the envelope glycoprotein-D (gD) as a viral 
ligand for HVEM to infect epithelial cells. Inflammation and adaptive immune responses 
are regulated by a complex network of signaling pathways initiated by HVEM, the LTβ 
receptor and two receptors for TNF, which cross utilize the same ligand proteins.  
HVEM signaling is mainly controlled at the cell membrane. Similarly to the Eph 
receptors, the activation of HVEM by its ligands can generate bidirectional signaling. 
Moreover HVEM can also function as a ligand for BTLA. The soluble or membrane-
bound forms of a specific ligand and the cis and trans ligand-receptor interactions can 
control the initiation of inflammatory signaling pathways mediated by HVEM in T cells 
(Cheung et al. 2009; Ware and Sedy 2011).  
The ligand protein LIGHT can activate the receptor HVEM as a membrane-bound 
trimer or as a soluble form by binding in trans to the ectodomain of HVEM (Ware and 
Sedy 2011). In the same way, BTLA in the trans configuration can activate the receptor 
HVEM. The soluble form of ligand LIGHT can bind to the receptor together with BTLA, 
because the two ligands recognize different regions of the receptor ectodomain. In 
contrast, this is not possible with the membrane-bound form of LIGHT, which blocks 
BTLA binding to HVEM by an uncompetitive mechanism. In addition, CD160 in his 
trimeric form can activate HVEM in trans. Once activated, HVEM starts the TRAF2 E3 
ligase pathway, which culminates with the activation of the NFkB subfamily protein 






Figure 13: HVEM receptor cis and trans binding. On the left side of the figure: the binding in 
trans of the ligand proteins BTLA, CD160 and LIGHT activates HVEM signaling and the NFkB 
survival pathway. HVEM can also activate BTLA, generating bidirectional signals. On the right 
side of the figure: the cis-inhibition of HVEM by BTLA ligand coexpression blocks the binding 
in trans of other ligands to HVEM and therefore its signaling. 
 
It has been reported that HVEM and BTLA are constitutively co-expressed on the 
cell surface of naive human and mouse T cells, where they form a stable cis-complex. 
Mutations that affect the binding in trans of BTLA to HVEM also interfere with the 
binding in cis, demonstrating the involvement of the same receptor interface. The cis-
interaction between HVEM and BTLA prevents the binding in trans of the ligands BTLA 
and CD160 to the receptor and inhibits HVEM-dependent NFkB activation, maintaining 
the T cells in the naive state. The soluble form of the ligand LIGHT can bind to the 
receptor ectodomain within the cis-complex with BTLA, but cannot activate HVEM 
signaling. In contrast, the membrane-bound form of LIGHT can bind and activate the 
receptor, but much less compared to the level of activation observed when HVEM is 
expressed alone (Fig. 13). Interestingly, the viral protein gD can engage HVEM in a cis-
complex, but with an opposite effect to that of BTLA, since gD activates the NFkB 
signaling pathway. The cis-interaction of the viral gD protein with the HVEM receptor 
may induce a conformational change that activates the receptor and the cell survival 
signaling pathway, providing a selective advantage for the virus (Cheung et al. 2009; 
Ware and Sedy 2011). Further studies to understand the biological role of HVEM cis and 





5- EPH RECEPTORS AND CANCER 
 
 
The Eph receptors play an important role in the regulation of fundamental cellular 
processes, like axon guidance, homeostasis and cell development. A growing body of 
evidence has implicated Eph receptor and ephrin signaling in oncogenic processes, 
including cell proliferation, invasion, metastasis and tumor angiogenesis (Pasquale 2005). 
Beside the Eph-ephrin system, other signaling molecules involved in axon guidance have 
recently been linked to cancer, for example Notch and Delta, semaphorins and plexins, 
VEGF and the VEGF receptor (Chen 2012). 
The role of the Eph-ephrin system in cancer is complex and controversial. Recent 
studies have shown that Eph receptor expression levels are often dysregulated in cancer 
(Pasquale 2010). Both increased and decreased receptor expression level can be linked to 
carcinogenesis. Furthermore, the Eph receptors can both promote and inhibit cancer 
progression depending on the presence of their ligand or cross-talk with other proteins. 
For example, EphA2 and EphB4 upregulation has been linked with cancer progression 
and tumor malignancy in several tumor types. In contrast, decreased expression levels of 
EphA1 and EphB6 have been observed in colorectal and lung cancer respectively. Eph 
receptor downregulation can be a secondary step that manifests in advanced stages of 
cancer after an initial cancer initiation process with higher expression level. This 
downregulation can be due to epigenetic silencing, chromosomal alterations and 
modifications of mRNA stability (Pasquale 2010).  
Somatic mutations in numerous Eph receptors have also been identified in most 
cancers. The EphA3 receptor is one of the most mutated in human lung adenocarcinoma. 
The Eph receptor mutations are scattered throughout the entire receptor gene and is still 
not clear if some are “driver” mutations of cancer pathogenesis. Nevertheless, the 
participation of the Eph receptors in cancer progression makes them promising 
therapeutic targets (Pasquale 2010; Chen 2012). 
 
 
5.1- PRO AND ANTI- ONCOGENIC ROLES OF EPHA2 
 
The expression and function of the EphA2 receptor are often altered in human cancers. 
This protein is highly expressed in most cancer cell types, like breast, colon, prostate and 
lung cancer. EphA2 overexpression has also been linked to malignant progression in 
glioblastoma multiforme (GBM) (Ireton and Chen 2005). In human breast cancer and 
mouse skin cancer an unbalanced expression between the EphA2 receptor and his ligand 
ephrin-A1 has been observed. Indeed, the role of EphA2 as oncoprotein is independent of 
ephrin-ligand binding and kinase activity (Macrae et al. 2005; Miao et al. 2009). 
In contrast, EphA2 stimulation by its ephrin ligands inhibits integrin signaling and 
the RAS-MAP kinase pathway, which is often upregulated in malignant cancers, 
revealing EphA2 as a tumor suppressor protein (Miao et al. 2000; Pasquale 2010). 
Miao et al. (2009) analyzed the role of EphA2 in human glioma and described a 
possible cause for this controversial and dual role of EphA2 in cancer, linking this kinase 
receptor to the RTK-PI3K-Akt pathway, which regulates chemotactic cell migration 
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through cytoskeletal reorganization (Miao et al. 2009). In the absence of ephrin-A1 and 
in the presence of multiple growth factors, Akt phosphorylates the EphA2 receptor on 
serine S897 in the segment between the kinase and the SAM domain. This S897 
phosphorylation promotes assembly of the actin cytoskeleton and extension of 
lamellipodia, which is required for tumor cell invasion and malignant progression. 
Interestingly, the ligand-activated form of EphA2 negatively regulates Akt. Upon 
stimulation of EphA2 with ephrin-A1, Akt is inactivated and EphA2 is rapidly 
dephosphorylated at the S897 site with a resulting anti-oncogenic effect. The tumor 
suppressor role of EphA2 was observed even when the PTEN phosphatase is mutated and 
consequently the Akt-mTORC1 pathway is hyperactivated. This pathway promotes cell 
growth, migration and invasiveness and is regulated by the tumor suppressor lipid 
phosphatase PTEN. Ephrin-dependent activation of EphA2 causes dephosphorylation of 
Akt and inactivation of the Akt-mTORC1 oncogenic pathway, through a cross-talk 
mechanism with a PPI-like serine/threonine phosphatase (Yang et al. 2011). Miao et al. 
proposed a model for the EphA2 role in cancerogenesis whereby in the presence of the 
ephrin ligand the EphA2 receptor suppresses tumor development. However, in the 
presence of growth factors and in the absence of ephrin stimulation EphA2 is 
phosphorylated by Akt and promotes tumor progression and migration (Miao et al. 2009).  
In summary, activation of EphA2 can be a new route for the treatment of tumors 
where the PI3K/Akt and Akt-mTORC1 pathways are hyperactivated (Miao et al. 2009; 
Yang et al. 2011).  
 
 
5.2- THE MULTIFACETED ROLE OF EPHB4 IN CANCER 	  
EphB4 is another Eph receptor highly expressed in epithelial cells. This receptor is 
present in epithelial cells of human breast tissue and notably tyrosine phosphorylated in 
MCF-10A cells, which are a non-transformed epithelial cell line derived from human 
fibrocystic mammary tissue (Berclaz et al. 2002; Noren et al. 2006; Noren and Pasquale 
2007). EphB4 modulates with the Abl/Crk pathway, which regulates the maintenance of 
epithelial characteristics in MCF-10A cells (Noren et al. 2006). Like EphA2, EphB4 also 
has a dual role in cancer regulation. In several human breast cancer cell lines EphB4 
expression is upregulated, but the receptor is poorly activated. This may be the 
consequence of low ephrin-B2 expression. In these cells Abl is not activated and Crk 
functions as an adaptor protein, which promotes oncogenic transformation (Lamorte et al. 
2002). In contrast, EphB4 activation by a soluble form of ephrin-B2 (ephrin-B2 Fc) 
promotes the anti-oncogenic effect of the EphB4-Abl-Crk pathway, where Abl activated 
by EphB4 can inhibit cell invasion through inhibitory phosphorylation of Crk (Noren and 
Pasquale 2007). Furthermore, it has been shown that ephrin-B2 reverse signaling induced 
by EphB4 can promote angiogenesis and tumor progression (Noren et al. 2004).  
In summary, the available information regarding the role of EphA2 and EphB4 in 
cancer suggests that ephrin-Eph signaling is important for the maintenance of 
homeostasis in normal tissues and its disruption may be the cause of cell transformation 
and cancer progression (Noren and Pasquale 2007). 
Recent work has also shown that ephrin-B2-mediated activation of EphB4 has a 
completely opposite outcome in cell growth and regulation of the MAP kinase pathway 
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in other cellular contests (Xiao et al. 2012). This apparent paradox of EphB4 signaling is 
explained by the engagement of different downstream effector molecules in distinct cell 
types. In human umbilical vein endothelial cells (HuVECs), EphB4 stimulation by 
ephrin-B2 engages the protein p120 RasGAP and promotes inactivation of the MAP 
kinase signaling pathway leading to suppression of cell growth. Interestingly, upon 
ephrin-B2 treatment of MCF7 breast cancer cells, EphB4 promotes MAP kinase (Erk1/2) 
activation and cell growth through PP2A, an essential serine/threonine phosphatase that 
removes the inhibitory phosphorylation of c-Raf and consequently upregulates Erk1/2 
(Fig. 14).  
 
 
             
 
Figure 14: Model of EphB4 signaling effects on the MAP kinase (Erk1/2) pathway upon 
ephrin-B2 Fc stimulation in HuVEC and MCF7 cells (Xiao et al. 2012). 
 
Further research is needed to better understand the controversial role of EphB4 in 
different types of cancer and cellular contests in order to develop appropriate EphB4-
targeted cancer therapies. 
 
 
5.3- EPHA3 AND CANCER 
 
Among all Eph receptors, EphA3 is one of the most frequently mutated in lung cancer 
together with EphA5. Currently about sixty EphA3 missense mutations have been 
identified just in lung cancer samples, but many others have also been reported in other 
cancers, for example glioblastoma, melanoma, pancreatic and colorectal cancer 
(COSMIC http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/) (Bardelli et al. 
2003; Balakrishnan et al. 2007; Corbo et al. 2010). The mutations are scattered 
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throughout the entire EphA3 gene and the functional implications of some of the 
mutations have been studied (Fig. 15) (Lisabeth et al. 2012; Zhuang et al. 2012). 
 
      
 
Figure 15: EphA3 domain structure with some of the somatic cancer mutations identified. 
In orange: EphA3 lung cancer mutations. In black: Different cancer mutations. In blue: control 
mutations known to interfere with ephrin-binding (T102Q) and kinase activity (K653R) (Lisabeth 
et al. 2012). 
 
Several EphA3 mutations in the ephrin-binding domain disrupt the normal 
conformation of the domain and reduce the binding of the ephrins to the receptor. Some 
of these mutations diminish receptor surface localization, impairing the physiological 
EphA3-ephrin cell-cell communication system. In addition, few mutations localized 
within the cysteine-rich region also can affect the conformation of the receptor ligand-
binding domain reducing the binding of ephrin-A5 to EphA3. Interestingly, some 
mutations localized in the fibronectin type III domains alter the lateral interaction 
between EphA3 and the ligand, and may affect receptor silencing by co-expressed 
ephrins (see Chapter 2, paragraph 2.4.2). Finally, mutations localized in the conserved 
EphA3 kinase domain completely abolish the kinase activity of the receptor (Lisabeth et 
al. 2012).  
Although the role of EphA3 in cancer is still not well defined, these loss-of-
function mutations, which impair the signaling ability of the receptor, suggest that EphA3 
may be a tumor suppressor. In support of this hypothesis, it has been reported that in lung 
cancer cells EphA3 wild-type re-expression increases cellular apoptosis by suppressing 
Akt activation as well as inhibits tumor growth in vivo (Zhuang et al. 2012). In addition, 
in some hematopoietic tumors and in colorectal cancer, the EphA3 promoter is silenced 
by methylation (Dottori et al. 1999; Hinoue et al. 2009; Lisabeth et al. 2012).  
However, high EphA3 expression has been reported in some tumor specimens 
(Guan et al. 2011; Valsesia et al. 2011; Day et al. 2013). Therefore, a tumor promoting 
role for EphA3 cannot be excluded. As in the case of the previously described EphA2 and 
EphB4 receptors, EphA3 may also have a dual role in carcinogenesis depending on 
ephrin ligand binding or cross-talk with other signaling proteins.  
Recent work has also shown that EphA3 is highly expressed in the mesenchymal 
subtype of glioblastoma multiforme (GBM). This subtype is particularly aggressive and 
contains undifferentiated tumor-initiating cells. EphA3 plays an active role in 
maintaining these cells undifferentiated by reducing MAP kinase signaling, which is 
normally capable of promoting differentiation of neuronal progenitors. Loss of EphA3 
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expression in these cells shifted the balance towards differentiation and reduced cell 
proliferation, suggesting that the development of an EphA3-based target therapy may be 
effective for the treatment of glioblastoma multiforme (Day et al. 2013). 
EphA3 is considered a promising target for anticancer therapies. However, it is 
still unclear how EphA3 expression and activity can interfere with the onset and 
progression of different tumors. Therefore, further studies are needed to shed light on this 
promising target and develop specific therapeutics approaches for different types of 
cancer. 
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6- AIM OF THE REASERCH 
 
 
Members of the large Eph receptor tyrosine kinase family, and particularly EphA2 and 
EphB4, are overexpressed in a wide variety of tumor types (Pasquale 2010; Lisabeth et 
al. 2013a). Eph receptors signal by interacting “in trans” with ephrins expressed on 
neighboring cells, which promotes receptor clustering, autophosphorylation and kinase 
activity (Pasquale 2005). Soluble forms of the ephrin-A ligands released from the cell 
surface by matrix metalloproteases can also activate EphA receptors (Bartley et al. 1994; 
Hattori et al. 2000; Alford et al. 2007; Beauchamp et al. 2012). However, Eph receptors 
in cancer cells are often poorly tyrosine phosphorylated (Pasquale 2005). This suggests 
low activation by ephrin ligands and is consistent with the tumor suppressing effects 
reported for a number of Eph receptor downstream signaling pathways (Miao et al. 2001; 
Pasquale 2010; Yang et al. 2011).  
The lack of substantial Eph receptor activation is in some cases due to low 
expression of ephrin ligands in cancer cells with high receptor expression (Batlle et al. 
2002; Macrae et al. 2005; Noren et al. 2006; Pasquale 2010; Ji et al. 2011). In addition, 
several other mechanisms can keep Eph receptor activation low in cancer cells that also 
express ephrin ligands. For example, cancer mutations have been shown to disrupt the 
ephrin binding ability or kinase activity of Eph receptors (Lisabeth et al. 2012; Zhuang et 
al. 2012). Furthermore, lack of E-cadherin-dependent cell-cell adhesion can impair 
EphA2 receptor activation in breast cancer cells, suggesting inefficient EphA2 trans 
interaction with ephrins (Zantek et al. 1999). Another potential mechanism to attenuate 
Eph receptor downstream signaling in cancer cells could involve inhibitory lateral cis 
interactions between Eph receptors and ephrins coexpressed in the same cells (Yin et al. 
2004; Carvalho et al. 2006; Lisabeth et al. 2013a). Inhibitory cis interactions with ephrins 
have been shown to play an important role in fine tuning Eph receptor activation in the 
nervous system to precisely control axon pathfinding and synaptic function (Hornberger 
et al. 1999; Carvalho et al. 2006; Antion et al. 2010; Pasquale 2010; Kao and Kania 
2011). However, cis interactions do not occur in all neurons coexpressing Eph receptors 
and ephrins because in some neurons receptors and ligands occupy distinct microdomains 
of the plasma membrane and thus cannot intermingle (Marquardt et al. 2005; Kao and 
Kania 2011). Whether cis interactions between Eph receptors and ephrins can also occur 
in cancer cells has not been previously investigated. 
Biochemical and structural studies have shown that cis interaction involves an 
Eph receptor-ephrin binding interface distinct from that mediating the high affinity 
interaction in trans (Carvalho et al. 2006; Seiradake et al. 2010). The extracellular region 
of both EphA and EphB receptor classes contains an N-terminal ligand-binding domain, a 
cysteine-rich region and two fibronectin type III domains (Pasquale 2005). The second 
fibronectin domain is followed by a transmembrane segment and a cytoplasmic region 
that includes the tyrosine kinase domain, a SAM domain and a PDZ-binding motif. The 
ephrins consist of an N-terminal Eph receptor-binding domain connected by a short linker 
region to a glycosylphosphatidylinositol (GPI) anchor for the ephrin-As and a 
transmembrane segment followed by a short cytoplasmic region for the ephrin-Bs. Eph 
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receptor-ephrin binding in trans mainly involves the interaction between the G-H loop of 
the ephrin and a pocket within the ligand-binding domain of the Eph receptor (Himanen 
et al. 2001). These interfaces predominantly support the promiscuous interactions of Eph 
receptors with ephrins belonging to the same A or B class. On the other hand, cis 
interactions have been proposed to involve the fibronectin type III domains of the Eph 
receptor and a region of the receptor-binding domain of the ephrin that is distinct from 
the G-H loop (Carvalho et al. 2006; Seiradake et al. 2010).  
Here we show that Eph receptors and ephrins coexpressed in cancer cells can 
engage in cis interactions that inhibit Eph receptor activation by ephrins in trans. 
Interestingly, we detected inhibition of EphA3 activation through cis interaction with not 
only ephrin-A3 but also ephrin-B2, which is not an activating ligand for EphA3 
(Flanagan and Vanderhaeghen 1998), suggesting that cis interactions do not exhibit the 
same receptor-ligand selectivity as trans interactions. We also found that a lung cancer 
mutation identified in the second fibronectin type III repeat of EphA3 enhances the cis 
association of the receptor with ephrin-A3 (Falivelli et al. 2013).  
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7- MATERIALS AND METHODS 
 
 
7.1- Plasmids and lentiviruses 
 
The human EphA3 cDNA was purchased from Invitrogen/Life Technologies (Carlsbad, 
CA; clone MGC:71556; GenBank accession number NP_005224.2), PCR amplified to 
include appropriate restriction sites and cloned in pcDNA3. EphA3 was also subcloned 
into the pLVX-IRES-ZsGreen lentiviral vector (Clontech Laboratories, Mountain View, 
CA). The truncated versions EphA3 ΔN, comprising a signal peptide followed by amino 
acids 318-984 of EphA3, was also generated by PCR amplification of full-length EphA3 
and cloned in pcDNA3. The EphA3 ΔN G518L mutant was similarly generated by PCR 
amplification from the previously described full-length EphA3 G518L mutant (Lisabeth 
et al. 2012). Mouse ephrin-A3 cDNA in pcDNA3, including nucleotides 40-744 
(GeneBank accession number NM_010108.1), was used as template to generate the 
ephrin-A3 E129K mutant using the QuickChange Site-Direct mutagenesis kit 
(Stratagene/Agilent Technologies, La Jolla, CA). The CS-Mm30127-Lv105-ephrin-A3 
lentivirus, with mCherry inserted between the signal peptide and the mature coding 
sequence of mouse ephrin-A3, and the EX-mCHER-Lv105 control lentivirus encoding 
mCherry were purchased from GeneCopoeia. The mouse mCherry-ephrin-A3 E129K 
mutant was generated in pcDNA3 using the QuickChange Site-Direct mutagenesis kit 
and subcloned in the pLVX-IRES-Neo lentiviral vector (Clontech Laboratories). Mouse 
ephrin-B2 (GeneBank accession number NM_010111.5) with an N-terminal EGFP tag 
inserted between a signal peptide and the mature coding sequence (Makinen et al. 2005; 
Salvucci et al. 2009) was cloned in the pCCLsin.PPT.hPGK.GFP. pre lentiviral vector 
(Follenzi and Naldini 2002) replacing the EGFP insert of the vector. The 
pCCLsin.PPT.hPGK.GFP. pre lentiviral vector encoding EGFP was used as a control. All 
PCR-amplified and mutated cDNAs were verified by sequencing. 
 
 
7.2- Cell culture, transfections and infections  
 
The human embryonic kidney (HEK) 293T cell line (ATCC, Manassas, VA), the HEK 
AD-293 cell line (Cell Biolabs, Inc.), which is a derivative of the HEK 293 cell line with 
increased adherence, the SKBR3 and MCF7 cell lines (ATCC) were grown in Dulbecco’s 
Modified Eagle’s Medium (DMEM; Cellgro, Manassas, VA) supplemented with 1 mM 
L-glutamine, 10% fetal bovine serum, 1 mM sodium pyruvate and antibiotics. The A549 
human lung adenocarcinoma and NCI-H226 human squamous cell carcinoma cell lines 
(ATCC) were grown in Roswell Park Memorial Institute (RPMI) culture medium with 
the same supplements used for DMEM.  
To activate EphA2 and EphA3 in lung cancer cells, the cells were stimulated for 
20 min in complete medium with 2 µg/ml ephrin-A3 Fc fusion protein (R&D Systems, 
Minneapolis, MN) or Fc (MP Biomedical, Solon, OH) preclustered with 1/10 polyclonal 
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goat anti-human Fc antibody (Jackson ImmunoResearch). To activate EphA2 in breast 
cancer cells, the cells were stimulated for 20 min with 0.5 µg/ml ephrin-A1 Fc or Fc 
without preclustering. In addition, some wells were pretreated for 4 hours with 1 U/ml PI-
PLC (Invitrogen/Life Technologies) and, in some experiments, some wells were 
pretreated for 24 hours with 100 µM GM-6001 (stock dissolved in DMSO; Enzo Life 
Sciences, Farmingdale, NY) or an equivalent DMSO concentration (0.4%) as a control. 
To activate EphB4, cells were stimulated for 20 min with 2 µg/ml ephrin-B2 Fc 
preclustered with 6 µg/ml anti-human Fc antibody. 
To produce alkaline phosphatase fusion proteins, plasmids encoding EphA3 AP, 
ephrin-A3 AP, ephrin-A5 AP or ephrin-B2 AP were transiently transfected in HEK293T 
cells using Lipofectamine 2000 (Invitrogen/Life Technologies) according to the 
manufacturer’s instructions. Plasmids encoding EphA3, EphA3 ΔN or EphA3 ΔN G518L 
were transiently transfected in HEK AD-293 cells using Lipofectamine 2000 and the cells 
were lysed one day after transfection. NCI-H226 and A549 cells were infected with the 
lentivirus encoding EphA3 and ZsGreen and FACS-sorted. The sorted cells were then 
infected with lentiviruses encoding mCherry-ephrin-A3 or mCherry and selected with 1 
µg/ml puromycin. Alternatively, the sorted cells were infected with lentiviruses encoding 
EGFP-ephrin-B2 or EGFP. HEK AD-293 cells infected with lentiviruses encoding 
mCherry-ephrin-A3 or mCherry were selected with puromycin while cells infected with 
the lentivirus encoding the mCherry-ephrin-A3 E129K mutant were selected with 1.5 
mg/ml G418 (Roche Applied Science, Indianapolis, IN). 
 
 
7.3- Immunoprecipitations, pull-downs and immunoblotting 
 
Cells were washed with cold phosphate-buffered saline (PBS) and lysed in modified 
RIPA buffer (50 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% Triton X-100, 0.5% sodium 
deoxycholate, 0.1% SDS, and 2 mM EDTA) or Triton-X100 buffer (50 mM Tris pH 7.5, 
150 mM NaCl, 1% Triton, 10% glycerol) with protease and phosphatase inhibitors. The 
cells were then briefly sonicated. 
For immunoprecipitations, cells lysed in modified RIPA buffer were precleared 
for 15 min at 4 ºC with GammaBind Plus sepharose beads and then incubated for 90 min 
at 4 ºC with 2.5 µg anti-EphA2 monoclonal antibody (clone D7; Upstate 
Biotechnology/Millipore, Lake Placid, NY), anti-EphA3 monoclonal antibody 
(Invitrogen/Life Technologies), an affinity-purified rabbit polyclonal anti-EphB4 
antibody to the human EphB4 C terminal region (Noren et al. 2004), or anti-dsRed 
polyclonal antibody (Clontech Laboratories) immobilized on GammaBind Plus sepharose 
beads (GE Healthcare Bio-Sciences, Piscataway, NJ). For coimmunoprecipitations, cells 
lysed in Triton X-100 buffer were precleared with GammaBind Plus sepharose beads and 
then incubated for 3 hours at 4ºC with 2.5 µg anti-EphA3 monoclonal antibody 
immobilized on GammaBind Plus sepharose beads.  
For pull-down of ephrin-A3 from cell culture medium and cell lysates, A549 and 
H226 cells were grown to confluency in 60 mm plates with 1.5 ml medium for 24 hours 
(A549 cells) or 48 hours (H226 cells). The conditioned medium was collected and the 
cells were washed with cold PBS and lysed in 1.5 ml modified RIPA buffer. Culture 
medium and cell lysates were precleared with GammaBind Plus sepharose beads and then 
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incubated for 1 hour at 4 ºC with 1 µg EphA3 Fc (R&D Systems) immobilized on 
GammaBind Plus sepharose beads.  
Immunoprecipitates, pull-downs and cell lysates were analyzed by 
immunoblotting with the following antibodies: anti-phosphotyrosine conjugated to 
horseradish peroxidase (HRP; BD Bioscience, San Jose, CA), anti-EphA3 rabbit 
polyclonal (sc-919, Santa Cruz Biotechnology, Dallas, TX), anti-EphA2 rabbit polyclonal 
(Invitrogen/Life Technologies), anti-EphB4 mouse monoclonal (Invitrogen/Life 
Technologies), anti-ephrin-A1 rabbit monoclonal (Abcam, Cambridge, MA), anti-ephrin-
A3 rabbit polyclonal (Santa Cruz Biotechnology), anti-ephrin-A3 chicken immune serum 
obtained by injecting a mouse ephrin-A3 Fc fusion protein including amino acids 31-213 
(Noberini et al. 2012b), rabbit anti-human Fc  (Jackson ImmunoResearch Laboratories, 
West Grove, PA), anti-dsRed rabbit polyclonal (Clontech Laboratories, Inc), and anti-
GFP rabbit polyclonal (Gentex). Incubation with primary antibodies was followed by 
incubation with anti-rabbit, anti-mouse or anti-chicken secondary antibodies conjugated 
to HRP (anti-rabbit and anti-mouse from Millipore, Billerica, MA, and anti-chicken from 
Sigma-Aldrich, St. Louis, MO) or fluorescently labeled anti-rabbit and anti-mouse 
secondary antibodies (Odyssey LI-COR, Lincoln, NE). Immunoblots were developed 
with ECL chemiluminescence HRP detection reagent (GE Healthcare) and the bands 
quantified using Photoshop. The Odyssey LI-COR system was used for detection in the 
immunoblots shown in Fig. 6, where the bands were quantified with Image Studio 
Software version 3.1.4. 
 
 
7.4- Production of AP fusion proteins and AP cell binding 
assays 
 
Culture medium containing the secreted AP fusion proteins was concentrated using 
Amicon Ultra Centrifugal filters (Millipore, Billerica, MA) and the concentration of the 
AP fusion proteins was estimated from AP activity measurements (Lisabeth et al. 2012). 
Assays to measure binding of EphA3 AP or ephrin AP proteins to cells were carried out 
as previously described (Lisabeth et al. 2012). The cells were washed once with cold 
Hanks’ balanced salt solution (HBAH) containing 0.5 mg/ml bovine serum albumin, 
0.1% NaN3 and 20 mM HEPES pH 7.0 and then incubated for 90 min with 12 nM of AP 
fusion protein followed by 6 washes with cold HBAH. The cells were then lysed in 1% 
Triton X-100, 10 mM Tris-HCl pH 8.0 at room temperature, centrifuged at maximum 
speed in an Eppendorf benchtop microcentrifuge, and the supernatants were heated at 
65ºC for 10 min to inactivate endogenous alkaline phosphatase. AP fusion proteins bound 
to the cells were quantified by measuring the absorbance of the cleaved p-nitrophenyl 
phosphate chromogenic substrate (Pierce/Thermo Scientific, Rockford, IL).  
 
 
7.5- Cell surface biotinylation  
 
To biotinylate cell surface proteins, A549 cells were first kept at 4 ºC for 10 min to block 
endocytosis. The cells were then incubated with 0.5 mg/ml of EZ-link SulfoNHS-LC-
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Biotin (Pierce/Thermo Scientific) in PBS for 30 min at 4ºC, followed by two washes with 
cold PBS and incubation in quenching buffer (100 mM glycine in PBS) for 14 min at 4 
ºC. The cells were then lysed in modified RIPA buffer. For quantification of cell surface 
(biotinylated) EphA3, protein A-coated 96-well plates were incubated with 100 µl anti-
EphA3 polyclonal antibody recognizing an epitope in the cytoplasmic region of the 
receptor (Santa Cruz Biotechnology) at a final concentration of 0.5 µg/ml, washed to 
remove unbound antibody, then incubated for one hour with cell lysates and washed. 
EphA3 biotinylation was measured using a streptavidin-HRP conjugate (Pierce/Thermo 
Scientific) with 2,2'-azino-bis[3-ethylbenzothiazoline-6-sulphonic acid] (ABTS)  
chromogenic substrate followed by quantification of optical absorbance at 405 nm. For 
quantification of cell surface ephrin-A3, proteins on the surface of A549 cells were 
similarly biotinylated. The cells were then lysed in RIPA buffer, mCherry-ephrin-A3 was 
immunoprecipitated with dsRed antibody, and the immunoprecipitates were probed with 
a streptavidin-HRP conjugate.   
 
 
7.6- Statistical analyses 
 
All statistical analyses were performed with the Program Prism from GraphPad Software 







8.1- Ephrin-A3 coexpression in cancer cells attenuates EphA 
receptor activation in trans by soluble ephrin-A3 
 
To investigate the effect of ephrin coexpression on Eph receptor signaling in cancer cells, 
we examined EphA3 (an Eph receptor for which inhibitory cis interactions with ephrin-
As have been extensively studied in neurons (Yin et al. 2004; Carvalho et al. 2006; Kao 
and Kania 2011)) and EphA2 (the EphA receptor most widely expressed in cancer cells 
(Wykosky and Debinski 2008; Pasquale 2010; Biao-Xue et al. 2011; Tandon et al. 2011) 
but for which the effects of cis interactions were not previously investigated). We 
infected the NCI-H226 and A549 lung cancer cell lines with lentiviruses encoding EphA3 
and ZsGreen from a bicistronic transcript or only ZsGreen as a control. After selection by 
FACS sorting, we further infected the cells with lentiviruses encoding ephrin-A3 tagged 
with mCherry or only mCherry as a control, followed by selection. The two lentivirally 
infected cancer cell lines, which do not express detectable endogenous EphA3 or ephrin-
A3 (Figure 1), were then treated with ephrin-A3 Fc (a soluble form of the ephrin-A3 
ligand fused to the Fc portion of human IgG1) to activate EphA3 through ephrin binding 
in trans. Ephrin-A3 Fc increased receptor tyrosine phosphorylation in the cells 
coexpressing EphA3 with control mCherry, as expected, but not in the cells coexpressing 
EphA3 with mCherry-ephrin-A3 (Figure 1A,B). Ephrin-A3 coexpression also attenuated 
ephrin-A3 Fc-induced activation of endogenous EphA2 in A549 cells (Figure 1C). Thus, 








Figure 1. Coexpressed ephrin-A3 attenuates EphA receptor activation in cancer cells. (A,B) 
NCI-H226 and A549 lung cancer cells were infected with a lentivirus encoding EphA3 and 
ZsGreen alone or together with a lentivirus encoding mCherry-ephrin-A3; control cells were 
infected with lentiviruses encoding ZsGreen and mCherry. EphA3 immunoprecipitates were 
probed by immunoblotting for phosphotyrosine (PTyr) and reprobed for EphA3. Lysates were 
probed for mCherry-ephrin-A3 with an anti-dsRed antibody that also recognizes mCherry, for 
EphA3, and for β-tubulin as loading control. The histograms show normalized means ± SE 
quantified from 3 immunoblots in both A and B. In one of the A549 experiments used for 
quantification, the cells were stimulated with ephrin-A5 Fc. **p<0.01 by one sample t test for the 
comparison of ephrin-A3 Fc-treated cells expressing both EphA3 and ephrin-A3 with ephrin-A3 
Fc-treated cells expressing only EphA3. Of note, EphA3 levels were higher in A549 cells co-
expressing ephrin-A3/ephrin-B2 (see also Figs. 2A, 3B, 4A and 5C,D), suggesting that this 
receptor may be stabilized by the coexpressed ephrins. (C) A549 cells were infected with a 
lentivirus encoding mCherry-ephrin-A3 or mCherry as a control. Immunoprecipitated 
endogenous EphA2 was probed by immunoblotting for phosphotyrosine (PTyr) and reprobed for 
EphA2. Lysates were probed with an anti-dsRed antibody and β-tubulin as loading control. The 
histogram shows normalized means ± SE quantified from 3 immunoblots. **p<0.01 by one 





8.2- Coexpression with ephrin-A3 in cancer cells impairs the 
ability of EphA3 to bind ephrin-As in trans  
 
To examine whether in cancer cells ephrin-A3 coexpression impairs the ability of EphA3 
to bind ephrin-A ligands in trans, we measured the binding of soluble forms of ephrin-A5 
or ephrin-A3 fused to alkaline phosphatase (AP) to NCI-H226 and A549 cells expressing 
EphA3 alone or together with mCherry-ephrin-A3. We detected ephrin-A AP binding to 
cells only expressing EphA3 but not to cells coexpressing ephrin-A3 with EphA3 (Figure 
2A). Immunoblotting verified that ephrin-A3 coexpression does not decrease overall 
EphA3 levels (Figure 2A). Biotinylation of cell surface proteins followed by an ELISA in 
which EphA3 was captured with an antibody and its level of biotinylation was detected 
with streptavidin conjugated to horseradish peroxidase (HRP) showed that ephrin-A3 
coexpression does not affect the fraction of EphA3 present on the cell surface (Figure 
2B). Thus, coexpressed ephrin-A3 in lung cancer cells inhibits ephrin binding to EphA3 
in trans without reducing EphA3 expression or surface localization. 
 A possible explanation for these results could be that soluble ephrin-A3 released 
in the culture medium by matrix metalloproteases (Bartley et al. 1994; Hattori et al. 2000; 
Beauchamp et al. 2012) would compete with ephrin-A3 AP for binding to the EphA3 
ligand-binding domain. To address this possibility, we used the extracellular domain of 
EphA3 fused with Fc to pull-down ephrin-A3 from the culture medium or the cells lysed 
in a volume equivalent to that of the culture medium. Ephrin-A3 could be detected by 
immunoblotting in the pull-downs from cell lysates but not from the culture medium 
(Figure 2C), indicating that the great majority of the ephrin-A3 remained associated with 
the cells during the 24-48 hour time period of our experiments. In addition, a single 
mCherry-ephrin-A3 band was observed in the immunoblots, making it unlikely that a 
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substantial portion of the ephrin was cleaved to generate a smaller form remaining 
associated with the cells by binding to an EphA receptor. Biotinylation of cell surface 
proteins followed by detection of the immunoprecipitated biotinylated ephrin-A3 with 
streptavidin-HRP confirmed that ephrin-A3 is similarly localized on the A549 cell 









Figure	  2.	  Coexpressed	  cell	  surface-­‐associated	  ephrin-­‐A3	  inhibits	  the	  binding	  in	  trans	  
of	   soluble	   ephrins	   to	   EphA3	   in	   lung	   cancer	   cells.	   (A)	  NCI-­‐H226	  and	  A549	   lung	  cancer	  cells	  were	  infected	  with	  a	  lentivirus	  encoding	  EphA3	  and	  ZsGreen	  alone	  or	  together	  with	  a	  lentivirus	   encoding	   mCherry-­‐ephrin-­‐A3;	   control	   cells	   were	   infected	   with	   lentiviruses	  encoding	  ZsGreen	  and	  mCherry.	  The	  histograms	  show	  the	  binding	  of	  ephrin-­‐A5	  AP	  to	  NCI-­‐H226	  cells	  and	  ephrin-­‐A3	  AP	  to	  A549	  cells,	  revealing	  that	  ephrin-­‐A3	  coexpression	  prevents	  the	  binding	  of	  ephrin	  AP	  proteins	   to	  EphA3.	  Normalized	  means	   from	  2	  experiments	  (each	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8.3- EphA3-ephrin-A3 cis interaction does not require the 
receptor ligand-binding domain 
 
Previous studies have shown that cis interactions require membrane localization of the 
Eph receptor and the ephrin (Carvalho et al. 2006). Therefore, to examine whether the 
EphA3 ligand-binding domain is necessary for cis interaction with ephrin-A3 or whether 
the fibronectin type III repeats are sufficient to mediate cis binding (Carvalho et al. 2006; 
Seiradake et al. 2010), we transiently transfected HEK293 cells stably expressing 
mCherry-ephrin-A3 with plasmids encoding EphA3 ΔN (a truncated form of EphA3 that 
lacks the N terminal ligand-binding domain and cysteine-rich region) or full-length 
EphA3. In coimmunoprecipitation experiments with an anti-EphA3 antibody that 
recognizes the C-terminal region of the receptor, we detected association of ephrin-A3 
with both full-length and truncated EphA3 (Figure 3A). This confirms that the EphA3 
ligand-binding domain, which mediates high affinity binding in trans, is not necessary for 
EphA3-ephrin-A3 cis interaction.  
To investigate the effect of mutating the ephrin G-H loop, we examined the 
E129K mutation in ephrin-A3. This mutation did not prevent the cis association of 
ephrin-A3 with EphA3 ΔN (Figure 3B), even though it abolished the trans interaction 
with EphA3 AP (Figure 3C). These results are consistent with those obtained with the 
corresponding ephrin-A5 E129K mutant, which can also still attenuate through cis 
interaction EphA3 phosphorylation as well as EphA-mediated growth cone collapse and 
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axon guidance triggered by ephrin-A ligands in trans (Carvalho et al. 2006; Kao and 
Kania 2011). Hence, EphA3 and ephrin-A3 can associate with each other even when 
lacking the regions that mediate high affinity binding in trans, supporting the general 
involvement in cis interactions of the Eph fibronectin type III domains and an ephrin 







Figure	  3.	  Cis	  interaction	  between	  coexpressed	  EphA3	  and	  ephrin-­‐A3	  does	  not	  require	  
the	   regions	   involved	   in	   trans	   interaction.	   (A)	   HEK	   AD-­‐293	   cells	   were	   infected	  with	   a	  lentivirus	   encoding	   mCherry-­‐ephrin-­‐A3	   or	   mCherry	   as	   a	   control.	   Subsequently,	   the	   cells	  were	  transfected	  with	  plasmids	  encoding	  full-­‐length	  EphA3	  or	  a	  truncated	  form	  lacking	  the	  ligand-­‐binding	   domain	   and	   cysteine-­‐rich	   region	   (EphA3	   ΔN).	   EphA3	   immunoprecipitates	  were	  probed	  with	  anti-­‐ephrin-­‐A3	  antiserum	  and	  reprobed	  for	  EphA3,	  revealing	  that	  ephrin-­‐A3	   association	   with	   EphA3	   does	   not	   require	   the	   EphA3	   ligand-­‐binding	   domain.	   The	  histogram	   shows	   normalized	   means	   ±	   SE	   quantified	   from	   the	   immunoblots	   from	   2	  experiments.	  p>0.05	  by	  one	  sample	  t	  test	  for	  the	  comparison	  of	  ephrin-­‐A3	  bound	  to	  EphA3	  ΔN	  or	  full-­‐length	  EphA3.	  (B)	  HEK	  AD-­‐293	  cells	  infected	  with	  a	  lentivirus	  encoding	  mCherry-­‐ephrin-­‐A3,	   the	   mCherry-­‐ephrin-­‐A3	   E129K	   mutant,	   or	   mCherry	   as	   a	   control,	   were	  transfected	  with	   a	   plasmid	   encoding	   EphA3	  ΔN.	   EphA3	   immunoprecipitates	  were	   probed	  for	  ephrin-­‐A3	  and	  reprobed	  for	  EphA3,	  revealing	  that	  the	  E129K	  mutation	  does	  not	  abolish	  the	   cis	   interaction	   with	   EphA3.	   The	   histogram	   shows	   normalized	  means	   ±	   SE	   quantified	  from	  3	  immunoblots.	  p>0.05	  by	  one	  sample	  t	   test	   for	  the	  comparison	  of	  ephrin-­‐A3	  E129K	  versus	   ephrin-­‐A3	   wild-­‐type	   bound	   to	   EphA3	   ΔN.	   (C)	   HEK	   AD-­‐293	   cells	   were	   transfected	  with	   control	   pcDNA3,	   pcDNA3-­‐ephrin-­‐A3,	   or	   pcDNA3-­‐ephrin-­‐A3	   E129K.	   The	   histogram	  shows	  means	  from	  two	  experiments	  for	  the	  binding	  of	  EphA3	  AP	  to	  ephrin-­‐A3,	  confirming	  that	  ephrin-­‐A3	  E129K	  mutant	  does	  not	  bind	  EphA3	  in	  trans.	  ***p<0.001	  by	  one-­‐way	  ANOVA	  and	  Dunnett’s	  post-­‐hoc	  test	   for	  the	  comparison	  with	  cells	  expressing	  wild-­‐type	  ephrin-­‐A3.	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8.4- The EphA3 G518L lung cancer mutation enhances cis 
interaction with coexpressed ephrin-A3 
 
Recent sequencing studies have identified EphA3 mutations in lung cancer and other 
cancers, and functional characterization has revealed that many are loss-of-function 
mutations that inhibit ephrin binding, kinase activity and/or cell surface localization, 
suggesting a tumor suppressor role for wild-type EphA3 (Ding et al. 2008; Lisabeth et al. 
2012; Zhuang et al. 2012). One of the few mutations that were not found to impair any of 
the EphA3 properties examined in a previous study, but rather slightly increased EphA3 
cell surface localization, is the G518L mutation in the second fibronectin type III domain 
(Lisabeth et al. 2012). Since G518 in EphA3 corresponds to a conserved residue that in 
the EphA2-ephrin-A5 crystal structure participates in the cis interface, we examined 
whether the G518L mutation might affect the cis association of EphA3 with coexpressed 
ephrin-A3. To focus on the role of the cis interaction, we used EphA3 ΔN or the EphA3 
ΔN G518L mutant. Coimmunoprecipitation experiments using HEK293 cells 
coexpressing mCherry-ephrin-A3 with EphA3 ΔN or the ΔN G518L mutant revealed 
more ephrin-A3 associated with the mutant (Figure 4A). Measurement of ephrin-A5 AP 
binding verified that ephrin-A3 coexpression with the full-length EphA3 G518 mutant 
inhibited its ability to bind ephrins in trans (Figure 4B). These results suggest that the 
G518L mutation enhances EphA3-ephrin binding in cis and supports the involvement in 
the cis interface of the conserved glycine in the second fibronectin type III domain 







Figure	   4.	   The	   EphA3	   G518L	   lung	   cancer	   mutation	   enhances	   cis	   interaction	   with	  









8.5- Ephrin-B2 coexpression in cancer cells attenuates not only 
EphB4 but also EphA3 activation and ligand-binding capacity 
in trans 
 
Cis interactions between the Eph fibronectin type III domains and ephrins could have 
distinctive selectivity compared to trans interactions involving the Eph ligand-binding 
domain and the ephrin G-H loop (Seiradake et al. 2010). To investigate this, we used 
ephrin-B2, which does not bind with high affinity to the EphA3 ligand-binding domain 
(Flanagan and Vanderhaeghen 1998). We infected A549 lung cancer cells and MCF7 
breast cancer cells with a lentivirus encoding ephrin-B2 fused to EGFP and first 
examined the effects on endogenous EphB4, which binds the ephrin-B2 ligand in trans. 
Like EphA2, EphB4 is widely expressed in cancer cells (Noren and Pasquale 2007; 
Pasquale 2010) and its ability to be regulated by ephrins in cis was not previously 
examined. We found that ephrin-B2 expression inhibits the binding of ephrin-B2 AP to 
the cell surface (Figure 5A) and EphB4 tyrosine phosphorylation induced in trans by 
ephrin-B2 Fc (Figure 5B). Thus, cis interaction with coexpressed ephrin-B2 inhibits 
EphB4 ligand binding in trans and activation in cancer cells. To examine whether EphA3 
can also be regulated by cis interaction with ephrin-B2, we infected A549 lung cancer 
cells expressing EphA3 with lentiviruses encoding EGFP-ephrin-B2 or only EGFP as a 
control. Interestingly, ephrin-B2 coexpression attenuated EphA3 activation by ephrin-A3 
Fc (Figure 5C) and inhibited the ability of EphA3 to bind ephrin-A5 AP without 
decreasing overall EphA3 levels (Figure 5D). EphA3 expression only slightly increased 
the binding of the extracellular domain of ephrin-B2 AP to the cells (Figure 5D), 
confirming that ephrin-B2 does not efficiently bind to EphA3 in trans (Flanagan and 
Vanderhaeghen 1998). These results suggest that although ephrin-B2 is not an activating 
ligand for EphA3, it can affect EphA3 function through cis interaction. This implies that 
the binding specificities that govern cis and trans Eph receptor-ephrin interactions are not 









Figure	   5.	   Coexpressed	   ephrin-­‐B2	   attenuates	   EphB4	   as	   well	   as	   EphA3	   activation	   in	  
cancer	   cells.	   (A)	  The	  histogram	  shows	  the	  binding	  of	  ephrin-­‐B2	  AP	  to	  A549	  cells	  infected	  with	  lentiviruses	  encoding	  EGFP-­‐ephrin-­‐B2	  or	  EGFP,	  revealing	  that	  ephrin-­‐B2	  coexpression	  inhibits	  ephrin-­‐B2	  AP	  binding	  to	  EphB4.	  Normalized	  means	  from	  3	  experiments	  (each	  with	  triplicate	  samples)	  ±	  SE	  are	  shown.	  ***p<0.001	  by	  unpaired	  t	  test	  for	  the	  comparison	  of	  cells	  expressing	   ephrin-­‐B2	   with	   cells	   not	   expressing	   ephrin-­‐B2.	   The	   immunoblot	   of	   the	   cell	  lysates	   shows	  expression	  of	  EphB4,	   ephrin-­‐B2	  and	  β-­‐tubulin	   as	   loading	   control.	   (B)	  A549	  lung	   cancer	   cells	   and	  MCF7	   breast	   cancer	   cells	   were	   infected	   with	   lentiviruses	   encoding	  EGFP-­‐ephrin-­‐B2	  or	  EGFP.	  EphB4	   immunoprecipitates	  were	  probed	  by	   immunoblotting	   for	  phosphotyrosine	   (PTyr)	   and	   reprobed	   for	   EphB4.	   Cell	   lysates	  were	   probed	   for	   ephrin-­‐B2	  with	   an	   anti-­‐EGFP	   antibody	   and	   for	   β-­‐tubulin	   as	   loading	   control.	   The	   histograms	   show	  normalized	  means	  ±	  SE	  quantified	   from	  2	   immunoblots	   for	  each	   cell	   line.	   *p<0.05	  by	  one	  sample	   t	   test	   for	   the	   comparison	   of	   ephrin-­‐B2	  Fc-­‐treated	   cells	   expressing	   ephrin-­‐B2	  with	  cells	   not	   expressing	   ephrin-­‐B2. (C)	   A549	   cells	   were	   infected	   with	   a	   lentivirus	   encoding	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8.6- Endogenous ephrin-As attenuate activation of coexpressed 
EphA2 in cancer cells 
 
To investigate whether ephrins endogenously expressed in cancer cells can also engage in 
cis interactions that inhibit the activation of coexpressed endogenous Eph receptors, we 
chose the SKBR3 and MCF7 breast cancer cell lines. These lines express high levels of 
ephrin-A ligands together with EphA2 (Macrae et al. 2005) (broadinstitute.org/ccle), 
although the receptor is expressed at relatively low levels, consistent with the 
complementary expression of Eph receptors and ephrins observed in many cancer cell 
lines (Pasquale 2010). Since both SKBR3 and MCF7 cells express multiple ephrin-A 
ligands, which are GPI-anchored, we used the enzyme phosphatidylinositol-specific 
phospholipase C (PI-PLC) to remove all ephrin-As from the cell surface. In both cell 
lines, removal of endogenous ephrin-As from the cell surface resulted in enhanced 
EphA2 activation by ephrin-A1 Fc in trans compared to untreated cells (Figure 6 A,B). In 
contrast, PI-PLC treatment of control Fc-treated cells decreased the low basal EphA2 
activation, suggesting that endogenous ephrin-As can induce some EphA2 activation. 
Since ephrin-A1 has been reported to be cleaved from the surface of cancer cells by 
matrix metalloproteases, we also treated SKBR3 cells with the broad-spectrum matrix 
metalloprotease inhibitor GM-6001 (Bartley et al. 1994; Alford et al. 2010; Beauchamp 
et al. 2012). Treatment with the inhibitor for 24 hours further increased cell surface 
associated ephrin-A1. However, it did not substantially affect EphA2 tyrosine 
phosphorylation induced by ephrin-A1 Fc binding in trans, possibly due to already high 
cis-inhibition by the high levels of ephrin-A1 present even in the absence of GM-6001. 
Thus, in cancer cells cis interaction with endogenous ephrin-A ligands can attenuate 
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EphA2 activation by ephrin-As presented in trans, supporting the significance of cis 







Figure	  6.	  Removal	  of	  endogenous	  ephrin-­‐As	  from	  the	  cell	  surface	  potentiates	  EphA2	  
activation	   by	   soluble	   ephrin-­‐A1	   in	   trans.	   (A)	   SKBR3	   and	   (B)	  MCF7	  breast	   cancer	   cells	  were	   treated	   with	   PI-­‐PLC	   for	   4	   hours	   and	   then	   stimulated	   with	   ephrin-­‐A1	   Fc.	   EphA2	  immunoprecipitates	   were	   probed	   by	   immunoblotting	   for	   phosphotyrosine	   (PTyr)	   and	  reprobed	  for	  EphA2.	  Lysates	  probed	  with	  anti-­‐ephrin-­‐A1	  antibody	  verify	  removal	  of	  ephrin-­‐As	  by	  PI-­‐PLC;	  β-­‐tubulin	  verifies	  equal	  loading	  of	  the	  lanes.	  The	  Odyssey	  LI-­‐COR	  system	  was	  used	  for	  detection	  and	  the	  color	   images	  were	  converted	  to	  greyscale	  with	  Photoshop.	  The	  histograms	  show	  the	  normalized	  data	  from	  3	  different	  experiments	  *p<0.05	  and	  ***p<0.001	  by	  one	  sample	  t	  test	  for	  the	  comparison	  of	  ephrin-­‐A1	  Fc-­‐stimulated	  cells	  treated	  or	  not	  with	  PI-­‐PLC.	  (C)	  SKBR3	  cells	  were	  treated	  with	  PI-­‐PLC	  as	  in	  A	  or	  with	  the	  broad-­‐spectrum	  matrix	  metalloprotease	   inhibitor	   GM-­‐6001	   for	   24	   hours.	   Immunoprecipitates	   and	   lysates	   were	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probed	  as	  indicated.	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Different families of receptors and cell surface-associated ligands that together mediate 
juxtacrine signals by interacting in trans across cell-cell junctions can also, when 
coexpressed on the same cell surface, interact laterally in cis (Yaron and Sprinzak 2012). 
These cis interactions, which have been mostly studied in the nervous system and the 
immune system, typically attenuate the signals triggered by the trans interactions through 
mechanisms that in many cases are not well understood (Nitschke 2009; Ware and Sedy 
2011; Yaron and Sprinzak 2012). Recent studies have uncovered key functional roles for 
inhibitory cis interactions between Eph receptors and ephrin ligands coexpressed in 
neurons (Hornberger et al. 1999; Yin et al. 2004; Carvalho et al. 2006; Antion et al. 2010; 
Kao and Kania 2011). However, despite the importance of the Eph/ephrin system in 
cancer pathogenesis, Eph receptor-ephrin cis interactions have not yet been investigated 
in cancer cells. 
We have detected inhibitory cis interactions with ephrins in cancer cells not only 
for EphA3, which had been previously studied in neurons, but also for endogenous 
EphA2 and EphB4, for which the effects of cis interactions have not been previously 
investigated. Among the Eph receptors, EphA2 and EphB4 are the most widely expressed 
in epithelial and cancer cells, although most other Eph receptors including EphA3 are 
also aberrantly expressed in at least some cancers (Pasquale 2008; Pasquale 2010; Xi and 
Zhao 2011; Keane et al. 2012; Xi et al. 2012; Day et al. 2013). Cis interactions between 
coexpressed Eph receptors and ephrins may represent one of the strategies adopted by 
cancer cells to escape the tumor suppressing effects of Eph receptor signaling induced by 
ephrins binding in trans, including inhibition of cell growth and invasiveness (Clevers 
and Batlle 2006; Chen et al. 2008; Pasquale 2008; Astin et al. 2010; Pasquale 2010; Yang 
et al. 2011; Li et al. 2012). 
We found that in cancer cells cis interactions can inhibit ephrin binding to Eph 
receptors in trans, consistent with previous studies in other systems (Yin et al. 2004; Kao 
and Kania 2011). This effect, which likely explains the observed inhibition of Eph 
receptor activation by ephrins in trans, could be due to different underlying mechanisms. 
We have shown that the levels of EphA3 on the cancer cell surface are not decreased by 
coexpression of ephrin-A3. We have also excluded occupancy of the EphA3 ligand-
binding domain by ephrin-A3 that may be released into the medium by proteases 
(Beauchamp et al. 2012). Another possible mechanism by which cis interactions could 
lead to inhibition of the binding of soluble ephrins in trans could be by stabilizing the 
assembly of coexpressed Eph receptors and ephrins into lattice-like arrays that span cell-
cell contacts and engage both cis and trans interfaces (Seiradake et al. 2010). However, 
we did not observe enrichment of EphA3 and ephrin-A3 in regions of cell-cell contact in 
A549 lung cancer cells coexpressing these proteins (not shown). Furthermore, 
coexpressed ephrins can block ephrin binding to Eph receptors in trans even in the 
absence of cell-cell contacts (Yin et al. 2004; Kao and Kania 2011). Taken together, these 
data suggest that ephrin binding in cis to the fibronectin type III domains of an Eph 
receptor may promote an additional cis interaction between the ephrin-binding pocket of 
the Eph receptor and the G-H loop of the ephrin. This may occur even when the second 
interaction is very weak, as in the case of EphA3 and ephrin-B2, since we found that 
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ephrin-B2 coexpression can prevent ephrin-A3 binding to EphA3 in trans. A contribution 
of the Eph receptor ligand-binding domain is also consistent with the trend towards a 
weaker cis association and the weaker attenuation of EphA receptor activation and 
functional effects observed when interaction between the Eph receptor ligand-binding 
domain and co-expressed ephrin is prevented (Fig. 6 and (Carvalho et al. 2006)). 
However, other possible mechanisms explaining the inhibitory effects of cis interactions 
on Eph receptor activation cannot be excluded, including allosteric conformational 
changes blocking access to the ephrin-binding pocket of the Eph receptor or intercalation 
of the ephrin preventing the receptor clustering needed for activation (Yin et al. 2004; 
Carvalho et al. 2006; Kao and Kania 2011; Yaron and Sprinzak 2012). 
Previous studies have assumed that Eph receptor-ephrin cis interactions exhibit 
the same A or B class selectivity as trans interactions (Yin et al. 2004; Carvalho et al. 
2006; Kao and Kania 2011). However, the fibronectin type III domains of an Eph 
receptor could conceivably bind a different subset of ephrins than the ligand-binding 
domain, particularly because the two Eph receptor regions also interact with distinct parts 
of the ephrins. Our data indeed show that coexpressed ephrin-B2 can strongly inhibit 
EphA3 interaction with ephrins in trans and tyrosine phosphorylation, even though this 
ephrin does not efficiently bind to the EphA3 ligand-binding domain (Flanagan and 
Vanderhaeghen 1998). However, we could not detect coimmunoprecipitation of ephrin-
B2 with EphA3 (data not shown), suggesting that the cis association of EphA3 with 
ephrin-B2 may be weaker than with ephrin-A3 or ephrin-A5 (Figure 3) (Carvalho et al. 
2006). Nevertheless, the cis-inhibition of EphA3 by ephrin-B2 suggests that in at least 
some cases ephrins that cannot activate a particular Eph receptor can instead inhibit its 
signaling ability through cis association. This represents a novel facet of Eph receptor-
ephrin signaling and has functional implications in cancer cells, which can express 
multiple Eph receptors and ephrins of different classes (Stahl et al. 2011; Noberini et al. 
2012b) (http://www.broadinstitute.org/ccle/). It will therefore be interesting to investigate 
the extent of these interclass cis interactions and whether this mechanism could explain 
some puzzling findings. For example, ephrin-B3 knockdown revealed that this ephrin 
increases EphA2 expression in the U-1810 lung cancer cell line (Stahl et al. 2011). Since 
ephrin-B3 is not an activating ligand for EphA2 (Flanagan and Vanderhaeghen 1998), an 
explanation for these findings could be that ephrin-B3 interacting in cis prevents EphA2 
activation and degradation induced by ephrin-A1 in trans (Walker-Daniels et al. 2002; 
Stahl et al. 2011; Yang et al. 2011).  
Studies in the nervous system have suggested that cis interactions are favored 
under conditions of high ephrin expression, which promotes colocalization of Eph 
receptors and ephrins in the same plasma membrane microdomains enabling their 
intermingling (Kao and Kania 2011). We indeed found that ephrin-A3 overexpressed in 
lung cancer cells can inhibit EphA2 and EphA3 activation by ephrins in trans while 
overexpression of ephrin-B2 can inhibit activation of EphA3 and EphB4. Importantly, 
ephrins endogenously expressed at high levels in cancer cells can also participate in 
inhibitory cis interactions, since removal of endogenous GPI-linked ephrin-As from the 
surface of SKBR3 and MCF7 breast cancer cells with PI-PLC allows increased activation 
of endogenous EphA2 by soluble ephrin-A1 in trans. In contrast, inhibiting the release of 
GPI-linked ephrin-As through inactivation of matrix metalloproteases in SKBR3 cells did 
not detectably affect EphA2 activation in trans by ephrin-A1 Fc under the conditions of 
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our experiments, presumably due to the already high levels of ephrin-A1 expressed in 
these cells. It will be interesting to determine whether in cancer cells with moderate 
ephrin-A levels, inhibiting matrix metalloproteases could enhance the inhibitory effect of 
cis interactions on EphA receptor signaling. 
Some of the Eph receptor residues that are predicted to participate in cis 
interaction with ephrins have been reported to be mutated in cancer specimens (Seiradake 
et al. 2010). We found that the EphA3 G518L lung cancer mutation strengthens the cis 
association of EphA3 with coexpressed ephrin-A3. It will be interesting to examine 
whether other cancer mutations involving residues predicted to participate in the cis 
interface of other Eph receptors – such as EphA1 R337Q, EphB1 R327H and I332M, and 
EphB3 E358K in the first fibronectin type III domain as well as EphA5 G547S, EphA6 
T493K and R494M, and EphA7 E482D in the second fibronectin type III domain 
(http://cancer.sanger.ac.uk/cosmic/) – also have functional consequences on cis 
associations with ephrins.  
In summary, our data reveal a signaling mechanism previously uncharacterized in 
cancer cells whereby ephrin-mediated cis attenuation of Eph receptor signaling can 
inhibit responsiveness to ephrins expressed by other cancer cells or by cells of the tumor 
microenvironment. Further investigations of the selectivity and functional effects of Eph 
receptor-ephrin cis interactions will provide new information on Eph receptor signaling 
mechanisms in cancer pathogenesis, which may help the development of new therapeutic 






 Afshari	  FT,	  Kwok	  JC,	  Fawcett	  JW.	  2010.	  Astrocyte-­‐produced	  ephrins	  inhibit	  schwann	  cell	  migration	  via	  VAV2	  signaling.	  J	  Neurosci	  30:	  4246-­‐4255.	  Alberi	  L,	  Liu	  S,	  Wang	  Y,	  Badie	  R,	  Smith-­‐Hicks	  C,	  Wu	  J,	  Pierfelice	  TJ,	  Abazyan	  B,	  Mattson	  MP,	  Kuhl	  D	  et	  al.	  2011.	  Activity-­‐induced	  Notch	  signaling	  in	  neurons	  requires	  Arc/Arg3.1	  and	  is	  essential	  for	  synaptic	  plasticity	  in	  hippocampal	  networks.	  Neuron	  69:	  437-­‐444.	  Alford	  S,	  Watson-­‐Hurthig	  A,	  Scott	  N,	  Carette	  A,	  Lorimer	  H,	  Bazowski	  J,	  Howard	  PL.	  2010.	  Soluble	  ephrin	  a1	  is	  necessary	  for	  the	  growth	  of	  HeLa	  and	  SK-­‐BR3	  cells.	  
Cancer	  Cell	  Int	  10:	  41.	  Alford	  SC,	  Bazowski	  J,	  Lorimer	  H,	  Elowe	  S,	  Howard	  PL.	  2007.	  Tissue	  transglutaminase	  clusters	  soluble	  A-­‐type	  ephrins	  into	  functionally	  active	  high	  molecular	  weight	  oligomers.	  Exp	  Cell	  Res	  313:	  4170-­‐4179.	  Antion	  MD,	  Christie	  LA,	  Bond	  AM,	  Dalva	  MB,	  Contractor	  A.	  2010.	  Ephrin-­‐B3	  regulates	  glutamate	  receptor	  signaling	  at	  hippocampal	  synapses.	  Mol	  Cell	  
Neurosci	  45:	  378-­‐388.	  Argenzio	  E,	  Bange	  T,	  Oldrini	  B,	  Bianchi	  F,	  Peesari	  R,	  Mari	  S,	  Di	  Fiore	  PP,	  Mann	  M,	  Polo	  S.	  2011.	  Proteomic	  snapshot	  of	  the	  EGF-­‐induced	  ubiquitin	  network.	  Mol	  
Syst	  Biol	  7:	  462.	  Artavanis-­‐Tsakonas	  S,	  Muskavitch	  MA.	  2010.	  Notch:	  the	  past,	  the	  present,	  and	  the	  future.	  Current	  topics	  in	  developmental	  biology	  92:	  1-­‐29.	  Arvanitis	  D,	  Davy	  A.	  2008.	  Eph/ephrin	  signaling:	  networks.	  Genes	  Dev	  22:	  416-­‐429.	  Arvanitis	  DN,	  Jungas	  T,	  Behar	  A,	  Davy	  A.	  2010.	  Ephrin-­‐B1	  reverse	  signaling	  controls	  a	  posttranscriptional	  feedback	  mechanism	  via	  miR-­‐124.	  Mol	  Cell	  Biol	  30:	  2508-­‐2517.	  Astin	  JW,	  Batson	  J,	  Kadir	  S,	  Charlet	  J,	  Persad	  RA,	  Gillatt	  D,	  Oxley	  JD,	  Nobes	  CD.	  2010.	  Competition	  amongst	  Eph	  receptors	  regulates	  contact	  inhibition	  of	  locomotion	  and	  invasiveness	  in	  prostate	  cancer	  cells.	  Nat	  Cell	  Biol	  12:	  1194-­‐1204.	  Attwood	  BK,	  Bourgognon	  JM,	  Patel	  S,	  Mucha	  M,	  Schiavon	  E,	  Skrzypiec	  AE,	  Young	  KW,	  Shiosaka	  S,	  Korostynski	  M,	  Piechota	  M	  et	  al.	  2011.	  Neuropsin	  cleaves	  EphB2	  in	  the	  amygdala	  to	  control	  anxiety.	  Nature	  473:	  372-­‐375.	  Baba	  A,	  Akagi	  K,	  Takayanagi	  M,	  Flanagan	  JG,	  Kobayashi	  T,	  Hattori	  M.	  2009.	  Fyn	  tyrosine	  kinase	  regulates	  the	  surface	  expression	  of	  glycosylphosphatidylinositol-­‐linked	  ephrin	  via	  the	  modulation	  of	  sphingomyelin	  metabolism.	  J	  Biol	  Chem	  284:	  9206-­‐9214.	  Balakrishnan	  A,	  Bleeker	  FE,	  Lamba	  S,	  Rodolfo	  M,	  Daniotti	  M,	  Scarpa	  A,	  van	  Tilborg	  AA,	  Leenstra	  S,	  Zanon	  C,	  Bardelli	  A.	  2007.	  Novel	  somatic	  and	  germline	  mutations	  in	  cancer	  candidate	  genes	  in	  glioblastoma,	  melanoma,	  and	  pancreatic	  carcinoma.	  Cancer	  Res	  67:	  3545-­‐3550.	  Bardelli	  A,	  Parsons	  DW,	  Silliman	  N,	  Ptak	  J,	  Szabo	  S,	  Saha	  S,	  Markowitz	  S,	  Willson	  JK,	  Parmigiani	  G,	  Kinzler	  KW	  et	  al.	  2003.	  Mutational	  analysis	  of	  the	  tyrosine	  kinome	  in	  colorectal	  cancers.	  Science	  300:	  949.	  
References 
 63 
Bartley	  TD,	  Hunt	  RW,	  Welcher	  AA,	  Boyle	  WJ,	  Parker	  VP,	  Lindberg	  RA,	  Lu	  HS,	  Colombero	  AM,	  Elliott	  RL,	  Guthrie	  BA.	  1994.	  B61	  is	  a	  ligand	  for	  the	  ECK	  receptor	  protein-­‐tyrosine	  kinase.	  Nature	  368:	  558-­‐560.	  Batlle	  E,	  Henderson	  JT,	  Beghtel	  H,	  van	  den	  Born	  MM,	  Sancho	  E,	  Huls	  G,	  Meeldijk	  J,	  Robertson	  J,	  van	  de	  Wetering	  M,	  Pawson	  T	  et	  al.	  2002.	  beta-­‐Catenin	  and	  TCF	  Mediate	  Cell	  Positioning	  in	  the	  Intestinal	  Epithelium	  by	  Controlling	  the	  Expression	  of	  EphB/EphrinB.	  Cell	  111:	  251-­‐263.	  Beauchamp	  A,	  Lively	  MO,	  Mintz	  A,	  Gibo	  D,	  Wykosky	  J,	  Debinski	  W.	  2012.	  EphrinA1	  is	  released	  in	  three	  forms	  from	  cancer	  cells	  by	  matrix	  metalloproteases.	  Mol	  
Cell	  Biol	  32:	  3253-­‐3264.	  Becam	  I,	  Fiuza	  UM,	  Arias	  AM,	  Milan	  M.	  2010.	  A	  role	  of	  receptor	  Notch	  in	  ligand	  cis-­‐inhibition	  in	  Drosophila.	  Curr	  Biol	  20:	  554-­‐560.	  Beg	  AA,	  Sommer	  JE,	  Martin	  JH,	  Scheiffele	  P.	  2007.	  alpha2-­‐Chimaerin	  Is	  an	  Essential	  EphA4	  Effector	  in	  the	  Assembly	  of	  Neuronal	  Locomotor	  Circuits.	  Neuron	  55:	  768-­‐778.	  Berclaz	  G,	  Flutsch	  B,	  Altermatt	  HJ,	  Rohrbach	  V,	  Djonov	  V,	  Ziemiecki	  A,	  Dreher	  E,	  Andres	  AC.	  2002.	  Loss	  of	  EphB4	  receptor	  tyrosine	  kinase	  protein	  expression	  during	  carcinogenesis	  of	  the	  human	  breast.	  Oncol	  Rep	  9:	  985-­‐989.	  Bhushan	  L,	  Kandpal	  RP.	  2011.	  EphB6	  receptor	  modulates	  micro	  RNA	  profile	  of	  breast	  carcinoma	  cells.	  PLoS	  One	  6:	  e22484.	  Biao-­‐Xue	  R,	  Xi-­‐Guang	  C,	  Shuan-­‐Ying	  Y,	  Wei	  L,	  Zong-­‐Juan	  M.	  2011.	  EphA2-­‐Dependent	  Molecular	  Targeting	  Therapy	  for	  Malignant	  Tumors.	  Curr	  Cancer	  Drug	  
Targets	  11:	  1082-­‐1097.	  Binns	  KL,	  Taylor	  PP,	  Sicheri	  F,	  Pawson	  T,	  Holland	  SJ.	  2000.	  Phosphorylation	  of	  tyrosine	  residues	  in	  the	  kinase	  domain	  and	  juxtamembrane	  region	  regulates	  the	  biological	  and	  catalytic	  activities	  of	  Eph	  receptors.	  Molecular	  &	  Cellular	  
Biology	  20:	  4791-­‐4805.	  Bohme	  B,	  VandenBos	  T,	  Cerretti	  DP,	  Park	  LS,	  Holtrich	  U,	  Rubsamen-­‐Waigmann	  H,	  Strebhardt	  K.	  1996.	  Cell-­‐cell	  adhesion	  mediated	  by	  binding	  of	  membrane-­‐anchored	  ligand	  LERK-­‐2	  to	  the	  EPH-­‐related	  receptor	  human	  embryonal	  kinase	  2	  promotes	  tyrosine	  kinase	  activity.	  Journal	  of	  Biological	  Chemistry	  
271:	  24747-­‐24752.	  Bonanomi	  D,	  Chivatakarn	  O,	  Bai	  G,	  Abdesselem	  H,	  Lettieri	  K,	  Marquardt	  T,	  Pierchala	  BA,	  Pfaff	  SL.	  2012.	  Ret	  Is	  a	  Multifunctional	  Coreceptor	  that	  Integrates	  Diffusible-­‐	  and	  Contact-­‐Axon	  Guidance	  Signals.	  Cell	  148:	  568-­‐582.	  Bong	  YS,	  Lee	  HS,	  Carim-­‐Todd	  L,	  Mood	  K,	  Nishanian	  TG,	  Tessarollo	  L,	  Daar	  IO.	  2007.	  ephrinB1	  signals	  from	  the	  cell	  surface	  to	  the	  nucleus	  by	  recruitment	  of	  STAT3.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A	  104:	  17305-­‐17310.	  Bouzioukh	  F,	  Wilkinson	  GA,	  Adelmann	  G,	  Frotscher	  M,	  Stein	  V,	  Klein	  R.	  2007.	  Tyrosine	  phosphorylation	  sites	  in	  ephrinB2	  are	  required	  for	  hippocampal	  long-­‐term	  potentiation	  but	  not	  long-­‐term	  depression.	  J	  Neurosci	  27:	  11279-­‐11288.	  Brantley-­‐Sieders	  DM,	  Zhuang	  G,	  Hicks	  D,	  Fang	  WB,	  Hwang	  Y,	  Cates	  JM,	  Coffman	  K,	  Jackson	  D,	  Bruckheimer	  E,	  Muraoka-­‐Cook	  RS	  et	  al.	  2008.	  The	  receptor	  tyrosine	  kinase	  EphA2	  promotes	  mammary	  adenocarcinoma	  tumorigenesis	  
References 
 64 
and	  metastatic	  progression	  in	  mice	  by	  amplifying	  ErbB2	  signaling.	  J	  Clin	  
Invest	  118:	  64-­‐78.	  Bray	  SJ.	  2006.	  Notch	  signalling:	  a	  simple	  pathway	  becomes	  complex.	  Nat	  Rev	  Mol	  Cell	  
Biol	  7:	  678-­‐689.	  Bush	  JO,	  Soriano	  P.	  2009.	  Ephrin-­‐B1	  regulates	  axon	  guidance	  by	  reverse	  signaling	  through	  a	  PDZ-­‐dependent	  mechanism.	  Genes	  Dev	  23:	  1586-­‐1599.	  -­‐.	  2010.	  Ephrin-­‐B1	  forward	  signaling	  regulates	  craniofacial	  morphogenesis	  by	  controlling	  cell	  proliferation	  across	  Eph-­‐ephrin	  boundaries.	  Genes	  Dev	  24:	  2068-­‐2080.	  -­‐.	  2012.	  Eph/ephrin	  signaling:	  genetic,	  phosphoproteomic,	  and	  transcriptomic	  approaches.	  Semin	  Cell	  Dev	  Biol	  23:	  26-­‐34.	  Cadena	  DL,	  Chan	  CL,	  Gill	  GN.	  1994.	  The	  intracellular	  tyrosine	  kinase	  domain	  of	  the	  epidermal	  growth	  factor	  receptor	  undergoes	  a	  conformational	  change	  upon	  autophosphorylation.	  J	  Biol	  Chem	  269:	  260-­‐265.	  Campbell	  TN,	  Attwell	  S,	  Arcellana-­‐Panlilio	  M,	  Robbins	  SM.	  2006.	  Ephrin	  A5	  expression	  promotes	  invasion	  and	  transformation	  of	  murine	  fibroblasts.	  
Biochem	  Biophys	  Res	  Commun	  350:	  623-­‐628.	  Carmona	  MA,	  Murai	  KK,	  Wang	  L,	  Roberts	  AJ,	  Pasquale	  EB.	  2009.	  Glial	  ephrin-­‐A3	  regulates	  hippocampal	  dendritic	  spine	  morphology	  and	  glutamate	  transport.	  
Proc	  Natl	  Acad	  Sci	  U	  S	  A	  106:	  12524-­‐12529.	  Carvalho	  RF,	  Beutler	  M,	  Marler	  KJ,	  Knoll	  B,	  Becker-­‐Barroso	  E,	  Heintzmann	  R,	  Ng	  T,	  Drescher	  U.	  2006.	  Silencing	  of	  EphA3	  through	  a	  cis	  interaction	  with	  ephrinA5.	  Nat	  Neurosci	  9:	  322-­‐330.	  Chandarlapaty	  S,	  Sawai	  A,	  Scaltriti	  M,	  Rodrik-­‐Outmezguine	  V,	  Grbovic-­‐Huezo	  O,	  Serra	  V,	  Majumder	  PK,	  Baselga	  J,	  Rosen	  N.	  2011.	  AKT	  inhibition	  relieves	  feedback	  suppression	  of	  receptor	  tyrosine	  kinase	  expression	  and	  activity.	  
Cancer	  Cell	  19:	  58-­‐71.	  Chang	  Q,	  Jorgensen	  C,	  Pawson	  T,	  Hedley	  DW.	  2008.	  Effects	  of	  dasatinib	  on	  EphA2	  receptor	  tyrosine	  kinase	  activity	  and	  downstream	  signalling	  in	  pancreatic	  cancer.	  Br	  J	  Cancer	  99:	  1074-­‐1082.	  Chang-­‐Yew	  Leow	  C,	  Gerondakis	  S,	  Spencer	  A.	  2013.	  MEK	  inhibitors	  as	  a	  chemotherapeutic	  intervention	  in	  multiple	  myeloma.	  Blood	  cancer	  journal	  3:	  e105.	  Chen	  J.	  2012.	  Regulation	  of	  tumor	  initiation	  and	  metastatic	  progression	  by	  Eph	  receptor	  tyrosine	  kinases.	  Advances	  in	  cancer	  research	  114:	  1-­‐20.	  Chen	  J,	  Zhuang	  G,	  Frieden	  L,	  Debinski	  W.	  2008.	  Eph	  receptors	  and	  Ephrins	  in	  cancer:	  common	  themes	  and	  controversies.	  Cancer	  Res	  68:	  10031-­‐10033.	  Cheung	  TC,	  Oborne	  LM,	  Steinberg	  MW,	  Macauley	  MG,	  Fukuyama	  S,	  Sanjo	  H,	  D'Souza	  C,	  Norris	  PS,	  Pfeffer	  K,	  Murphy	  KM	  et	  al.	  2009.	  T	  cell	  intrinsic	  heterodimeric	  complexes	  between	  HVEM	  and	  BTLA	  determine	  receptivity	  to	  the	  surrounding	  microenvironment.	  J	  Immunol	  183:	  7286-­‐7296.	  Chiarugi	  P,	  Taddei	  ML,	  Schiavone	  N,	  Papucci	  L,	  Giannoni	  E,	  Fiaschi	  T,	  Capaccioli	  S,	  Raugei	  G,	  Ramponi	  G.	  2004.	  LMW-­‐PTP	  is	  a	  positive	  regulator	  of	  tumor	  onset	  and	  growth.	  Oncogene	  23:	  3905-­‐3914.	  
References 
 65 
Cisse	  M,	  Halabisky	  B,	  Harris	  J,	  Devidze	  N,	  Dubal	  DB,	  Sun	  B,	  Orr	  A,	  Lotz	  G,	  Kim	  DH,	  Hamto	  P	  et	  al.	  2011.	  Reversing	  EphB2	  depletion	  rescues	  cognitive	  functions	  in	  Alzheimer	  model.	  Nature	  469:	  47-­‐52.	  Clevers	  H,	  Batlle	  E.	  2006.	  EphB/EphrinB	  receptors	  and	  Wnt	  signaling	  in	  colorectal	  cancer.	  Cancer	  Res	  66:	  2-­‐5.	  Corbo	  V,	  Ritelli	  R,	  Barbi	  S,	  Funel	  N,	  Campani	  D,	  Bardelli	  A,	  Scarpa	  A.	  2010.	  Mutational	  profiling	  of	  kinases	  in	  human	  tumours	  of	  pancreatic	  origin	  identifies	  candidate	  cancer	  genes	  in	  ductal	  and	  ampulla	  of	  vater	  carcinomas.	  
PLoS	  One	  5:	  e12653.	  Cowan	  CA,	  Henkemeyer	  M.	  2001.	  The	  SH2/SH3	  adaptor	  Grb4	  transduces	  B-­‐ephrin	  reverse	  signals.	  Nature	  413:	  174-­‐179.	  Cowan	  CW,	  Shao	  YR,	  Sahin	  M,	  Shamah	  SM,	  Lin	  MZ,	  Greer	  PL,	  Gao	  S,	  Griffith	  EC,	  Brugge	  JS,	  Greenberg	  ME.	  2005.	  Vav	  family	  GEFs	  link	  activated	  Ephs	  to	  endocytosis	  and	  axon	  guidance.	  Neuron	  46:	  205-­‐217.	  Dail	  M,	  Richter	  M,	  Godement	  P,	  Pasquale	  EB.	  2006.	  Eph	  receptors	  inactivate	  R-­‐Ras	  through	  different	  mechanisms	  to	  achieve	  cell	  repulsion.	  J	  Cell	  Sci	  119:	  1244-­‐1254.	  Davy	  A,	  Bush	  JO,	  Soriano	  P.	  2006.	  Inhibition	  of	  gap	  junction	  communication	  at	  ectopic	  Eph/ephrin	  boundaries	  underlies	  craniofrontonasal	  syndrome.	  PLoS	  
Biol	  4:	  e315.	  Davy	  A,	  Feuerstein	  C,	  Robbins	  SM.	  2000.	  Signaling	  within	  a	  caveolae-­‐like	  membrane	  microdomain	  in	  human	  neuroblastoma	  cells	  in	  response	  to	  fibroblast	  growth	  factor.	  J	  Neurochem	  74:	  676-­‐683.	  Davy	  A,	  Gale	  NW,	  Murray	  EW,	  Klinghoffer	  RA,	  Soriano	  P,	  Feuerstein	  C,	  Robbins	  SM.	  1999.	  Compartmentalized	  signaling	  by	  GPI-­‐anchored	  ephrin-­‐A5	  requires	  the	  Fyn	  tyrosine	  kinase	  to	  regulate	  cellular	  adhesion.	  Genes	  &	  Development	  13:	  3125-­‐3135.	  Day	  BW,	  Stringer	  BW,	  Al-­‐Ejeh	  F,	  Ting	  MJ,	  Wilson	  J,	  Ensbey	  KS,	  Jamieson	  PR,	  Bruce	  ZC,	  Lim	  YC,	  Offenhauser	  C	  et	  al.	  2013.	  EphA3	  maintains	  tumorigenicity	  and	  is	  a	  therapeutic	  target	  in	  glioblastoma	  multiforme.	  Cancer	  Cell	  23:	  238-­‐248.	  Ding	  L,	  Getz	  G,	  Wheeler	  DA,	  Mardis	  ER,	  McLellan	  MD,	  Cibulskis	  K,	  Sougnez	  C,	  Greulich	  H,	  Muzny	  DM,	  Morgan	  MB	  et	  al.	  2008.	  Somatic	  mutations	  affect	  key	  pathways	  in	  lung	  adenocarcinoma.	  Nature	  455:	  1069-­‐1075.	  Dottori	  M,	  Down	  M,	  Huttmann	  A,	  Fitzpatrick	  DR,	  Boyd	  AW.	  1999.	  Cloning	  and	  characterization	  of	  EphA3	  (Hek)	  gene	  promoter:	  DNA	  methylation	  regulates	  expression	  in	  hematopoietic	  tumor	  cells.	  Blood	  94:	  2477-­‐2486.	  Du	  J,	  Fu	  C,	  Sretavan	  DW.	  2007.	  Eph/ephrin	  signaling	  as	  a	  potential	  therapeutic	  target	  after	  central	  nervous	  system	  injury.	  Current	  pharmaceutical	  design	  13:	  2507-­‐2518.	  Elowe	  S,	  Holland	  SJ,	  Kulkarni	  S,	  Pawson	  T.	  2001.	  Downregulation	  of	  the	  Ras-­‐Mitogen-­‐Activated	  Protein	  Kinase	  Pathway	  by	  the	  EphB2	  Receptor	  Tyrosine	  Kinase	  Is	  Required	  for	  Ephrin-­‐Induced	  Neurite	  Retraction.	  Mol	  Cell	  Biol	  21:	  7429-­‐7441.	  Essmann	  CL,	  Martinez	  E,	  Geiger	  JC,	  Zimmer	  M,	  Traut	  MH,	  Stein	  V,	  Klein	  R,	  Acker-­‐Palmer	  A.	  2008.	  Serine	  phosphorylation	  of	  ephrinB2	  regulates	  trafficking	  of	  synaptic	  AMPA	  receptors.	  Nat	  Neurosci	  11:	  1035-­‐1043.	  
References 
 66 
Eswarakumar	  VP,	  Lax	  I,	  Schlessinger	  J.	  2005.	  Cellular	  signaling	  by	  fibroblast	  growth	  factor	  receptors.	  Cytokine	  &	  growth	  factor	  reviews	  16:	  139-­‐149.	  Falivelli	  G,	  Lisabeth	  EM,	  Rubio	  de	  la	  Torre	  E,	  Perez-­‐Tenorio	  G,	  Tosato	  G,	  Salvucci	  O,	  Pasquale	  EB.	  2013.	  Attenuation	  of	  eph	  receptor	  kinase	  activation	  in	  cancer	  cells	  by	  coexpressed	  ephrin	  ligands.	  PLoS	  One	  8:	  e81445.	  Faoro	  L,	  Singleton	  PA,	  Cervantes	  GM,	  Lennon	  FE,	  Choong	  NW,	  Kanteti	  R,	  Ferguson	  BD,	  Husain	  AN,	  Tretiakova	  MS,	  Ramnath	  N	  et	  al.	  2010.	  EphA2	  mutation	  in	  lung	  squamous	  cell	  carcinoma	  promotes	  increased	  cell	  survival,	  cell	  invasion,	  focal	  adhesions,	  and	  mammalian	  target	  of	  rapamycin	  activation.	  J	  Biol	  Chem	  
285:	  18575-­‐18585.	  Fasen	  K,	  Cerretti	  DP,	  Huynh-­‐Do	  U.	  2008.	  Ligand	  binding	  induces	  Cbl-­‐dependent	  EphB1	  receptor	  degradation	  through	  the	  lysosomal	  pathway.	  Traffic	  9:	  251-­‐266.	  Filosa	  A,	  Paixao	  S,	  Honsek	  SD,	  Carmona	  MA,	  Becker	  L,	  Feddersen	  B,	  Gaitanos	  L,	  Rudhard	  Y,	  Schoepfer	  R,	  Klopstock	  T	  et	  al.	  2009.	  Neuron-­‐glia	  communication	  via	  EphA4/ephrin-­‐A3	  modulates	  LTP	  through	  glial	  glutamate	  transport.	  Nat	  
Neurosci	  12:	  1285-­‐1292.	  Flanagan	  JG,	  Vanderhaeghen	  P.	  1998.	  The	  ephrins	  and	  Eph	  receptors	  in	  neural	  development.	  Annu	  Rev	  Neurosci	  21:	  309-­‐345.	  Follenzi	  A,	  Naldini	  L.	  2002.	  Generation	  of	  HIV-­‐1	  derived	  lentiviral	  vectors.	  Methods	  
Enzymol	  346:	  454-­‐465.	  Fremin	  C,	  Meloche	  S.	  2010.	  From	  basic	  research	  to	  clinical	  development	  of	  MEK1/2	  inhibitors	  for	  cancer	  therapy.	  Journal	  of	  hematology	  &	  oncology	  3:	  8.	  Fu	  WY,	  Chen	  Y,	  Sahin	  M,	  Zhao	  XS,	  Shi	  L,	  Bikoff	  JB,	  Lai	  KO,	  Yung	  WH,	  Fu	  AK,	  Greenberg	  ME	  et	  al.	  2007.	  Cdk5	  regulates	  EphA4-­‐mediated	  dendritic	  spine	  retraction	  through	  an	  ephexin1-­‐dependent	  mechanism.	  Nat	  Neurosci	  10:	  67-­‐76.	  Gaiano	  N,	  Fishell	  G.	  2002.	  The	  role	  of	  notch	  in	  promoting	  glial	  and	  neural	  stem	  cell	  fates.	  Annu	  Rev	  Neurosci	  25:	  471-­‐490.	  Gale	  NW,	  Flenniken	  A,	  Compton	  DC,	  Jenkins	  N,	  Copeland	  NG,	  Gilbert	  DJ,	  Davis	  S,	  Wilkinson	  DG,	  Yancopoulos	  GD.	  1996.	  Elk-­‐L3,	  a	  novel	  transmembrane	  ligand	  for	  the	  Eph	  family	  of	  receptor	  tyrosine	  kinases,	  expressed	  in	  embryonic	  floor	  plate,	  roof	  plate	  and	  hindbrain	  segments.	  Oncogene	  13:	  1343-­‐1352.	  Genander	  M,	  Frisen	  J.	  2010.	  Ephrins	  and	  Eph	  receptors	  in	  stem	  cells	  and	  cancer.	  Curr	  
Opin	  Cell	  Biol	  22:	  611-­‐616.	  Georgakopoulos	  A,	  Litterst	  C,	  Ghersi	  E,	  Baki	  L,	  Xu	  C,	  Serban	  G,	  Robakis	  NK.	  2006.	  Metalloproteinase/Presenilin1	  processing	  of	  ephrinB	  regulates	  EphB-­‐induced	  Src	  phosphorylation	  and	  signaling.	  EMBO	  J	  25:	  1242-­‐1252.	  Georgakopoulos	  A,	  Xu	  J,	  Xu	  C,	  Mauger	  G,	  Barthet	  G,	  Robakis	  NK.	  2011.	  Presenilin1/gamma-­‐secretase	  promotes	  the	  EphB2-­‐induced	  phosphorylation	  of	  ephrinB2	  by	  regulating	  phosphoprotein	  associated	  with	  glycosphingolipid-­‐enriched	  microdomains/Csk	  binding	  protein.	  FASEB	  J	  25:	  3594-­‐3604.	  Gopal	  U,	  Bohonowych	  JE,	  Lema-­‐Tome	  C,	  Liu	  A,	  Garrett-­‐Mayer	  E,	  Wang	  B,	  Isaacs	  JS.	  2011.	  A	  novel	  extracellular	  Hsp90	  mediated	  co-­‐receptor	  function	  for	  LRP1	  regulates	  EphA2	  dependent	  glioblastoma	  cell	  invasion.	  PLoS	  One	  6:	  e17649.	  
References 
 67 
Greulich	  H,	  Pollock	  PM.	  2011.	  Targeting	  mutant	  fibroblast	  growth	  factor	  receptors	  in	  cancer.	  Trends	  Mol	  Med	  17:	  283-­‐292.	  Gschwind	  A,	  Fischer	  OM,	  Ullrich	  A.	  2004.	  The	  discovery	  of	  receptor	  tyrosine	  kinases:	  targets	  for	  cancer	  therapy.	  Nat	  Rev	  Cancer	  4:	  361-­‐370.	  Guan	  M,	  Liu	  L,	  Zhao	  X,	  Wu	  Q,	  Yu	  B,	  Shao	  Y,	  Yang	  H,	  Fu	  X,	  Wan	  J,	  Zhang	  W.	  2011.	  Copy	  number	  variations	  of	  EphA3	  are	  associated	  with	  multiple	  types	  of	  hematologic	  malignancies.	  Clinical	  lymphoma,	  myeloma	  &	  leukemia	  11:	  50-­‐53.	  Haj	  FG,	  Sabet	  O,	  Kinkhabwala	  A,	  Wimmer-­‐Kleikamp	  S,	  Roukos	  V,	  Han	  HM,	  Grabenbauer	  M,	  Bierbaum	  M,	  Antony	  C,	  Neel	  BG	  et	  al.	  2012.	  Regulation	  of	  signaling	  at	  regions	  of	  cell-­‐cell	  contact	  by	  endoplasmic	  reticulum-­‐bound	  protein-­‐tyrosine	  phosphatase	  1B.	  PLoS	  One	  7:	  e36633.	  Haklai-­‐Topper	  L,	  Mlechkovich	  G,	  Savariego	  D,	  Gokhman	  I,	  Yaron	  A.	  2010.	  Cis	  interaction	  between	  Semaphorin6A	  and	  Plexin-­‐A4	  modulates	  the	  repulsive	  response	  to	  Sema6A.	  EMBO	  J	  29:	  2635-­‐2645.	  Harada	  K,	  Hiramoto-­‐Yamaki	  N,	  Negishi	  M,	  Katoh	  H.	  2011.	  Ephexin4	  and	  EphA2	  mediate	  resistance	  to	  anoikis	  through	  RhoG	  and	  phosphatidylinositol	  3-­‐kinase.	  Exp	  Cell	  Res	  317:	  1701-­‐1713.	  Hattori	  M,	  Osterfield	  M,	  Flanagan	  JG.	  2000.	  Regulated	  cleavage	  of	  a	  contact-­‐mediated	  axon	  repellent.	  Science	  289:	  1360-­‐1365.	  Heasman	  SJ,	  Ridley	  AJ.	  2008.	  Mammalian	  Rho	  GTPases:	  new	  insights	  into	  their	  functions	  from	  in	  vivo	  studies.	  Nat	  Rev	  Mol	  Cell	  Biol	  9:	  690-­‐701.	  Himanen	  JP,	  Rajashankar	  KR,	  Lackmann	  M,	  Cowan	  CA,	  Henkemeyer	  M,	  Nikolov	  DB.	  2001.	  Crystal	  structure	  of	  an	  Eph	  receptor-­‐ephrin	  complex.	  Nature	  414:	  933-­‐938.	  Himanen	  JP,	  Yermekbayeva	  L,	  Janes	  PW,	  Walker	  JR,	  Xu	  K,	  Atapattu	  L,	  Rajashankar	  KR,	  Mensinga	  A,	  Lackmann	  M,	  Nikolov	  DB	  et	  al.	  2010.	  Architecture	  of	  Eph	  receptor	  clusters.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A	  107:	  10860-­‐10865.	  Hinoue	  T,	  Weisenberger	  DJ,	  Pan	  F,	  Campan	  M,	  Kim	  M,	  Young	  J,	  Whitehall	  VL,	  Leggett	  BA,	  Laird	  PW.	  2009.	  Analysis	  of	  the	  association	  between	  CIMP	  and	  BRAF	  in	  colorectal	  cancer	  by	  DNA	  methylation	  profiling.	  PLoS	  One	  4:	  e8357.	  Hiramoto-­‐Yamaki	  N,	  Takeuchi	  S,	  Ueda	  S,	  Harada	  K,	  Fujimoto	  S,	  Negishi	  M,	  Katoh	  H.	  2010.	  Ephexin4	  and	  EphA2	  mediate	  cell	  migration	  through	  a	  RhoG-­‐dependent	  mechanism.	  J	  Cell	  Biol	  190:	  461-­‐477.	  Holen	  HL,	  Shadidi	  M,	  Narvhus	  K,	  Kjosnes	  O,	  Tierens	  A,	  Aasheim	  HC.	  2008.	  Signaling	  through	  ephrin-­‐A	  ligand	  leads	  to	  activation	  of	  Src-­‐family	  kinases,	  Akt	  phosphorylation,	  and	  inhibition	  of	  antigen	  receptor-­‐induced	  apoptosis.	  J	  
Leukoc	  Biol	  84:	  1183-­‐1191.	  Holen	  HL,	  Zernichow	  L,	  Fjelland	  KE,	  Evenroed	  IM,	  Prydz	  K,	  Tveit	  H,	  Aasheim	  HC.	  2011.	  Ephrin-­‐B3	  binds	  to	  a	  sulfated	  cell-­‐surface	  receptor.	  Biochem	  J	  433:	  215-­‐223.	  Hollingworth	  P	  Harold	  D	  Sims	  R	  Gerrish	  A	  Lambert	  JC	  Carrasquillo	  MM	  Abraham	  R	  Hamshere	  ML	  Pahwa	  JS	  Moskvina	  V	  et	  al.	  2011.	  Common	  variants	  at	  ABCA7,	  MS4A6A/MS4A4E,	  EPHA1,	  CD33	  and	  CD2AP	  are	  associated	  with	  Alzheimer's	  disease.	  Nat	  Genet	  43:	  429-­‐435.	  
References 
 68 
Holmberg	  J,	  Armulik	  A,	  Senti	  KA,	  Edoff	  K,	  Spalding	  K,	  Momma	  S,	  Cassidy	  R,	  Flanagan	  JG,	  Frisen	  J.	  2005.	  Ephrin-­‐A2	  reverse	  signaling	  negatively	  regulates	  neural	  progenitor	  proliferation	  and	  neurogenesis.	  Genes	  Dev	  19:	  462-­‐471.	  Holmberg	  J,	  Clarke	  DL,	  Frisen	  J.	  2000.	  Regulation	  of	  repulsion	  versus	  adhesion	  by	  different	  splice	  forms	  of	  an	  Eph	  receptor.	  Nature	  408:	  203-­‐206.	  Hornberger	  MR,	  Dutting	  D,	  Ciossek	  T,	  Yamada	  T,	  Handwerker	  C,	  Lang	  S,	  Weth	  F,	  Huf	  J,	  Wessel	  R,	  Logan	  C	  et	  al.	  1999.	  Modulation	  of	  EphA	  receptor	  function	  by	  coexpressed	  ephrinA	  ligands	  on	  retinal	  ganglion	  cell	  axons.	  Neuron	  22:	  731-­‐742.	  Huang	  X,	  Wu	  D,	  Jin	  H,	  Stupack	  D,	  Wang	  JY.	  2008.	  Induction	  of	  cell	  retraction	  by	  the	  combined	  actions	  of	  Abl-­‐CrkII	  and	  Rho-­‐ROCK1	  signaling.	  J	  Cell	  Biol	  183:	  711-­‐723.	  Hubbard	  SR.	  1999.	  Structural	  analysis	  of	  receptor	  tyrosine	  kinases.	  Progress	  in	  
biophysics	  and	  molecular	  biology	  71:	  343-­‐358.	  Hubbard	  SR,	  Till	  JH.	  2000.	  Protein	  tyrosine	  kinase	  structure	  and	  function.	  Annu	  Rev	  
Biochem	  69:	  373-­‐398.	  Hunter	  SG,	  Zhuang	  G,	  Brantley-­‐Sieders	  D,	  Swat	  W,	  Cowan	  CW,	  Chen	  J.	  2006.	  Essential	  Role	  of	  Vav	  Family	  Guanine	  Nucleotide	  Exchange	  Factors	  in	  EphA	  Receptor-­‐Mediated	  Angiogenesis.	  Mol	  Cell	  Biol	  26:	  4830-­‐4842.	  Huusko	  P,	  Ponciano-­‐Jackson	  D,	  Wolf	  M,	  Kiefer	  JA,	  Azorsa	  DO,	  Tuzmen	  S,	  Weaver	  D,	  Robbins	  C,	  Moses	  T,	  Allinen	  M	  et	  al.	  2004.	  Nonsense-­‐mediated	  decay	  microarray	  analysis	  identifies	  mutations	  of	  EPHB2	  in	  human	  prostate	  cancer.	  
Nat	  Genet	  36:	  979-­‐983.	  Ikeda	  M,	  Tomita	  Y,	  Mouri	  A,	  Koga	  M,	  Okochi	  T,	  Yoshimura	  R,	  Yamanouchi	  Y,	  Kinoshita	  Y,	  Hashimoto	  R,	  Williams	  HJ	  et	  al.	  2010.	  Identification	  of	  novel	  candidate	  genes	  for	  treatment	  response	  to	  risperidone	  and	  susceptibility	  for	  schizophrenia:	  integrated	  analysis	  among	  pharmacogenomics,	  mouse	  expression,	  and	  genetic	  case-­‐control	  association	  approaches.	  Biol	  Psychiatry	  
67:	  263-­‐269.	  Inoue	  E,	  Deguchi-­‐Tawarada	  M,	  Togawa	  A,	  Matsui	  C,	  Arita	  K,	  Katahira-­‐Tayama	  S,	  Sato	  T,	  Yamauchi	  E,	  Oda	  Y,	  Takai	  Y.	  2009.	  Synaptic	  activity	  prompts	  gamma-­‐secretase-­‐mediated	  cleavage	  of	  EphA4	  and	  dendritic	  spine	  formation.	  J	  Cell	  
Biol	  185:	  551-­‐564.	  Ireton	  RC,	  Chen	  J.	  2005.	  EphA2	  receptor	  tyrosine	  kinase	  as	  a	  promising	  target	  for	  cancer	  therapeutics.	  Curr	  Cancer	  Drug	  Targets	  5:	  149-­‐157.	  Irie	  F,	  Okuno	  M,	  Matsumoto	  K,	  Pasquale	  EB,	  Yamaguchi	  Y.	  2008.	  Heparan	  sulfate	  regulates	  ephrin-­‐A3/EphA	  receptor	  signaling.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A	  105:	  12307-­‐12312.	  Irie	  F,	  Yamaguchi	  Y.	  2002.	  EphB	  receptors	  regulate	  dendritic	  spine	  development	  via	  intersectin,	  Cdc42	  and	  N-­‐WASP.	  Nat	  Neurosci	  5:	  1117-­‐1118.	  Iwasato	  T,	  Katoh	  H,	  Nishimaru	  H,	  Ishikawa	  Y,	  Inoue	  H,	  Saito	  YM,	  Ando	  R,	  Iwama	  M,	  Takahashi	  R,	  Negishi	  M	  et	  al.	  2007.	  Rac-­‐GAP	  alpha-­‐Chimerin	  Regulates	  Motor-­‐Circuit	  Formation	  as	  a	  Key	  Mediator	  of	  EphrinB3/EphA4	  Forward	  Signaling.	  Cell	  130:	  742-­‐753.	  Janes	  PW,	  Griesshaber	  B,	  Atapattu	  L,	  Nievergall	  E,	  Hii	  LL,	  Mensinga	  A,	  Chheang	  C,	  Day	  BW,	  Boyd	  AW,	  Bastiaens	  PI	  et	  al.	  2011.	  Eph	  receptor	  function	  is	  
References 
 69 
modulated	  by	  heterooligomerization	  of	  A	  and	  B	  type	  Eph	  receptors.	  J	  Cell	  Biol	  
195:	  1033-­‐1045.	  Janes	  PW,	  Saha	  N,	  Barton	  WA,	  Kolev	  MV,	  Wimmer-­‐Kleikamp	  SH,	  Nievergall	  E,	  Blobel	  CP,	  Himanen	  JP,	  Lackmann	  M,	  Nikolov	  DB.	  2005.	  Adam	  meets	  Eph:	  an	  ADAM	  substrate	  recognition	  module	  acts	  as	  a	  molecular	  switch	  for	  ephrin	  cleavage	  in	  trans.	  Cell	  123:	  291-­‐304.	  Janes	  PW,	  Wimmer-­‐Kleikamp	  SH,	  Frangakis	  AS,	  Treble	  K,	  Griesshaber	  B,	  Sabet	  O,	  Grabenbauer	  M,	  Ting	  AY,	  Saftig	  P,	  Bastiaens	  PI	  et	  al.	  2009.	  Cytoplasmic	  relaxation	  of	  active	  Eph	  controls	  ephrin	  shedding	  by	  ADAM10.	  PLoS	  Biol	  7:	  e1000215.	  Ji	  XD,	  Li	  G,	  Feng	  YX,	  Zhao	  JS,	  Li	  JJ,	  Sun	  ZJ,	  Shi	  S,	  Deng	  YZ,	  Xu	  JF,	  Zhu	  YQ	  et	  al.	  2011.	  EphB3	  is	  overexpressed	  in	  non-­‐small-­‐cell	  lung	  cancer	  and	  promotes	  tumor	  metastasis	  by	  enhancing	  cell	  survival	  and	  migration.	  Cancer	  Res	  71:	  1156-­‐1166.	  Jorgensen	  C,	  Sherman	  A,	  Chen	  GI,	  Pasculescu	  A,	  Poliakov	  A,	  Hsiung	  M,	  Larsen	  B,	  Wilkinson	  DG,	  Linding	  R,	  Pawson	  T.	  2009.	  Cell-­‐specific	  information	  processing	  in	  segregating	  populations	  of	  Eph	  receptor	  ephrin-­‐expressing	  cells.	  Science	  326:	  1502-­‐1509.	  Jun	  G,	  Guo	  H,	  Klein	  BE,	  Klein	  R,	  Wang	  JJ,	  Mitchell	  P,	  Miao	  H,	  Lee	  KE,	  Joshi	  T,	  Buck	  M	  et	  al.	  2009.	  EPHA2	  is	  associated	  with	  age-­‐related	  cortical	  cataract	  in	  mice	  and	  humans.	  PLoS	  Genet	  5:	  e1000584.	  Kageyama	  R,	  Ohtsuka	  T,	  Shimojo	  H,	  Imayoshi	  I.	  2008.	  Dynamic	  Notch	  signaling	  in	  neural	  progenitor	  cells	  and	  a	  revised	  view	  of	  lateral	  inhibition.	  Nat	  Neurosci	  
11:	  1247-­‐1251.	  Kao	  TJ,	  Kania	  A.	  2011.	  Ephrin-­‐mediated	  cis-­‐attenuation	  of	  Eph	  receptor	  signaling	  is	  essential	  for	  spinal	  motor	  axon	  guidance.	  Neuron	  71:	  76-­‐91.	  Keane	  N,	  Freeman	  C,	  Swords	  R,	  Giles	  FJ.	  2012.	  EPHA3	  as	  a	  novel	  therapeutic	  target	  in	  the	  hematological	  malignancies.	  Expert	  review	  of	  hematology	  5:	  325-­‐340.	  Khodayari	  N,	  Mohammed	  KA,	  Goldberg	  EP,	  Nasreen	  N.	  2011.	  EphrinA1	  inhibits	  malignant	  mesothelioma	  tumor	  growth	  via	  let-­‐7	  microRNA-­‐mediated	  repression	  of	  the	  RAS	  oncogene.	  Cancer	  Gene	  Ther	  18:	  806-­‐816.	  Kikawa	  KD,	  Vidale	  DR,	  Van	  Etten	  RL,	  Kinch	  MS.	  2002.	  Regulation	  of	  the	  EphA2	  Kinase	  by	  the	  Low	  Molecular	  Weight	  Tyrosine	  Phosphatase	  Induces	  Transformation.	  J	  Biol	  Chem	  277:	  39274-­‐39279.	  Klein	  R.	  2009.	  Bidirectional	  modulation	  of	  synaptic	  functions	  by	  Eph/ephrin	  signaling.	  Nat	  Neurosci	  12:	  15-­‐20.	  Klein	  T,	  Arias	  AM.	  1998.	  Interactions	  among	  Delta,	  Serrate	  and	  Fringe	  modulate	  Notch	  activity	  during	  Drosophila	  wing	  development.	  Development	  125:	  2951-­‐2962.	  Klein	  T,	  Brennan	  K,	  Arias	  AM.	  1997.	  An	  intrinsic	  dominant	  negative	  activity	  of	  serrate	  that	  is	  modulated	  during	  wing	  development	  in	  Drosophila.	  Dev	  Biol	  
189:	  123-­‐134.	  Konstantinova	  I,	  Nikolova	  G,	  Ohara-­‐Imaizumi	  M,	  Meda	  P,	  Kucera	  T,	  Zarbalis	  K,	  Wurst	  W,	  Nagamatsu	  S,	  Lammert	  E.	  2007.	  EphA-­‐Ephrin-­‐A-­‐mediated	  beta	  cell	  communication	  regulates	  insulin	  secretion	  from	  pancreatic	  islets.	  Cell	  129:	  359-­‐370.	  
References 
 70 
Kuzina	  I,	  Song	  JK,	  Giniger	  E.	  2011.	  How	  Notch	  establishes	  longitudinal	  axon	  connections	  between	  successive	  segments	  of	  the	  Drosophila	  CNS.	  
Development	  138:	  1839-­‐1849.	  Lackmann	  M,	  Boyd	  AW.	  2008.	  Eph,	  a	  protein	  family	  coming	  of	  age:	  more	  confusion,	  insight,	  or	  complexity?	  Sci	  Signal	  1:	  re2.	  Lai	  KO,	  Chen	  Y,	  Po	  HM,	  Lok	  KC,	  Gong	  K,	  Ip	  NY.	  2004.	  Identification	  of	  the	  Jak/Stat	  proteins	  as	  novel	  downstream	  targets	  of	  EphA4	  signaling	  in	  muscle:	  implications	  in	  the	  regulation	  of	  acetylcholinesterase	  expression.	  J	  Biol	  Chem	  
279:	  13383-­‐13392.	  Lamorte	  L,	  Royal	  I,	  Naujokas	  M,	  Park	  M.	  2002.	  Crk	  adapter	  proteins	  promote	  an	  epithelial-­‐mesenchymal-­‐like	  transition	  and	  are	  required	  for	  HGF-­‐mediated	  cell	  spreading	  and	  breakdown	  of	  epithelial	  adherens	  junctions.	  Mol	  Biol	  Cell	  
13:	  1449-­‐1461.	  Larsen	  AB,	  Pedersen	  MW,	  Stockhausen	  MT,	  Grandal	  MV,	  van	  Deurs	  B,	  Poulsen	  HS.	  2007.	  Activation	  of	  the	  EGFR	  gene	  target	  EphA2	  inhibits	  epidermal	  growth	  factor-­‐induced	  cancer	  cell	  motility.	  Mol	  Cancer	  Res	  5:	  283-­‐293.	  Lee	  HJ,	  Hota	  PK,	  Chugha	  P,	  Guo	  H,	  Miao	  H,	  Zhang	  L,	  Kim	  SJ,	  Stetzik	  L,	  Wang	  BC,	  Buck	  M.	  2012.	  NMR	  Structure	  of	  a	  Heterodimeric	  SAM:SAM	  Complex:	  Characterization	  and	  Manipulation	  of	  EphA2	  Binding	  Reveal	  New	  Cellular	  Functions	  of	  SHIP2.	  Structure	  20:	  41-­‐55.	  Lee	  HS,	  Nishanian	  TG,	  Mood	  K,	  Bong	  YS,	  Daar	  IO.	  2008.	  EphrinB1	  controls	  cell-­‐cell	  junctions	  through	  the	  Par	  polarity	  complex.	  Nat	  Cell	  Biol	  10:	  979-­‐986.	  Lee	  JC,	  Vivanco	  I,	  Beroukhim	  R,	  Huang	  JH,	  Feng	  WL,	  DeBiasi	  RM,	  Yoshimoto	  K,	  King	  JC,	  Nghiemphu	  P,	  Yuza	  Y	  et	  al.	  2006.	  Epidermal	  growth	  factor	  receptor	  activation	  in	  glioblastoma	  through	  novel	  missense	  mutations	  in	  the	  extracellular	  domain.	  PLoS	  Med	  3:	  e485.	  Lemmon	  MA,	  Schlessinger	  J.	  2010.	  Cell	  signaling	  by	  receptor	  tyrosine	  kinases.	  Cell	  
141:	  1117-­‐1134.	  Lesnick	  TG,	  Sorenson	  EJ,	  Ahlskog	  JE,	  Henley	  JR,	  Shehadeh	  L,	  Papapetropoulos	  S,	  Maraganore	  DM.	  2008.	  Beyond	  Parkinson	  disease:	  amyotrophic	  lateral	  sclerosis	  and	  the	  axon	  guidance	  pathway.	  PLoS	  One	  3:	  e1449.	  Li	  G,	  Ji	  XD,	  Gao	  H,	  Zhao	  JS,	  Xu	  JF,	  Sun	  ZJ,	  Deng	  YZ,	  Shi	  S,	  Feng	  YX,	  Zhu	  YQ	  et	  al.	  2012.	  EphB3	  suppresses	  non-­‐small-­‐cell	  lung	  cancer	  metastasis	  via	  a	  PP2A/RACK1/Akt	  signalling	  complex.	  Nat	  Commun	  3:	  667.	  Li	  JJ,	  Liu	  DP,	  Liu	  GT,	  Xie	  D.	  2009.	  EphrinA5	  acts	  as	  a	  tumor	  suppressor	  in	  glioma	  by	  negative	  regulation	  of	  epidermal	  growth	  factor	  receptor.	  Oncogene	  28:	  1759-­‐1768.	  Lieber	  T,	  Kidd	  S,	  Struhl	  G.	  2011.	  DSL-­‐Notch	  signaling	  in	  the	  Drosophila	  brain	  in	  response	  to	  olfactory	  stimulation.	  Neuron	  69:	  468-­‐481.	  Lim	  YS,	  McLaughlin	  T,	  Sung	  TC,	  Santiago	  A,	  Lee	  KF,	  O'Leary	  DD.	  2008.	  p75(NTR)	  mediates	  ephrin-­‐A	  reverse	  signaling	  required	  for	  axon	  repulsion	  and	  mapping.	  Neuron	  59:	  746-­‐758.	  Lisabeth	  EM,	  Falivelli	  G,	  Pasquale	  EB.	  2013a.	  Eph	  receptor	  signaling	  and	  ephrins.	  
Cold	  Spring	  Harb	  Perspect	  Biol:	  (in	  press).	  Lisabeth	  EM,	  Falivelli	  G,	  Pasquale	  EB.	  2013b.	  Eph	  receptor	  signaling	  and	  ephrins.	  
Cold	  Spring	  Harbor	  perspectives	  in	  biology	  5.	  
References 
 71 
Lisabeth	  EM,	  Fernandez	  C,	  Pasquale	  EB.	  2012.	  Cancer	  somatic	  mutations	  disrupt	  functions	  of	  the	  EphA3	  receptor	  tyrosine	  kinase	  through	  multiple	  mechanisms.	  Biochemistry	  51:	  1464-­‐1475.	  Litterst	  C,	  Georgakopoulos	  A,	  Shioi	  J,	  Ghersi	  E,	  Wisniewski	  T,	  Wang	  R,	  Ludwig	  A,	  Robakis	  NK.	  2007.	  Ligand	  binding	  and	  calcium	  influx	  induce	  distinct	  ectodomain/gamma-­‐secretase-­‐processing	  pathways	  of	  EphB2	  receptor.	  J	  Biol	  
Chem	  282:	  16155-­‐16163.	  Lu	  Q,	  Sun	  EE,	  Klein	  RS,	  Flanagan	  JG.	  2001.	  Ephrin-­‐B	  reverse	  signaling	  is	  mediated	  by	  a	  novel	  PDZ-­‐RGS	  protein	  and	  selectively	  inhibits	  G	  protein-­‐coupled	  chemoattraction.	  Cell	  105:	  69-­‐79.	  Macrae	  M,	  Neve	  RM,	  Rodriguez-­‐Viciana	  P,	  Haqq	  C,	  Yeh	  J,	  Chen	  C,	  Gray	  JW,	  McCormick	  F.	  2005.	  A	  conditional	  feedback	  loop	  regulates	  Ras	  activity	  through	  EphA2.	  Cancer	  Cell	  8:	  111-­‐118.	  Maddigan	  A,	  Truitt	  L,	  Arsenault	  R,	  Freywald	  T,	  Allonby	  O,	  Dean	  J,	  Narendran	  A,	  Xiang	  J,	  Weng	  A,	  Napper	  S	  et	  al.	  2011.	  EphB	  receptors	  trigger	  Akt	  activation	  and	  suppress	  Fas	  receptor-­‐induced	  apoptosis	  in	  malignant	  T	  lymphocytes.	  J	  
Immunol	  187:	  5983-­‐5994.	  Makarov	  R,	  Steiner	  B,	  Gucev	  Z,	  Tasic	  V,	  Wieacker	  P,	  Wieland	  I.	  2010.	  The	  impact	  of	  CFNS-­‐causing	  EFNB1	  mutations	  on	  ephrin-­‐B1	  function.	  BMC	  Med	  Genet	  11:	  98.	  Makinen	  T,	  Adams	  RH,	  Bailey	  J,	  Lu	  Q,	  Ziemiecki	  A,	  Alitalo	  K,	  Klein	  R,	  Wilkinson	  GA.	  2005.	  PDZ	  interaction	  site	  in	  ephrinB2	  is	  required	  for	  the	  remodeling	  of	  lymphatic	  vasculature.	  Genes	  Dev	  19:	  397-­‐410.	  Manning	  BD,	  Cantley	  LC.	  2007.	  AKT/PKB	  signaling:	  navigating	  downstream.	  Cell	  
129:	  1261-­‐1274.	  Margolis	  SS,	  Salogiannis	  J,	  Lipton	  DM,	  Mandel-­‐Brehm	  C,	  Wills	  ZP,	  Mardinly	  AR,	  Hu	  L,	  Greer	  PL,	  Bikoff	  JB,	  Ho	  HY	  et	  al.	  2010.	  EphB-­‐mediated	  degradation	  of	  the	  RhoA	  GEF	  Ephexin5	  relieves	  a	  developmental	  brake	  on	  excitatory	  synapse	  formation.	  Cell	  143:	  442-­‐455.	  Marler	  KJ,	  Becker-­‐Barroso	  E,	  Martinez	  A,	  Llovera	  M,	  Wentzel	  C,	  Poopalasundaram	  S,	  Hindges	  R,	  Soriano	  E,	  Comella	  J,	  Drescher	  U.	  2008.	  A	  TrkB/EphrinA	  interaction	  controls	  retinal	  axon	  branching	  and	  synaptogenesis.	  J	  Neurosci	  
28:	  12700-­‐12712.	  Marler	  KJ,	  Poopalasundaram	  S,	  Broom	  ER,	  Wentzel	  C,	  Drescher	  U.	  2010.	  Pro-­‐neurotrophins	  secreted	  from	  retinal	  ganglion	  cell	  axons	  are	  necessary	  for	  ephrinA-­‐p75NTR-­‐mediated	  axon	  guidance.	  Neural	  Dev	  5:	  30.	  Marquardt	  T,	  Shirasaki	  R,	  Ghosh	  S,	  Andrews	  SE,	  Carter	  N,	  Hunter	  T,	  Pfaff	  SL.	  2005.	  Coexpressed	  EphA	  Receptors	  and	  Ephrin-­‐A	  Ligands	  Mediate	  Opposing	  Actions	  on	  Growth	  Cone	  Navigation	  from	  Distinct	  Membrane	  Domains.	  Cell	  
121:	  127-­‐139.	  Marston	  DJ,	  Dickinson	  S,	  Nobes	  CD.	  2003.	  Rac-­‐dependent	  trans-­‐endocytosis	  of	  ephrinBs	  regulates	  Eph-­‐ephrin	  contact	  repulsion.	  Nat	  Cell	  Biol	  5:	  879-­‐888.	  McKay	  MM,	  Morrison	  DK.	  2007.	  Integrating	  signals	  from	  RTKs	  to	  ERK/MAPK.	  
Oncogene	  26:	  3113-­‐3121.	  Meier	  C,	  Anastasiadou	  S,	  Knoll	  B.	  2011.	  Ephrin-­‐A5	  Suppresses	  Neurotrophin	  Evoked	  Neuronal	  Motility,	  ERK	  Activation	  and	  Gene	  Expression.	  PLoS	  One	  6:	  e26089.	  
References 
 72 
Mellitzer	  G,	  Xu	  QL,	  Wilkinson	  DG.	  1999.	  Eph	  receptors	  and	  ephrins	  restrict	  cell	  intermingling	  and	  communication.	  Nature	  400:	  77-­‐81.	  Menges	  CW,	  McCance	  DJ.	  2008.	  Constitutive	  activation	  of	  the	  Raf-­‐MAPK	  pathway	  causes	  negative	  feedback	  inhibition	  of	  Ras-­‐PI3K-­‐AKT	  and	  cellular	  arrest	  through	  the	  EphA2	  receptor.	  Oncogene	  27:	  2934-­‐2940.	  Miao	  H,	  Burnett	  E,	  Kinch	  M,	  Simon	  E,	  Wang	  B.	  2000.	  Activation	  of	  EphA2	  kinase	  suppresses	  integrin	  function	  and	  causes	  focal-­‐adhesion-­‐kinase	  dephosphorylation.	  Nat	  Cell	  Biol	  2:	  62-­‐69.	  Miao	  H,	  Li	  DQ,	  Mukherjee	  A,	  Guo	  H,	  Petty	  A,	  Cutter	  J,	  Basilion	  JP,	  Sedor	  J,	  Wu	  J,	  Danielpour	  D	  et	  al.	  2009.	  EphA2	  mediates	  ligand-­‐dependent	  inhibition	  and	  ligand-­‐independent	  promotion	  of	  cell	  migration	  and	  invasion	  via	  a	  reciprocal	  regulatory	  loop	  with	  Akt.	  Cancer	  Cell	  16:	  9-­‐20.	  Miao	  H,	  Wei	  BR,	  Peehl	  DM,	  Li	  Q,	  Alexandrou	  T,	  Schelling	  JR,	  Rhim	  JS,	  Sedor	  JR,	  Burnett	  E,	  Wang	  BC.	  2001.	  Activation	  of	  EphA	  receptor	  tyrosine	  kinase	  inhibits	  the	  Ras/MAPK	  pathway.	  Nat	  Cell	  Biol	  3:	  527-­‐530.	  Miller	  AC,	  Lyons	  EL,	  Herman	  TG.	  2009.	  cis-­‐Inhibition	  of	  Notch	  by	  endogenous	  Delta	  biases	  the	  outcome	  of	  lateral	  inhibition.	  Curr	  Biol	  19:	  1378-­‐1383.	  Minami	  M,	  Koyama	  T,	  Wakayama	  Y,	  Fukuhara	  S,	  Mochizuki	  N.	  2011.	  EphrinA/EphA	  signal	  facilitates	  insulin-­‐like	  growth	  factor-­‐I-­‐induced	  myogenic	  differentiation	  through	  suppression	  of	  the	  Ras/extracellular	  signal-­‐regulated	  kinase	  1/2	  cascade	  in	  myoblast	  cell	  lines.	  Mol	  Biol	  Cell	  22:	  3508-­‐3519.	  Moeller	  ML,	  Shi	  Y,	  Reichardt	  LF,	  Ethell	  IM.	  2006.	  EphB	  receptors	  regulate	  dendritic	  spine	  morphogenesis	  through	  the	  recruitment/phosphorylation	  of	  focal	  adhesion	  kinase	  and	  RhoA	  activation.	  J	  Biol	  Chem	  281:	  1587-­‐1598.	  Murai	  KK,	  Nguyen	  LN,	  Irie	  F,	  Yamaguchi	  Y,	  Pasquale	  EB.	  2003.	  Control	  of	  hippocampal	  dendritic	  spine	  morphology	  through	  ephrin-­‐A3/EphA4	  signaling.	  Nat	  Neurosci	  6:	  153-­‐160.	  Naj	  AC	  Jun	  G	  Beecham	  GW	  Wang	  LS	  Vardarajan	  BN	  Buros	  J	  Gallins	  PJ	  Buxbaum	  JD	  Jarvik	  GP	  Crane	  PK	  et	  al.	  2011.	  Common	  variants	  at	  MS4A4/MS4A6E,	  CD2AP,	  CD33	  and	  EPHA1	  are	  associated	  with	  late-­‐onset	  Alzheimer's	  disease.	  Nat	  
Genet	  43:	  436-­‐441.	  Nakada	  M,	  Drake	  KL,	  Nakada	  S,	  Niska	  JA,	  Berens	  ME.	  2006.	  Ephrin-­‐B3	  Ligand	  Promotes	  Glioma	  Invasion	  through	  Activation	  of	  Rac1.	  Cancer	  Res	  66:	  8492-­‐8500.	  Nie	  D,	  Di	  Nardo	  A,	  Han	  JM,	  Baharanyi	  H,	  Kramvis	  I,	  Huynh	  T,	  Dabora	  S,	  Codeluppi	  S,	  Pandolfi	  PP,	  Pasquale	  EB	  et	  al.	  2010.	  Tsc2-­‐Rheb	  signaling	  regulates	  EphA-­‐mediated	  axon	  guidance.	  Nat	  Neurosci	  13:	  163-­‐172.	  Nievergall	  E,	  Janes	  PW,	  Stegmayer	  C,	  Vail	  ME,	  Haj	  FG,	  Teng	  SW,	  Neel	  BG,	  Bastiaens	  PI,	  Lackmann	  M.	  2010.	  PTP1B	  regulates	  Eph	  receptor	  function	  and	  trafficking.	  J	  Cell	  Biol	  191:	  1189-­‐1203.	  Nitschke	  L.	  2009.	  CD22	  and	  Siglec-­‐G:	  B-­‐cell	  inhibitory	  receptors	  with	  distinct	  functions.	  Immunol	  Rev	  230:	  128-­‐143.	  Noberini	  R,	  Lamberto	  I,	  Pasquale	  EB.	  2012a.	  Targeting	  Eph	  receptors	  with	  peptides	  and	  small	  molecules:	  progress	  and	  challenges.	  Semin	  Cell	  Dev	  Biol	  23:	  51-­‐57.	  
References 
 73 
Noberini	  R,	  Rubio	  de	  la	  Torre	  E,	  Pasquale	  EB.	  2012b.	  Profiling	  Eph	  receptor	  expression	  in	  cells	  and	  tissues:	  a	  targeted	  mass	  spectrometry	  approach.	  Cell	  
Adh	  Migr	  6:	  102-­‐112.	  Noren	  NK,	  Foos	  G,	  Hauser	  CA,	  Pasquale	  EB.	  2006.	  The	  EphB4	  receptor	  suppresses	  breast	  cancer	  cell	  tumorigenicity	  through	  an	  Abl-­‐Crk	  pathway.	  Nat	  Cell	  Biol	  8:	  815-­‐825.	  Noren	  NK,	  Lu	  M,	  Freeman	  AL,	  Koolpe	  M,	  Pasquale	  EB.	  2004.	  Interplay	  between	  EphB4	  on	  tumor	  cells	  and	  vascular	  ephrin-­‐B2	  regulates	  tumor	  growth.	  Proc	  
Natl	  Acad	  Sci	  U	  S	  A	  101:	  5583-­‐5588.	  Noren	  NK,	  Pasquale	  EB.	  2007.	  Paradoxes	  of	  the	  EphB4	  receptor	  in	  cancer.	  Cancer	  
Res	  67:	  3994-­‐3997.	  Oricchio	  E,	  Nanjangud	  G,	  Wolfe	  AL,	  Schatz	  JH,	  Mavrakis	  KJ,	  Jiang	  M,	  Liu	  X,	  Bruno	  J,	  Heguy	  A,	  Olshen	  AB	  et	  al.	  2011.	  The	  eph-­‐receptor	  a7	  is	  a	  soluble	  tumor	  suppressor	  for	  follicular	  lymphoma.	  Cell	  147:	  554-­‐564.	  Palmer	  A,	  Zimmer	  M,	  Erdmann	  KS,	  Eulenburg	  V,	  Porthin	  A,	  Heumann	  R,	  Deutsch	  U,	  Klein	  R.	  2002.	  EphrinB	  phosphorylation	  and	  reverse	  signaling:	  regulation	  by	  Src	  kinases	  and	  PTP-­‐BL	  phosphatase.	  Molecular	  cell	  9:	  725-­‐737.	  Park	  EC,	  Cho	  GS,	  Kim	  GH,	  Choi	  SC,	  Han	  JK.	  2011.	  The	  involvement	  of	  Eph-­‐Ephrin	  signaling	  in	  tissue	  separation	  and	  convergence	  during	  Xenopus	  gastrulation	  movements.	  Dev	  Biol	  350:	  441-­‐450.	  Parri	  M,	  Buricchi	  F,	  Taddei	  ML,	  Giannoni	  E,	  Raugei	  G,	  Ramponi	  G,	  Chiarugi	  P.	  2005.	  EphrinA1	  repulsive	  response	  is	  regulated	  by	  an	  EphA2	  tyrosine	  phosphatase.	  
J	  Biol	  Chem	  280:	  34008-­‐34018.	  Parrinello	  S,	  Napoli	  I,	  Ribeiro	  S,	  Digby	  PW,	  Fedorova	  M,	  Parkinson	  DB,	  Doddrell	  RD,	  Nakayama	  M,	  Adams	  RH,	  Lloyd	  AC.	  2010.	  EphB	  signaling	  directs	  peripheral	  nerve	  regeneration	  through	  Sox2-­‐dependent	  Schwann	  cell	  sorting.	  Cell	  143:	  145-­‐155.	  Pasquale	  EB.	  2004.	  Eph-­‐ephrin	  promiscuity	  is	  now	  crystal	  clear.	  Nat	  Neurosci	  7:	  417-­‐418.	  -­‐.	  2005.	  Eph	  receptor	  signalling	  casts	  a	  wide	  net	  on	  cell	  behaviour.	  Nat	  Rev	  Mol	  Cell	  
Biol	  6:	  462-­‐475.	  -­‐.	  2008.	  Eph-­‐ephrin	  bidirectional	  signaling	  in	  physiology	  and	  disease.	  Cell	  133:	  38-­‐52.	  -­‐.	  2010.	  Eph	  receptors	  and	  ephrins	  in	  cancer:	  bidirectional	  signalling	  and	  beyond.	  
Nat	  Rev	  Cancer	  10:	  165-­‐180.	  Pawson	  T.	  1995.	  Protein	  modules	  and	  signalling	  networks.	  Nature	  373:	  573-­‐580.	  Peifer	  M,	  Fernandez-­‐Cuesta	  L,	  Sos	  ML,	  George	  J,	  Seidel	  D,	  Kasper	  LH,	  Plenker	  D,	  Leenders	  F,	  Sun	  R,	  Zander	  T	  et	  al.	  2012.	  Integrative	  genome	  analyses	  identify	  key	  somatic	  driver	  mutations	  of	  small-­‐cell	  lung	  cancer.	  Nat	  Genet	  44:	  1104-­‐1110.	  Penzes	  P,	  Beeser	  A,	  Chernoff	  J,	  Schiller	  MR,	  Eipper	  BA,	  Mains	  RE,	  Huganir	  RL.	  2003.	  Rapid	  Induction	  of	  Dendritic	  Spine	  Morphogenesis	  by	  trans-­‐Synaptic	  EphrinB-­‐EphB	  Receptor	  Activation	  of	  the	  Rho-­‐GEF	  Kalirin.	  Neuron	  37:	  263-­‐274.	  
References 
 74 
Peschard	  P,	  Park	  M.	  2003.	  Escape	  from	  Cbl-­‐mediated	  downregulation:	  a	  recurrent	  theme	  for	  oncogenic	  deregulation	  of	  receptor	  tyrosine	  kinases.	  Cancer	  Cell	  3:	  519-­‐523.	  Picco	  V,	  Hudson	  C,	  Yasuo	  H.	  2007.	  Ephrin-­‐Eph	  signalling	  drives	  the	  asymmetric	  division	  of	  notochord/neural	  precursors	  in	  Ciona	  embryos.	  Development	  
134:	  1491-­‐1497.	  Pitulescu	  ME,	  Adams	  RH.	  2010.	  Eph/ephrin	  molecules-­‐-­‐a	  hub	  for	  signaling	  and	  endocytosis.	  Genes	  Dev	  24:	  2480-­‐2492.	  Poliakov	  A,	  Cotrina	  ML,	  Pasini	  A,	  Wilkinson	  DG.	  2008.	  Regulation	  of	  EphB2	  activation	  and	  cell	  repulsion	  by	  feedback	  control	  of	  the	  MAPK	  pathway.	  J	  Cell	  
Biol	  183:	  933-­‐947.	  Prickett	  TD,	  Agrawal	  NS,	  Wei	  X,	  Yates	  KE,	  Lin	  JC,	  Wunderlich	  JR,	  Cronin	  JC,	  Cruz	  P,	  Rosenberg	  SA,	  Samuels	  Y.	  2009.	  Analysis	  of	  the	  tyrosine	  kinome	  in	  melanoma	  reveals	  recurrent	  mutations	  in	  ERBB4.	  Nat	  Genet	  41:	  1127-­‐1132.	  Qiu	  R,	  Wang	  J,	  Tsark	  W,	  Lu	  Q.	  2010.	  Essential	  role	  of	  PDZ-­‐RGS3	  in	  the	  maintenance	  of	  neural	  progenitor	  cells.	  Stem	  cells	  (Dayton,	  Ohio)	  28:	  1602-­‐1610.	  Richter	  M,	  Murai	  KK,	  Bourgin	  C,	  Pak	  D,	  Pasquale	  EB.	  2007.	  The	  EphA4	  receptor	  regulates	  neuronal	  morphology	  through	  SPAR-­‐mediated	  inactivation	  of	  Rap	  GTPases.	  J	  Neurosci	  27:	  14215-­‐14205.	  Riedl	  JA,	  Brandt	  DT,	  Batlle	  E,	  Price	  LS,	  Clevers	  H,	  Bos	  JL.	  2005.	  Down-­‐regulation	  of	  Rap1	  activity	  is	  involved	  in	  ephrinB1-­‐induced	  cell	  contraction.	  Biochem	  J	  
389:	  465-­‐469.	  Robinson	  DR,	  Wu	  YM,	  Lin	  SF.	  2000.	  The	  protein	  tyrosine	  kinase	  family	  of	  the	  human	  genome.	  Oncogene	  19:	  5548-­‐5557.	  Rohani	  N,	  Canty	  L,	  Luu	  O,	  Fagotto	  F,	  Winklbauer	  R.	  2011.	  EphrinB/EphB	  signaling	  controls	  embryonic	  germ	  layer	  separation	  by	  contact-­‐induced	  cell	  detachment.	  PLoS	  Biol	  9:	  e1000597.	  Sahin	  M,	  Greer	  PL,	  Lin	  MZ,	  Poucher	  H,	  Eberhart	  J,	  Schmidt	  S,	  Wright	  TM,	  Shamah	  SM,	  O'Connell	  S,	  Cowan	  CW	  et	  al.	  2005.	  Eph-­‐dependent	  tyrosine	  phosphorylation	  of	  ephexin1	  modulates	  growth	  cone	  collapse.	  Neuron	  46:	  191-­‐204.	  Sakamoto	  K,	  Ohara	  O,	  Takagi	  M,	  Takeda	  S,	  Katsube	  K.	  2002.	  Intracellular	  cell-­‐autonomous	  association	  of	  Notch	  and	  its	  ligands:	  a	  novel	  mechanism	  of	  Notch	  signal	  modification.	  Dev	  Biol	  241:	  313-­‐326.	  Salaita	  K,	  Groves	  JT.	  2010.	  Roles	  of	  the	  cytoskeleton	  in	  regulating	  EphA2	  signals.	  
Commun	  Integr	  Biol	  3:	  454-­‐457.	  Salvucci	  O,	  Maric	  D,	  Economopoulou	  M,	  Sakakibara	  S,	  Merlin	  S,	  Follenzi	  A,	  Tosato	  G.	  2009.	  EphrinB	  reverse	  signaling	  contributes	  to	  endothelial	  and	  mural	  cell	  assembly	  into	  vascular	  structures.	  Blood	  114:	  1707-­‐1716.	  Sawamiphak	  S,	  Seidel	  S,	  Essmann	  CL,	  Wilkinson	  GA,	  Pitulescu	  ME,	  Acker	  T,	  Acker-­‐Palmer	  A.	  2010.	  Ephrin-­‐B2	  regulates	  VEGFR2	  function	  in	  developmental	  and	  tumour	  angiogenesis.	  Nature	  465:	  487-­‐491.	  Segura	  I,	  Essmann	  CL,	  Weinges	  S,	  Acker-­‐Palmer	  A.	  2007.	  Grb4	  and	  GIT1	  transduce	  ephrinB	  reverse	  signals	  modulating	  spine	  morphogenesis	  and	  synapse	  formation.	  Nat	  Neurosci	  10:	  301-­‐310.	  
References 
 75 
Seiradake	  E,	  Harlos	  K,	  Sutton	  G,	  Aricescu	  AR,	  Jones	  EY.	  2010.	  An	  extracellular	  steric	  seeding	  mechanism	  for	  Eph-­‐ephrin	  signaling	  platform	  assembly.	  Nat	  Struct	  
Mol	  Biol	  17:	  398-­‐402.	  Senturk	  A,	  Pfennig	  S,	  Weiss	  A,	  Burk	  K,	  Acker-­‐Palmer	  A.	  2011.	  Ephrin	  Bs	  are	  essential	  components	  of	  the	  Reelin	  pathway	  to	  regulate	  neuronal	  migration.	  Nature	  
472:	  356-­‐360.	  Shamah	  SM,	  Lin	  MZ,	  Goldberg	  JL,	  Estrach	  S,	  Sahin	  M,	  Hu	  L,	  Bazalakova	  M,	  Neve	  RL,	  Corfas	  G,	  Debant	  A	  et	  al.	  2001.	  EphA	  receptors	  regulate	  growth	  cone	  dynamics	  through	  the	  novel	  guanine	  nucleotide	  exchange	  factor	  ephexin.	  Cell	  
105:	  233-­‐244.	  Sharma	  SV,	  Bell	  DW,	  Settleman	  J,	  Haber	  DA.	  2007.	  Epidermal	  growth	  factor	  receptor	  mutations	  in	  lung	  cancer.	  Nat	  Rev	  Cancer	  7:	  169-­‐181.	  Shi	  L,	  Fu	  WY,	  Hung	  KW,	  Porchetta	  C,	  Hall	  C,	  Fu	  AK,	  Ip	  NY.	  2007.	  Alpha2-­‐chimaerin	  interacts	  with	  EphA4	  and	  regulates	  EphA4-­‐dependent	  growth	  cone	  collapse.	  
Proc	  Natl	  Acad	  Sci	  U	  S	  A	  104:	  16347-­‐16352.	  Shi	  W,	  Levine	  M.	  2008.	  Ephrin	  signaling	  establishes	  asymmetric	  cell	  fates	  in	  an	  endomesoderm	  lineage	  of	  the	  Ciona	  embryo.	  Development	  135:	  931-­‐940.	  Shiels	  A,	  Bennett	  TM,	  Knopf	  HL,	  Maraini	  G,	  Li	  A,	  Jiao	  X,	  Hejtmancik	  JF.	  2008.	  The	  EPHA2	  gene	  is	  associated	  with	  cataracts	  linked	  to	  chromosome	  1p.	  Mol	  Vis	  
14:	  2042-­‐2055.	  Shintani	  T,	  Ihara	  M,	  Sakuta	  H,	  Takahashi	  H,	  Watakabe	  I,	  Noda	  M.	  2006.	  Eph	  receptors	  are	  negatively	  controlled	  by	  protein	  tyrosine	  phosphatase	  receptor	  type	  O.	  Nat	  Neurosci	  9:	  761-­‐769.	  Singla	  N,	  Erdjument-­‐Bromage	  H,	  Himanen	  JP,	  Muir	  TW,	  Nikolov	  DB.	  2011.	  A	  semisynthetic	  Eph	  receptor	  tyrosine	  kinase	  provides	  insight	  into	  ligand-­‐induced	  kinase	  activation.	  Chem	  Biol	  18:	  361-­‐371.	  Skaggs	  BJ,	  Gorre	  ME,	  Ryvkin	  A,	  Burgess	  MR,	  Xie	  Y,	  Han	  Y,	  Komisopoulou	  E,	  Brown	  LM,	  Loo	  JA,	  Landaw	  EM	  et	  al.	  2006.	  Phosphorylation	  of	  the	  ATP-­‐binding	  loop	  directs	  oncogenicity	  of	  drug-­‐resistant	  BCR-­‐ABL	  mutants.	  Proc	  Natl	  Acad	  Sci	  U	  
S	  A	  103:	  19466-­‐19471.	  Solanas	  G,	  Cortina	  C,	  Sevillano	  M,	  Batlle	  E.	  2011.	  Cleavage	  of	  E-­‐cadherin	  by	  ADAM10	  mediates	  epithelial	  cell	  sorting	  downstream	  of	  EphB	  signalling.	  Nat	  Cell	  Biol	  
13:	  1100-­‐1107.	  Sprinzak	  D,	  Lakhanpal	  A,	  LeBon	  L,	  Garcia-­‐Ojalvo	  J,	  Elowitz	  MB.	  2011.	  Mutual	  inactivation	  of	  Notch	  receptors	  and	  ligands	  facilitates	  developmental	  patterning.	  PLoS	  Comput	  Biol	  7:	  e1002069.	  Sprinzak	  D,	  Lakhanpal	  A,	  Lebon	  L,	  Santat	  LA,	  Fontes	  ME,	  Anderson	  GA,	  Garcia-­‐Ojalvo	  J,	  Elowitz	  MB.	  2010.	  Cis-­‐interactions	  between	  Notch	  and	  Delta	  generate	  mutually	  exclusive	  signalling	  states.	  Nature	  465:	  86-­‐90.	  Stahl	  S,	  Branca	  RM,	  Efazat	  G,	  Ruzzene	  M,	  Zhivotovsky	  B,	  Lewensohn	  R,	  Viktorsson	  K,	  Lehtio	  J.	  2011.	  Phosphoproteomic	  profiling	  of	  NSCLC	  cells	  reveals	  that	  ephrin	  B3	  regulates	  pro-­‐survival	  signaling	  through	  Akt1-­‐mediated	  phosphorylation	  of	  the	  EphA2	  receptor.	  J	  Proteome	  Res	  10:	  2566-­‐2578.	  Stein	  E,	  Lane	  AA,	  Cerretti	  DP,	  Schoecklmann	  HO,	  Schroff	  AD,	  Van	  Etten	  RL,	  Daniel	  TO.	  1998.	  Eph	  receptors	  discriminate	  specific	  ligand	  oligomers	  to	  determine	  
References 
 76 
alternative	  signaling	  complexes,	  attachment,	  and	  assembly	  responses.	  Genes	  
&	  Development	  12:	  667-­‐678.	  Tandon	  M,	  Vemula	  SV,	  Mittal	  SK.	  2011.	  Emerging	  strategies	  for	  EphA2	  receptor	  targeting	  for	  cancer	  therapeutics.	  Expert	  opinion	  on	  therapeutic	  targets	  15:	  31-­‐51.	  Tolias	  KF,	  Bikoff	  JB,	  Kane	  CG,	  Tolias	  CS,	  Hu	  L,	  Greenberg	  ME.	  2007.	  The	  Rac1	  guanine	  nucleotide	  exchange	  factor	  Tiam1	  mediates	  EphB	  receptor-­‐dependent	  dendritic	  spine	  development.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A	  104:	  7265-­‐7270.	  Truitt	  L,	  Freywald	  A.	  2011.	  Dancing	  with	  the	  dead:	  Eph	  receptors	  and	  their	  kinase-­‐null	  partners.	  Biochem	  Cell	  Biol	  89:	  115-­‐129.	  Trusolino	  L,	  Comoglio	  PM.	  2002.	  Scatter-­‐factor	  and	  semaphorin	  receptors:	  cell	  signalling	  for	  invasive	  growth.	  Nat	  Rev	  Cancer	  2:	  289-­‐300.	  Udayakumar	  D,	  Zhang	  G,	  Ji	  Z,	  Njauw	  CN,	  Mroz	  P,	  Tsao	  H.	  2011.	  EphA2	  is	  a	  critical	  oncogene	  in	  melanoma.	  Oncogene	  30:	  4921-­‐4929.	  Valsesia	  A,	  Rimoldi	  D,	  Martinet	  D,	  Ibberson	  M,	  Benaglio	  P,	  Quadroni	  M,	  Waridel	  P,	  Gaillard	  M,	  Pidoux	  M,	  Rapin	  B	  et	  al.	  2011.	  Network-­‐guided	  analysis	  of	  genes	  with	  altered	  somatic	  copy	  number	  and	  gene	  expression	  reveals	  pathways	  commonly	  perturbed	  in	  metastatic	  melanoma.	  PLoS	  One	  6:	  e18369.	  Van	  Hoecke	  A,	  Schoonaert	  L,	  Lemmens	  R,	  Timmers	  M,	  Staats	  KA,	  Laird	  AS,	  Peeters	  E,	  Philips	  T,	  Goris	  A,	  Dubois	  B	  et	  al.	  2012.	  EPHA4	  is	  a	  disease	  modifier	  of	  amyotrophic	  lateral	  sclerosis	  in	  animal	  models	  and	  in	  humans.	  Nat	  Med.	  Vindis	  C,	  Cerretti	  DP,	  Daniel	  TO,	  Huynh-­‐Do	  U.	  2003.	  EphB1	  recruits	  c-­‐Src	  and	  p52Shc	  to	  activate	  MAPK/ERK	  and	  promote	  chemotaxis.	  J	  Cell	  Biol	  162:	  661-­‐671.	  Wahl	  S,	  Barth	  H,	  Ciossek	  T,	  Aktories	  K,	  Mueller	  BK.	  2000.	  Ephrin-­‐A5	  induces	  collapse	  of	  growth	  cones	  by	  activating	  Rho	  and	  Rho	  kinase.	  J	  Cell	  Biol	  149:	  263-­‐270.	  Wakayama	  Y,	  Miura	  K,	  Sabe	  H,	  Mochizuki	  N.	  2011.	  EphrinA1-­‐EphA2	  Signal	  Induces	  Compaction	  and	  Polarization	  of	  Madin-­‐Darby	  Canine	  Kidney	  Cells	  by	  Inactivating	  Ezrin	  through	  Negative	  Regulation	  of	  RhoA.	  J	  Biol	  Chem	  286:	  44243-­‐44253.	  Walker-­‐Daniels	  J,	  Riese	  DJ,	  2nd,	  Kinch	  MS.	  2002.	  c-­‐Cbl-­‐Dependent	  EphA2	  Protein	  Degradation	  Is	  Induced	  by	  Ligand	  Binding.	  Mol	  Cancer	  Res	  1:	  79-­‐87.	  Wang	  Y,	  Nakayama	  M,	  Pitulescu	  ME,	  Schmidt	  TS,	  Bochenek	  ML,	  Sakakibara	  A,	  Adams	  S,	  Davy	  A,	  Deutsch	  U,	  Luthi	  U	  et	  al.	  2010.	  Ephrin-­‐B2	  controls	  VEGF-­‐induced	  angiogenesis	  and	  lymphangiogenesis.	  Nature	  465:	  483-­‐486.	  Ware	  CF,	  Sedy	  JR.	  2011.	  TNF	  Superfamily	  Networks:	  bidirectional	  and	  interference	  pathways	  of	  the	  herpesvirus	  entry	  mediator	  (TNFSF14).	  Curr	  Opin	  Immunol	  
23:	  627-­‐631.	  Wegmeyer	  H,	  Egea	  J,	  Rabe	  N,	  Gezelius	  H,	  Filosa	  A,	  Enjin	  A,	  Varoqueaux	  F,	  Deininger	  K,	  Schnutgen	  F,	  Brose	  N	  et	  al.	  2007.	  EphA4-­‐Dependent	  Axon	  Guidance	  Is	  Mediated	  by	  the	  RacGAP	  alpha2-­‐Chimaerin.	  Neuron	  55:	  756-­‐767.	  Wei	  S,	  Xu	  G,	  Bridges	  LC,	  Williams	  P,	  White	  JM,	  DeSimone	  DW.	  2010.	  ADAM13	  induces	  cranial	  neural	  crest	  by	  cleaving	  class	  B	  Ephrins	  and	  regulating	  Wnt	  signaling.	  Dev	  Cell	  19:	  345-­‐352.	  
References 
 77 
Wimmer-­‐Kleikamp	  SH,	  Janes	  PW,	  Squire	  A,	  Bastiaens	  PI,	  Lackmann	  M.	  2004.	  Recruitment	  of	  Eph	  receptors	  into	  signaling	  clusters	  does	  not	  require	  ephrin	  contact.	  J	  Cell	  Biol	  164:	  661-­‐666.	  Wimmer-­‐Kleikamp	  SH,	  Nievergall	  E,	  Gegenbauer	  K,	  Adikari	  S,	  Mansour	  M,	  Yeadon	  T,	  Boyd	  AW,	  Patani	  NR,	  Lackmann	  M.	  2008.	  Elevated	  protein	  tyrosine	  phosphatase	  activity	  provokes	  Eph/ephrin-­‐facilitated	  adhesion	  of	  pre-­‐B	  leukemia	  cells.	  Blood	  112:	  721-­‐732.	  Wu	  C,	  Qiu	  R,	  Wang	  J,	  Zhang	  H,	  Murai	  K,	  Lu	  Q.	  2009.	  ZHX2	  Interacts	  with	  Ephrin-­‐B	  and	  regulates	  neural	  progenitor	  maintenance	  in	  the	  developing	  cerebral	  cortex.	  J	  Neurosci	  29:	  7404-­‐7412.	  Wybenga-­‐Groot	  LE,	  Baskin	  B,	  Ong	  SH,	  Tong	  JF,	  Pawson	  T,	  Sicheri	  F.	  2001.	  Structural	  basis	  for	  autoinhibition	  of	  the	  EphB2	  receptor	  tyrosine	  kinase	  by	  the	  unphosphorylated	  juxtamembrane	  region.	  Cell	  106:	  745-­‐757.	  Wykosky	  J,	  Debinski	  W.	  2008.	  The	  EphA2	  receptor	  and	  ephrinA1	  ligand	  in	  solid	  tumors:	  function	  and	  therapeutic	  targeting.	  Mol	  Cancer	  Res	  6:	  1795-­‐1806.	  Wykosky	  J,	  Gibo	  DM,	  Stanton	  C,	  Debinski	  W.	  2005.	  EphA2	  as	  a	  novel	  molecular	  marker	  and	  target	  in	  glioblastoma	  multiforme.	  Mol	  Cancer	  Res	  3:	  541-­‐551.	  Wykosky	  J,	  Palma	  E,	  Gibo	  DM,	  Ringler	  S,	  Turner	  CP,	  Debinski	  W.	  2008.	  Soluble	  monomeric	  EphrinA1	  is	  released	  from	  tumor	  cells	  and	  is	  a	  functional	  ligand	  for	  the	  EphA2	  receptor.	  Oncogene	  27:	  7260-­‐7273.	  Xi	  HQ,	  Wu	  XS,	  Wei	  B,	  Chen	  L.	  2012.	  Aberrant	  expression	  of	  EphA3	  in	  gastric	  carcinoma:	  correlation	  with	  tumor	  angiogenesis	  and	  survival.	  Journal	  of	  
gastroenterology	  47:	  785-­‐794.	  Xi	  HQ,	  Zhao	  P.	  2011.	  Clinicopathological	  significance	  and	  prognostic	  value	  of	  EphA3	  and	  CD133	  expression	  in	  colorectal	  carcinoma.	  J	  Clin	  Pathol	  64:	  498-­‐503.	  Xiao	  Z,	  Carrasco	  R,	  Kinneer	  K,	  Sabol	  D,	  Jallal	  B,	  Coats	  S,	  Tice	  DA.	  2012.	  EphB4	  promotes	  or	  suppresses	  Ras/MEK/ERK	  pathway	  in	  a	  context-­‐dependent	  manner:	  Implications	  for	  EphB4	  as	  a	  cancer	  target.	  Cancer	  Biol	  Ther	  13:	  630-­‐637.	  Xu	  J,	  Litterst	  C,	  Georgakopoulos	  A,	  Zaganas	  I,	  Robakis	  NK.	  2009.	  Peptide	  EphB2/CTF2	  generated	  by	  the	  gamma-­‐secretase	  processing	  of	  EphB2	  receptor	  promotes	  tyrosine	  phosphorylation	  and	  cell	  surface	  localization	  of	  N-­‐methyl-­‐D-­‐aspartate	  receptors.	  J	  Biol	  Chem	  284:	  27220-­‐27228.	  Xu	  NJ,	  Henkemeyer	  M.	  2009.	  Ephrin-­‐B3	  reverse	  signaling	  through	  Grb4	  and	  cytoskeletal	  regulators	  mediates	  axon	  pruning.	  Nat	  Neurosci	  12:	  268-­‐276.	  Yamaguchi	  Y,	  Pasquale	  EB.	  2004.	  Eph	  receptors	  in	  the	  adult	  brain.	  Curr	  Opin	  
Neurobiol	  14:	  288-­‐296.	  Yang	  NY,	  Fernandez	  C,	  Richter	  M,	  Xiao	  Z,	  Valencia	  F,	  Tice	  DA,	  Pasquale	  EB.	  2011.	  Crosstalk	  of	  the	  EphA2	  receptor	  with	  a	  serine/threonine	  phosphatase	  suppresses	  the	  Akt-­‐mTORC1	  pathway	  in	  cancer	  cells.	  Cell	  Signal	  23:	  201-­‐212.	  Yaron	  A,	  Sprinzak	  D.	  2012.	  The	  cis	  side	  of	  juxtacrine	  signaling:	  a	  new	  role	  in	  the	  development	  of	  the	  nervous	  system.	  Trends	  Neurosci	  35:	  230-­‐239.	  Yin	  Y,	  Yamashita	  Y,	  Noda	  H,	  Okafuji	  T,	  Go	  MJ,	  Tanaka	  H.	  2004.	  EphA	  receptor	  tyrosine	  kinases	  interact	  with	  co-­‐expressed	  ephrin-­‐A	  ligands	  in	  cis.	  
Neuroscience	  Research	  48:	  285-­‐296.	  
References 
 78 
Yoo	  S,	  Kim	  Y,	  Noh	  H,	  Lee	  H,	  Park	  E,	  Park	  S.	  2011.	  Endocytosis	  of	  EphA	  receptors	  is	  essential	  for	  the	  proper	  development	  of	  the	  retinocollicular	  topographic	  map.	  
EMBO	  J	  30:	  1593-­‐1607.	  Yumoto	  N,	  Wakatsuki	  S,	  Kurisaki	  T,	  Hara	  Y,	  Osumi	  N,	  Frisen	  J,	  Sehara-­‐Fujisawa	  A.	  2008.	  Meltrin	  beta/ADAM19	  interacting	  with	  EphA4	  in	  developing	  neural	  cells	  participates	  in	  formation	  of	  the	  neuromuscular	  junction.	  PLoS	  ONE	  3:	  e3322.	  Yuzawa	  S,	  Opatowsky	  Y,	  Zhang	  Z,	  Mandiyan	  V,	  Lax	  I,	  Schlessinger	  J.	  2007.	  Structural	  basis	  for	  activation	  of	  the	  receptor	  tyrosine	  kinase	  KIT	  by	  stem	  cell	  factor.	  
Cell	  130:	  323-­‐334.	  Zafeiriou	  DI,	  Pavlidou	  EL,	  Vargiami	  E.	  2011.	  Diverse	  clinical	  and	  genetic	  aspects	  of	  craniofrontonasal	  syndrome.	  Pediatr	  Neurol	  44:	  83-­‐87.	  Zantek	  ND,	  Azimi	  M,	  Fedor-­‐Chaiken	  M,	  Wang	  BC,	  Brackenbury	  R,	  Kinch	  MS.	  1999.	  E-­‐cadherin	  regulates	  the	  function	  of	  the	  EphA2	  receptor	  tyrosine	  kinase.	  Cell	  
Growth	  &	  Differentiation	  10:	  629-­‐638.	  Zelinski	  DP,	  Zantek	  ND,	  Stewart	  JC,	  Irizarry	  AR,	  Kinch	  MS.	  2001.	  EphA2	  overexpression	  causes	  tumorigenesis	  of	  mammary	  epithelial	  cells.	  Cancer	  Res	  
61:	  2301-­‐2306.	  Zhang	  J,	  Yang	  PL,	  Gray	  NS.	  2009a.	  Targeting	  cancer	  with	  small	  molecule	  kinase	  inhibitors.	  Nat	  Rev	  Cancer	  9:	  28-­‐39.	  Zhang	  T,	  Hua	  R,	  Xiao	  W,	  Burdon	  KP,	  Bhattacharya	  SS,	  Craig	  JE,	  Shang	  D,	  Zhao	  X,	  Mackey	  DA,	  Moore	  AT	  et	  al.	  2009b.	  Mutations	  of	  the	  EPHA2	  receptor	  tyrosine	  kinase	  gene	  cause	  autosomal	  dominant	  congenital	  cataract.	  Hum	  Mutat	  30:	  E603-­‐611.	  Zhuang	  G,	  Hunter	  S,	  Hwang	  Y,	  Chen	  J.	  2007.	  Regulation	  of	  EphA2	  receptor	  endocytosis	  by	  SHIP2	  lipid	  phosphatase	  via	  phosphatidylinositol	  3-­‐Kinase-­‐dependent	  Rac1	  activation.	  J	  Biol	  Chem	  282:	  2683-­‐2694.	  Zhuang	  G,	  Song	  W,	  Amato	  K,	  Hwang	  Y,	  Lee	  K,	  Boothby	  M,	  Ye	  F,	  Guo	  Y,	  Shyr	  Y,	  Lin	  L	  et	  al.	  2012.	  Effects	  of	  cancer-­‐associated	  EPHA3	  mutations	  on	  lung	  cancer.	  J	  Natl	  
Cancer	  Inst	  104:	  1182-­‐1197.	  Zimmer	  M,	  Palmer	  A,	  Kohler	  J,	  Klein	  R.	  2003.	  EphB-­‐ephrinB	  bi-­‐directional	  endocytosis	  terminates	  adhesion	  allowing	  contact	  mediated	  repulsion.	  Nat	  
Cell	  Biol	  5:	  869-­‐878.	  Zisch	  AH,	  Pasquale	  EB.	  1997.	  The	  Eph	  family:	  a	  multitude	  of	  receptors	  that	  mediate	  cell	  recognition	  signals.	  Cell	  &	  Tissue	  Research	  290:	  217-­‐226.	  Zisch	  AH,	  Pazzagli	  C,	  Freeman	  AL,	  Schneller	  M,	  Hadman	  M,	  Smith	  JW,	  Ruoslahti	  E,	  Pasquale	  EB.	  2000.	  Replacing	  two	  conserved	  tyrosines	  of	  the	  EphB2	  receptor	  with	  glutamic	  acid	  prevents	  binding	  of	  SH2	  domains	  without	  abrogating	  kinase	  activity	  and	  biological	  responses.	  Oncogene	  19:	  177-­‐187.	  Zwick	  E,	  Bange	  J,	  Ullrich	  A.	  2002.	  Receptor	  tyrosine	  kinases	  as	  targets	  for	  anticancer	  drugs.	  Trends	  Mol	  Med	  8:	  17-­‐23.	  	  
 
